[
  {
    "model": "mcq.mcq",
    "pk": "e5d1fa23-c0b7-4c7d-b212-51c85eaffd43",
    "fields": {
      "question_number": "77",
      "question_text": "17-year-old boy who developed tic since the age of 11, it was multiple tics verbal and motor What is the diagnosis",
      "options": {
        "A": "Gills Tourette"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821530",
      "updated_at": "2025-05-15T20:25:21.821531"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "1e7531dd-23cc-4b70-86a3-36002bc70e7c",
    "fields": {
      "question_number": "80",
      "question_text": "a man who presented with abnormal movement (from psychiatry hospital) and being unable to sit still, on exam he is a fidget and move back and forth and keep crossing and uncrossing his legs what is the diagnosis",
      "options": {
        "A": "chorea",
        "B": "dystonia",
        "C": "akathesia"
      },
      "correct_answer": "C",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.821540",
      "updated_at": "2025-05-15T20:25:21.821541"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "619dae8c-0060-401d-83e5-7b8d64f06500",
    "fields": {
      "question_number": "74",
      "question_text": "Scenario about basilar migraine with vertigo? asking about dx:",
      "options": {
        "A": "Basilar migraine"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821549",
      "updated_at": "2025-05-15T20:25:21.821550"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "43d8134d-678d-4c31-ac75-57aa8c8ebec4",
    "fields": {
      "question_number": "78",
      "question_text": "Scenario about 50 y/o female with recent intention tremor and memory problem with MRI finding of cerebellar peduncle changes (fragile x but nor that clear scenario) dx:",
      "options": {
        "A": "Fragile x (it was mentioned as X permutation)",
        "B": "paraneoplastic"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821558",
      "updated_at": "2025-05-15T20:25:21.821559"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "70adb2a1-bf28-4513-bc24-526d2e31100f",
    "fields": {
      "question_number": "76",
      "question_text": "Mode of inheritance for Fahr disease:",
      "options": {
        "A": "AR",
        "B": "AD",
        "C": "X-linked"
      },
      "correct_answer": "B",
      "explanation": "There are 2 modes of transmission. Most common AD mode of inheritance.",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821568",
      "updated_at": "2025-05-15T20:25:21.821568"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "70b2329d-e693-4b54-973e-e92098f2921f",
    "fields": {
      "question_number": "88",
      "question_text": "Anxiety mostly commonly complicate which of the following diseases:",
      "options": {
        "A": "FTD",
        "B": "AD",
        "C": "Parkinson’s",
        "D": "Huntington"
      },
      "correct_answer": "C",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821577",
      "updated_at": "2025-05-15T20:25:21.821578"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "b820194e-dfa8-4caf-9b68-a681f7376e49",
    "fields": {
      "question_number": "123",
      "question_text": "Scenario of young pt. with absence like picture:",
      "options": {
        "A": "Frontal",
        "B": "temporal",
        "C": "parietal"
      },
      "correct_answer": "A",
      "explanation": "Frontal and thalamus",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821587",
      "updated_at": "2025-05-15T20:25:21.821587"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c77464c7-f31a-45b7-952a-7de4fcf26a51",
    "fields": {
      "question_number": "121",
      "question_text": "Scenario with child with walking during sleep and drooling, ictal speech (not remembering):",
      "options": {
        "A": "centrotemporal spikes"
      },
      "correct_answer": "A",
      "explanation": "Benign Rolandic Epilepsy of Childhood\n- Accounts for 25% of childhood seizures. Onset is usually between 2 -13 yrs., and the condition typically resolves in the mid-teenage years.\n- Seizures are characterized by focal motor, sensory, or autonomic manifestations involving predominantly the face, mouth, throat, or extremities.\n- These are seizures that classically occur nocturnally (70% only in sleep, 15% only awake, and 15% both).\n- The EEG classically: bilateral independent centrotemporal spikes on a normal background.\n- Seizures respond well to certain AED and CBZ is usually considered the 1st line.\n- Indication for AED use: prolonged or frequent seizures.\n- If antiepileptic medications are started, they can generally be stopped after adolescence.",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821596",
      "updated_at": "2025-05-15T20:25:21.821597"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "00b6491f-1f49-4190-ab44-67a75926cc3e",
    "fields": {
      "question_number": "89",
      "question_text": "36-year-old patient who present with memory complaint and visual-spatial defect what is the responsible gene (Alzheimer scenario):",
      "options": {
        "A": "TREM",
        "B": "ubiquitin",
        "C": "EPO4",
        "D": "APP"
      },
      "correct_answer": "D",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821606",
      "updated_at": "2025-05-15T20:25:21.821607"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "03aea653-b79c-4434-9375-130d09d0eac3",
    "fields": {
      "question_number": "124",
      "question_text": "Question about Landau-Kleffner syndrome (LKS):",
      "options": {},
      "correct_answer": null,
      "explanation": "AKA acquired epileptic aphasia\n- This is a condition of unknown cause, more common in boys, with a mean onset at 5.5 years.\n- 70% of these patients have an associated seizure (Various types; atypical absence, tonic, myoclonic, tonic-clonic).\n- The aphasia may be primarily receptive or expressive, and auditory agnosia may be so severe that the child is unaware of everyday sounds.\n- Hearing is normal, but behavioral problems, including irritability and poor attention span, are particularly common.\n- EEG showed multifocal cortical spikes (temporal and parietal)\n- Can be treated with valproic acid and lamotrigine",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821615",
      "updated_at": "2025-05-15T20:25:21.821616"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "2571fd0c-a393-41d0-a33b-e0b3fcb299ae",
    "fields": {
      "question_number": "90",
      "question_text": "A woman presented with 5 weeks history of mild psychiatric symptoms (forgot what was is, could be social withdraw and depression + sleep disturbances) on examination she had left homonymous hemi-anopia along with left quadrantanopia color changes and affected MMSE (no other clues mentioned) MRI is normal, what is the most likely diagnosis (vague scenario) going with (Heidenhain variant of cjd)",
      "options": {
        "A": "prion disease",
        "B": "LBD",
        "C": "Tau"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821625",
      "updated_at": "2025-05-15T20:25:21.821625"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "15845ee9-2859-4d15-a10a-f499916eb25a",
    "fields": {
      "question_number": "92",
      "question_text": "Scenario about Wilson what will confirm diagnosis:",
      "options": {
        "A": "Liver biopsy",
        "B": "Genetic"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821634",
      "updated_at": "2025-05-15T20:25:21.821635"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "d910113c-b1dc-4715-8514-e8bb227ce92c",
    "fields": {
      "question_number": "95",
      "question_text": "Essential tremor scenario with asthma rx;",
      "options": {
        "A": "Primidone"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821643",
      "updated_at": "2025-05-15T20:25:21.821644"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "2e3e0de7-7c73-4c6e-9cd7-bd5579320e6f",
    "fields": {
      "question_number": "95",
      "question_text": "Sydenham chorea what to do:",
      "options": {
        "A": "ASO titer"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821652",
      "updated_at": "2025-05-15T20:25:21.821653"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "103c14fd-0133-42bb-a305-ea498c1555b7",
    "fields": {
      "question_number": "110",
      "question_text": "A 3-year-old boy presented with developmental delay and seizure consisting of tonic seizures drop attacks and other kind of seizures EEG was done, what do you expect to find on his EEG (LGS)",
      "options": {
        "A": "3 Hz spike and wave",
        "B": "Epileptiform discharges less than 2Hz"
      },
      "correct_answer": "B",
      "explanation": "Lennox-Gastaut syndrome is a triad of: (1) multiple seizure types refractory to AEDs, (2) mental retardation, and (3) slow spike-and-wave activity on EEG (1.5 – 2.5 Hz).",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821661",
      "updated_at": "2025-05-15T20:25:21.821662"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "1659a69d-207d-4966-bcaf-e525a74d2760",
    "fields": {
      "question_number": "106-107-108",
      "question_text": "(repeated 3 times!) Abnormal accumulation of which protein is found in ALS/FTD COMPLEX",
      "options": {
        "A": "TDP 43",
        "B": "Tau"
      },
      "correct_answer": "A",
      "explanation": "Abnormal accumulations of tau or TDP-43 account for the majority of pathologically confirmed cases of FTD, with FUS inclusions most common in the remaining 10%. Abnormal aggregations of tau can be found in patients with sporadic bvFTD, CBS, nonfluent agrammatic variant PPA, and PSP as well as MAPT-associated familial FTD. TDP-43 pathology is found in patients with svPPA, FTD-MND, and bvFTD, as well as in genetic variants including C9ORF72, GRN, and VCP mutations. FUS pathology leads to an earlier age of onset of FTD, prominent neuropsychiatric features, and a more rapid course.",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821671",
      "updated_at": "2025-05-15T20:25:21.821671"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "bb6a955a-be97-4abb-8237-67aea1eca3ed",
    "fields": {
      "question_number": "97",
      "question_text": "RLS most commonly with:",
      "options": {
        "A": "Pregnancy is a risk factor"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821680",
      "updated_at": "2025-05-15T20:25:21.821681"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "51400040-a217-42cd-9fab-8534769edad0",
    "fields": {
      "question_number": "94",
      "question_text": "Pet scan in LBD:",
      "options": {
        "A": "Occipital",
        "B": "Temporoparietal"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821689",
      "updated_at": "2025-05-15T20:25:21.821690"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "26902899-3fda-4d27-b98e-f1eea35ee0aa",
    "fields": {
      "question_number": "145",
      "question_text": "Scenario of mucormycosis what is the route:",
      "options": {
        "A": "direct invasion (through emissary vain)"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821699",
      "updated_at": "2025-05-15T20:25:21.821699"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "cb94b454-017a-4adb-a8cc-a41ac6be98e9",
    "fields": {
      "question_number": "109",
      "question_text": "Scenario of old pt. Had stroke and became hyperactive, flight of ideas and pressured speech (mania) where will expect the lesion:",
      "options": {
        "A": "Caudate",
        "B": "Thalamus"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821708",
      "updated_at": "2025-05-15T20:25:21.821709"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "ff3502f5-31d4-4ab8-81a8-8b27631b9fe5",
    "fields": {
      "question_number": "144",
      "question_text": "Long scenario about sinusitis with DM",
      "options": {
        "A": "Mucormycosis"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821717",
      "updated_at": "2025-05-15T20:25:21.821718"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "47f41cc6-aae7-4914-aa66-e327b5f45bb6",
    "fields": {
      "question_number": "142",
      "question_text": "Intoxication with which of the following agent would cause sensory ataxia with proprioception and vibratory loss:",
      "options": {
        "A": "dapsone",
        "B": "zidovudine",
        "C": "tacrolimus",
        "D": "pyridoxine"
      },
      "correct_answer": "D",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821726",
      "updated_at": "2025-05-15T20:25:21.821727"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "4218822f-f094-456c-9bea-8eb7f311ce7e",
    "fields": {
      "question_number": "143",
      "question_text": "Duration of acyclovir that will most likely decrease the chance of HSV recurrence:",
      "options": {
        "A": "21 days",
        "B": "24",
        "C": "14"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821736",
      "updated_at": "2025-05-15T20:25:21.821736"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c120f38f-3dc6-476b-b420-13efcc123ced",
    "fields": {
      "question_number": "147",
      "question_text": "Scenario of cavernous sinus thrombosis what dx:",
      "options": {
        "A": "Cavernous sinus thrombosis"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821744",
      "updated_at": "2025-05-15T20:25:21.821745"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "97ad0d9b-7157-406c-b3bd-32573724ef53",
    "fields": {
      "question_number": "146",
      "question_text": "Scenario about cavernous sinus thrombosis what to:",
      "options": {
        "A": "Mri with mrv",
        "B": "Cta",
        "C": "Angi",
        "D": "Ct orbit"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821753",
      "updated_at": "2025-05-15T20:25:21.821754"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "07591520-c944-492c-8e87-dab561aaac02",
    "fields": {
      "question_number": "148",
      "question_text": "Scenario for GCA what is the most likely mechanism (or artery):",
      "options": {
        "A": "Posterior ciliary artery",
        "B": "RCAO"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821764",
      "updated_at": "2025-05-15T20:25:21.821765"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "dffdfe53-4288-4904-8dfc-a0ab20525810",
    "fields": {
      "question_number": "149",
      "question_text": "Giant cell arteritis what is next:",
      "options": {
        "A": "Steroid",
        "B": "biopsy"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821773",
      "updated_at": "2025-05-15T20:25:21.821774"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "17c6775d-687f-416d-a958-5e930bda65e5",
    "fields": {
      "question_number": "150",
      "question_text": "Best predictor for pt. In coma (this was exactly the question they didn't mention brain death or time):",
      "options": {
        "A": "Etiology",
        "B": "SomatosensoryEvoked potential (SSPE)"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821782",
      "updated_at": "2025-05-15T20:25:21.821783"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "7f060dcb-4e0d-48c2-80a3-791944dd61f0",
    "fields": {
      "question_number": "153",
      "question_text": "Old female treated for herpetic neuralgia 5 days after rx became lethargic and confused ct brain and csf normal what is dx:",
      "options": {
        "A": "VZV encephalitis",
        "B": "Drug induced",
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821791",
      "updated_at": "2025-05-15T20:25:21.821792"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "4755e75e-14b2-4ac9-8ec0-faa2974df8ee",
    "fields": {
      "question_number": "152",
      "question_text": "Long scenario for Pt. With neuropathy and asthma what to do:",
      "options": {
        "A": "ANCA",
        "B": "Churg Strauss"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821800",
      "updated_at": "2025-05-15T20:25:21.821801"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "dfa380b5-beef-4a76-962c-5822b3cbb409",
    "fields": {
      "question_number": "152",
      "question_text": "Infection with Retinal whitening with orang spot.. (they did not mention macular star or neuroretinitis).",
      "options": {
        "A": "Bartonella",
        "B": "TB",
        "C": "CMV",
        "D": "Toxoplasmosis",
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821809",
      "updated_at": "2025-05-15T20:25:21.821810"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "681072a9-10d4-4240-89d8-adc7b6f34d99",
    "fields": {
      "question_number": "151",
      "question_text": "Scenario with stiffness and difficult walking with episode of LOC Emg showed neuromyotonia and now pt is fully conscious normal mental status (question is conflicting between Isaac and morvan), and gene found K gated channel, what is Dx:",
      "options": {
        "A": "Morvan syndrome",
        "B": "Isaac syndrome"
      },
      "correct_answer": "A",
      "explanation": "Morvan and Isaac same except Morvan fluctuating delirium (Bradley)",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821818",
      "updated_at": "2025-05-15T20:25:21.821819"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c9858242-d88e-4b7a-b15b-54fd40282a69",
    "fields": {
      "question_number": "154",
      "question_text": "Scenario about meningitis prophylaxis:",
      "options": {
        "A": "Rifampin",
        "B": null,
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821828",
      "updated_at": "2025-05-15T20:25:21.821828"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "ac36ab13-28aa-4693-82b7-ed48bf9909f4",
    "fields": {
      "question_number": "155",
      "question_text": "What is the most common organism for bacterial meningitis: (Choices was not the organism’s name, only the genre):",
      "options": {
        "A": "Pneumococcus",
        "B": null,
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": "(they didn't mention streptococcus pneumonia)",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821837",
      "updated_at": "2025-05-15T20:25:21.821838"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "9b0f13e4-571d-4e00-b531-652fd0203e71",
    "fields": {
      "question_number": "157",
      "question_text": "Scenario of young with hx going with cns infection with labs and vital signs provided which showed fever and csf pleocytosis but negative c/s and gram stain, also negative for HSV PCR what is next:",
      "options": {
        "A": "Acyclovir",
        "B": "Paracetamol",
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": "? Aseptic meningitis go with paracetamol maybe",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821846",
      "updated_at": "2025-05-15T20:25:21.821847"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c9364833-76be-493d-8bfc-058ed5152190",
    "fields": {
      "question_number": "87",
      "question_text": "Case of an elderly patient and symptoms suggestive of MSA:\n-most common presenting symptoms is impairment of down gaze\n-Autonomic insufficiency is characteristic of autonomic type of This condition\n-the cognitive impairment of amnestic type\n-the pt may have pyramidal sign",
      "options": null,
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {},
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821856",
      "updated_at": "2025-05-15T20:25:21.821857"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "448013ee-9a49-42ec-bf6a-9e691b931963",
    "fields": {
      "question_number": "156",
      "question_text": "Scenario of pt. With orange retinal structure or vessel (not sure):",
      "options": {
        "A": "YAWS",
        "B": "TB",
        "C": "MALARIA",
        "D": null,
        "E": null
      },
      "correct_answer": "A,C",
      "explanation": "(maybe)",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821865",
      "updated_at": "2025-05-15T20:25:21.821866"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "6bb6932f-bb3f-4b70-9de9-830952aa30e7",
    "fields": {
      "question_number": "91",
      "question_text": "Vague Scenario about LBD ASKING ABOUT DIAGNOSIS",
      "options": null,
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {},
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821874",
      "updated_at": "2025-05-15T20:25:21.821875"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "9bc628e6-dda2-41dc-abe1-7b7ef8dd3771",
    "fields": {
      "question_number": "132",
      "question_text": "MS patient who presented with SOB and allergic reaction on the third infusion of natalizumab what is the most appropriate thing to do next:",
      "options": {
        "A": "Stop infusion and treat the patient",
        "B": "Refer patient to immunology to start desensitization",
        "C": "Start a less dose of natalizumab next time"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821884",
      "updated_at": "2025-05-15T20:25:21.821885"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "429a3128-31a4-4e09-9d14-c17a63503a64",
    "fields": {
      "question_number": "130",
      "question_text": "A woman who had repeating episodes of vomiting for one month visited ER and given omeprazole, and had visual changes in both eye with some time apart, now she presented with symptoms of TM what is the diagnosis?",
      "options": {
        "A": "NMO",
        "B": "MS"
      },
      "correct_answer": "A",
      "explanation": "Diagnostic criteria for NMO without AQP4-IgG or NMOSD with unknown AQP4-IgG status:\n1. At least two core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements:\n   a. At least one core clinical characteristic must be optic neuritis, acute myelitis with longitudinally extensive transverse myelitis, or area postrema syndrome\n   b. Dissemination in space (two or more different core clinical characteristics)\n   c. Fulfilment of additional MRI requirements, as applicable\n2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable\n3. Exclusion of alternative diagnoses",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821893",
      "updated_at": "2025-05-15T20:25:21.821894"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "0a7c3aae-0aee-4c08-8faa-b17ac1064542",
    "fields": {
      "question_number": "93",
      "question_text": "Q about psp asking about diagnosis",
      "options": null,
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {},
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821902",
      "updated_at": "2025-05-15T20:25:21.821902"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "22c12c5c-8765-45a7-a418-66152fb1945c",
    "fields": {
      "question_number": "79",
      "question_text": "What is the PET finding in CBDG:",
      "options": {},
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821910",
      "updated_at": "2025-05-15T20:25:21.821911"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "18822487-12b6-4662-b170-23b6a29d0b17",
    "fields": {
      "question_number": "134",
      "question_text": "Scenario of young female with picture of 2 attacks and 2 objective findings came with new relapse of sudden left-sided weakness for 5 days after hx of exhaustion what to do: (or scenario of clinical isolated syndrome not sure)",
      "options": {
        "A": "Start fingolimod",
        "B": "Start interferon",
        "C": "Emergent pulse steroid",
        "D": "MRI brain",
        "E": "MRI?"
      },
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821920",
      "updated_at": "2025-05-15T20:25:21.821921"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "619c0d4b-e5ca-4fa3-aa27-3b4b5d566941",
    "fields": {
      "question_number": "162",
      "question_text": "Almost same previous scenario dx?",
      "options": {
        "A": "Acute confusion state",
        "B": null,
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821929",
      "updated_at": "2025-05-15T20:25:21.821930"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "da7e3e8f-c873-42d3-b15c-663b814b640f",
    "fields": {
      "question_number": "135",
      "question_text": "Same previous scenario what you will give for her last 5 days sx:",
      "options": {
        "A": "Pulse steroid"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821938",
      "updated_at": "2025-05-15T20:25:21.821939"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "96b064c5-ac91-44c7-a6d9-30dee3d82e28",
    "fields": {
      "question_number": "137",
      "question_text": "Scenario of young male with central vision loss in rt.eye then month apart let central eye vision loss then develop hearing loss, diagnosis:",
      "options": {
        "A": "Susac",
        "B": "Leber"
      },
      "correct_answer": "A",
      "explanation": "Leber central vision, sasac tunnel vision\nGreen book pg 252\nNOT SUSAC\n\nCentral visual loss with leber",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821947",
      "updated_at": "2025-05-15T20:25:21.821948"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c9a10f2b-4d47-42cf-8c6c-5e68ea12181f",
    "fields": {
      "question_number": "136",
      "question_text": "For progressive MS what of the following precocity a primary progressive subtype:",
      "options": {
        "A": "Leg weakness",
        "B": "Upper limb weakness",
        "C": "Bladder",
        "D": "Cognitive",
        "E": "Alaa pg 15"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821956",
      "updated_at": "2025-05-15T20:25:21.821957"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "ec6a92c9-6ef1-479d-ac3f-c714ddd85dfd",
    "fields": {
      "question_number": "140",
      "question_text": "Patient presented its right eye optic neuritis what will see in VEP:",
      "options": {
        "A": "Prolonged s100 in the right eye"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821965",
      "updated_at": "2025-05-15T20:25:21.821966"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "e533079a-7995-423b-8449-14d2e1ae1a35",
    "fields": {
      "question_number": "139",
      "question_text": "Scenario of young male with spastic paraparesis and +ve family hx, MRI brain showing confluent white matter changes MRI spine normal, he has 2 first degree male relatives with the same presentation:",
      "options": {
        "A": "Adrenoleukodystrophy",
        "B": "Hereditary spastic paraparesis"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821974",
      "updated_at": "2025-05-15T20:25:21.821975"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "6d74761d-b3fd-4bd0-bfef-6d4779dbc936",
    "fields": {
      "question_number": "138",
      "question_text": "Young with one eye visual loss then develop hearing loss:",
      "options": {
        "A": "Susac"
      },
      "correct_answer": "A",
      "explanation": "Susac syndrome is a rare AD, poorly characterized disorder associated with the clinical triad of:\n· Visual loss caused by branch retinal artery occlusions,\n· Sensorineural hearing loss,\n· Subacute encephalopathy.\n\nThe presence of hyperintense lesions in the corpus callosum on T2-weighted MR images (snowball) may be a clue to the diagnosis.\n\nLeber hereditary optic neuropathy\n- have acute unilateral visual loss, almost always followed by involvement of the fellow eye within 1 year.\n- This condition is inherited via a maternal mitochondrial DNA point mutation and, therefore, is seen typically in young male offspring of an unaffected mother.\n- Patients with Leber have bilateral central visual loss and profound optic atrophy, and yet the pupil light reflexes are remarkably preserved.",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821984",
      "updated_at": "2025-05-15T20:25:21.821985"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "1dc91f28-c2f4-435a-9923-9b9b7e28a27f",
    "fields": {
      "question_number": "166",
      "question_text": "A brain tumor and histology of pseudorosette:",
      "options": {
        "A": "Ependymoma",
        "B": null,
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.821994",
      "updated_at": "2025-05-15T20:25:21.821994"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "d4d6cfe3-1fd0-421c-b4a3-f8156214e036",
    "fields": {
      "question_number": "168",
      "question_text": "A pediatric patient who presented with expansile spinal cord signal changes with partial enhancement:",
      "options": {
        "A": "Astrocytoma",
        "B": "Ependymoma",
        "C": "Hemangioma",
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822003",
      "updated_at": "2025-05-15T20:25:21.822004"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "5208a32e-6610-43bb-b703-5130aebb09f8",
    "fields": {
      "question_number": "164",
      "question_text": "Q about pt with corona but covid –ve (not clear) if it corona or meningitis. Chest x ray Rt-pcr ?",
      "options": {
        "A": "Vancomycin and ceftriaxone",
        "B": null,
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822012",
      "updated_at": "2025-05-15T20:25:21.822013"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "0dfc296c-9a74-4339-b2fb-c7a53cfb70cd",
    "fields": {
      "question_number": "163",
      "question_text": "Long scenario of pt. With risk factor for stroke had hx of dizziness went to ER given meclizine then second day developed fluctuation LOC then weakness then posturing in the ambulance. CT brain attached showing hyperdense basilar artery and lt. Temporal hypodensity what to do: (picture of basilar artery stroke vs seizure 2nd to stroke not sure)",
      "options": {
        "A": "IV AED",
        "B": "Acyclovir",
        "C": "Thrombolytics",
        "D": "Thrombectomy or IV AED if patient seizing",
        "E": null
      },
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822022",
      "updated_at": "2025-05-15T20:25:21.822022"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "3d30910e-7cf0-462c-8eb4-d7bac12ab18b",
    "fields": {
      "question_number": "165",
      "question_text": "A neonate developed seizures within 24 hours of birth and have high bilirubin what would be the most affected area on MRI:",
      "options": {
        "A": "Thalamus",
        "B": "Caudate",
        "C": "GP",
        "D": null,
        "E": null
      },
      "correct_answer": "C",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822031",
      "updated_at": "2025-05-15T20:25:21.822032"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "79786689-8235-4908-b8b6-74ba740c589c",
    "fields": {
      "question_number": "169",
      "question_text": "NF type 1 patient who presented with syncopal attacks and there is a lateral ventricular mass what is the tumor:",
      "options": {
        "A": "SEGA",
        "B": "Central neurocytoma",
        "C": "Choroid plexus papilloma",
        "D": null,
        "E": null
      },
      "correct_answer": null,
      "explanation": "Central neurocytoma ? Dr Musaad but he’s not sure. In adults. If pilocytic astrocytoma choose it it comes w nf1. Nf2 Ependymoma. If ts sega",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822040",
      "updated_at": "2025-05-15T20:25:21.822041"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "1a176dd1-be74-4e7a-a2bb-30fd73a46e4e",
    "fields": {
      "question_number": "170",
      "question_text": "Which of the following is a major criteria or TS:",
      "options": {
        "A": "Facial angiofibroma",
        "B": "Renal angiomyolipoma",
        "C": "Retinal achromic patch",
        "D": "Cardiac rhabdomyoma",
        "E": null
      },
      "correct_answer": "A,D",
      "explanation": "Both are major. 2 possible correct answers. If question Minor retinal achromatic patch. The other 3 are major",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822049",
      "updated_at": "2025-05-15T20:25:21.822050"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "8734f3b8-33f1-4333-bf6b-d4f6c97daf11",
    "fields": {
      "question_number": "138",
      "question_text": "A man with long history of malnutrition presented with peripheral neuropathy, ataxia, deafness and retinal degeneration and optic atrophy was diagnosed with Strachan syndrome which is a deficiency in:",
      "options": {
        "A": "vitamin A",
        "B": "vitamin E",
        "C": "vitamin B12"
      },
      "correct_answer": "C",
      "explanation": "Strachan syndrome (Strachan–Scott disease, Jamaican neuritis or Tropical Ataxic Neuropathy) is a nutritional neuropathy resembling pellagra, manifest as the combination of amblyopia due to optic neuritis, painful areflexic sensorimotor neuropathy with sensory ataxia, hearing loss, and orogenital dermatitis. The syndrome was originally described in the residents of Jamaica in 1897 but occurs in malnourished people with low levels of riboflavin (B2) regardless of where they live. The epidemic neuropathy found in Cuba today may reflect the result of malnourishment occasioned by the economic embargo placed on that country.",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822059",
      "updated_at": "2025-05-15T20:25:21.822060"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "0624714a-f858-4800-b10f-139b831673ec",
    "fields": {
      "question_number": "167",
      "question_text": "A brain tumor with characteristic cells encircling each other called psammoma bodies",
      "options": {
        "A": "Meningioma",
        "B": null,
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822068",
      "updated_at": "2025-05-15T20:25:21.822069"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c924c12f-b6b1-4800-8d58-431491910bdb",
    "fields": {
      "question_number": "139",
      "question_text": "A patient who is returning from Sudan had fever, confusion, headache, gave labs and CSF result. What test should you do:",
      "options": {
        "A": "Thick blood film",
        "B": "MRI"
      },
      "correct_answer": "A",
      "explanation": "Cerebral malaria is an encephalopathy that is caused by Plasmodium falciparum and leads to coma. The diagnosis should be considered in individuals living in or traveling to endemic areas. Diagnosis: Thick and thin blood smears with Giemsa stain, ELISA, PCR. Treatment: First line IV Artesunate. Alternative: IV Quinine.",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822077",
      "updated_at": "2025-05-15T20:25:21.822078"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "340def6e-ccc1-4d4d-b276-f9d8c666a986",
    "fields": {
      "question_number": "140",
      "question_text": "A patient came with fever and confusion, was anemic, had hypoglycemia, which was treated, CSF was given (normal) along with labs. What medication to treat:",
      "options": {
        "A": "Acyclovir",
        "B": "artemisinin (the one to treat cerebral malaria)",
        "C": "Vancomycin and ceftriaxone"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822086",
      "updated_at": "2025-05-15T20:25:21.822087"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "d861e7b3-e604-425a-b0c9-86ceb5cff9e7",
    "fields": {
      "question_number": "141",
      "question_text": "Scenario about HIV + patient with low CD4 count, MRI attached with multiple ring-enhancing lesion. What is the most likely responsible organism?",
      "options": {
        "A": "virus"
      },
      "correct_answer": null,
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822095",
      "updated_at": "2025-05-15T20:25:21.822096"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "cac32e9f-1d43-4e41-b35d-49ec5efac6c9",
    "fields": {
      "question_number": "158",
      "question_text": "Scenario of HSV encephalitis what you will find:",
      "options": {
        "A": "CSF Pleocytosis with RBC",
        "B": null,
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822105",
      "updated_at": "2025-05-15T20:25:21.822105"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "ab8664c7-6b56-494d-aac9-dd48996b7f66",
    "fields": {
      "question_number": "122",
      "question_text": "Vague scenario about localization they mention posturing and nocturnal seizures:",
      "options": {
        "A": "SMA"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822113",
      "updated_at": "2025-05-15T20:25:21.822114"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "e1c0c282-85d4-41dd-ad85-2632fcfd06d5",
    "fields": {
      "question_number": "160",
      "question_text": "Vague scenario of pt. With no hx available because no family around brought to ER with decrease level of consciousness and fever (not mentioned rigidity) ct brain and csf normal what to do:",
      "options": {
        "A": "Dantrolene",
        "B": "Acyclovir",
        "C": "Antibiotics",
        "D": "Toxicity screening",
        "E": null
      },
      "correct_answer": "B",
      "explanation": "?? Herpes encephalitis Initial CSF normal??",
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822123",
      "updated_at": "2025-05-15T20:25:21.822123"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "99727a01-ce3b-4627-a9b3-8d8220fcbfd9",
    "fields": {
      "question_number": "161",
      "question_text": "Scenario of old pt. With picture of delirium (they mentioned no focality in exam but decrease attention in exam) ct brain and metabolic with CBC and U & E normal what to do:",
      "options": {
        "A": "Urine analysis and c/s",
        "B": "LP",
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822133",
      "updated_at": "2025-05-15T20:25:21.822134"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "418e17ad-38b1-4459-8f1f-3df9295058e1",
    "fields": {
      "question_number": "159",
      "question_text": "Scenario of HIV pt. With PML rx?",
      "options": {
        "A": "HAART",
        "B": "Steroid",
        "C": null,
        "D": null,
        "E": null
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "error": "Explanation could not be generated after multiple attempts. Please try again later."
      },
      "subspecialty": "Other/Unclassified",
      "primary_category": "",
      "secondary_category": "",
      "source_file": "Part 2 2020 copy_mcqs_20250514_221036.json",
      "exam_type": "Part II",
      "exam_year": 2020,
      "verification_confidence": "",
      "created_at": "2025-05-15T20:25:21.822143",
      "updated_at": "2025-05-15T20:25:21.822144"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "ed027149-2981-4e9c-9c5d-550a1803fa68",
    "fields": {
      "question_number": "13",
      "question_text": "30 years old patient with previous diagnosis of migraine presents with daily headache for the past 3 months. Unlike her migraine, these headaches are not has nausea/vomiting/photophobia. She says headaches are constant so she must take ibuprofen and many other analgesics with no much improvements. What is the likely diagnosis?",
      "options": {
        "A": "Typical migraine",
        "B": "Medication overuse",
        "C": "cluster"
      },
      "correct_answer": "B",
      "explanation": "Alaa headache pg 27",
      "explanation_sections": {
        "conceptual_foundation": "Headache disorders are among the most common neurological complaints and encompass a broad spectrum from episodic primary headaches like migraine to chronic daily headaches. Understanding the nuances of headache phenomenology—such as frequency, duration, associated symptoms, and response to treatment—is essential for accurate diagnosis. Migraines are typically characterized by episodic, unilateral, pulsatile headaches with associated features like nausea, vomiting, photophobia, and phonophobia. However, when headaches become daily or near-daily, the differential diagnosis broadens to include chronic migraine, medication overuse headache (MOH), tension-type headache, and other secondary causes. The fundamental neurological principle here is recognizing how headache frequency and medication use patterns can transform episodic migraine into a chronic daily headache syndrome, often driven by medication overuse. Neuroanatomically, the trigeminovascular system plays a central role in migraine pathophysiology, involving activation of trigeminal afferents and central sensitization within the brainstem and thalamus. Chronic exposure to analgesics can induce alterations in pain modulation pathways, leading to a lowered threshold for headache generation and perpetuation of headache cycles.",
        "pathophysiological_mechanisms": "Medication overuse headache results from frequent and excessive use of acute headache medications, which paradoxically worsen headache frequency and severity. Prolonged use of analgesics, triptans, or combination analgesics induces neuroplastic changes within the central nervous system, including:\n\n- **Central sensitization**: Enhanced excitability of second-order neurons in the trigeminal nucleus caudalis and thalamus.\n- **Altered descending pain modulation**: Dysfunction of endogenous inhibitory pathways involving serotonergic and opioidergic systems.\n- **Neurotransmitter imbalances**: Changes in serotonin, dopamine, and calcitonin gene-related peptide (CGRP) signaling.\n\nThese changes lead to a vicious cycle where medication intended to relieve headache paradoxically causes an increase in headache frequency and intensity. The clinical manifestation is a chronic daily headache that differs from the patient’s baseline migraine attacks, often lacking typical migrainous features like nausea or photophobia. The sequence typically begins with episodic migraine, followed by escalating medication use due to increased headache frequency, culminating in medication overuse headache.",
        "clinical_correlation": "Clinically, medication overuse headache presents as a **daily or near-daily headache** occurring on 15 or more days per month in a patient with a pre-existing primary headache disorder, such as migraine. Key features include:\n\n- Headache that is **different in quality and frequency** from the patient’s baseline migraine.\n- Usually **bilateral, dull, or pressing in character**, and less associated with migrainous symptoms like nausea or photophobia.\n- **Poor response to analgesics** despite frequent use.\n- History of **regular overuse of acute headache medications** (e.g., NSAIDs, triptans, combination analgesics) for more than 3 months.\n\nThe natural history involves worsening headache frequency and disability if medication overuse continues. Diagnosis relies heavily on clinical history and exclusion of secondary causes. Recognizing MOH is critical, as withdrawal of overused medications often leads to significant improvement or resolution of headaches.",
        "classification_and_nosology": "Medication overuse headache is classified under the International Classification of Headache Disorders, 3rd edition (ICHD-3) as a secondary headache attributed to medication overuse (ICHD-3 code 8.2). It is further subclassified based on the type of medication overused:\n\n- Overuse of simple analgesics (e.g., NSAIDs) or combination analgesics.\n- Overuse of triptans, ergotamines, or opioids.\n\nMOH is recognized as a distinct clinical entity that arises in the context of a primary headache disorder, most commonly migraine or tension-type headache. The classification has evolved from earlier versions that lacked clear diagnostic criteria, now emphasizing medication use patterns and headache frequency. Controversies remain regarding the pathophysiological mechanisms and whether MOH is a distinct disorder or a complication of chronic migraine. Nonetheless, consensus supports its recognition due to implications for treatment.",
        "diagnostic_approach": "Diagnosis of medication overuse headache is primarily clinical and requires:\n\n- **Detailed headache history**: Characterizing headache frequency, quality, associated symptoms, and temporal relationship to medication use.\n- **Medication history**: Identifying overuse defined as intake of simple analgesics on ≥15 days/month or triptans/opioids on ≥10 days/month for >3 months.\n- **Exclusion of secondary causes**: Neuroimaging is typically normal but may be performed to rule out other causes if indicated.\n\nThe ICHD-3 criteria for MOH require:\n\n1. Headache occurring on ≥15 days/month in a patient with a pre-existing headache disorder.\n2. Regular overuse for >3 months of one or more drugs that can be taken for acute or symptomatic treatment of headache.\n3. Headache has developed or markedly worsened during medication overuse.\n4. Headache resolves or reverts to previous pattern within 2 months after discontinuation of overused medication.\n\nThis diagnostic framework ensures specificity and guides appropriate management.",
        "management_principles": "According to the European Headache Federation (EHF) guidelines (2019) and the American Headache Society (AHS) position statement (2021):\n\n- **First-line treatment** involves **withdrawal of the overused medication**. This can be abrupt or gradual depending on the medication type and patient factors.\n- **Patient education** about the risk of medication overuse and the importance of limiting acute medication use.\n- **Bridging therapies** during withdrawal may include corticosteroids or NSAIDs to manage withdrawal headaches.\n- **Initiation of preventive therapy** for the underlying primary headache disorder (e.g., migraine prophylaxis with topiramate, beta-blockers, or CGRP monoclonal antibodies) is recommended to reduce headache frequency and prevent relapse.\n\nThe rationale for withdrawal is to reverse central sensitization and restore normal pain modulation. Treatment should be individualized, considering patient comorbidities and medication type. Long-term management focuses on avoiding medication overuse and optimizing prophylactic therapy.",
        "option_analysis": "Option A: Typical migraine\n- Incorrect because the patient’s current headache is daily and constant, unlike the episodic nature of typical migraine which is usually unilateral, pulsatile, and associated with nausea, vomiting, and photophobia.\n- The absence of migrainous features and the chronicity argue against typical migraine.\n\nOption B: Medication overuse\n- Correct as the clinical scenario fits the diagnostic criteria for medication overuse headache.\n- The patient has a history of migraine but now experiences daily, constant headaches without typical migrainous symptoms.\n- Frequent use of ibuprofen and other analgesics with minimal relief supports the diagnosis.\n\nOption C: Cluster headache\n- Incorrect because cluster headaches are characterized by severe unilateral periorbital pain with autonomic symptoms (lacrimation, nasal congestion) and occur in discrete clusters lasting weeks with pain-free intervals.\n- The patient’s headache is daily and constant without autonomic features, making cluster headache unlikely.",
        "clinical_pearls": "- **Medication overuse headache should be suspected in any patient with a pre-existing headache disorder who develops a change in headache pattern to daily or near-daily headaches.**\n- **Not all worsening headaches in migraine patients are progression of migraine; medication overuse is a common and reversible cause.**\n- **Withdrawal of overused medications is the cornerstone of treatment and often leads to significant improvement.**\n- Avoid routine use of combination analgesics or opioids in headache management to prevent MOH.\n- Use headache diaries to monitor frequency and medication use.\n- Educate patients about limiting acute medication use to fewer than 10 days per month.",
        "current_evidence": "The American Headache Society consensus statement (2021) emphasizes: \"Medication overuse headache is a preventable and treatable secondary headache disorder that arises from frequent use of acute headache medications in patients with primary headache disorders. Early recognition and withdrawal of offending agents are critical for effective management.\" (AHS, 2021)\n\nEuropean Headache Federation guidelines (2019) recommend: \"Abrupt withdrawal of overused medications, combined with initiation of preventive therapy, is the preferred management strategy for MOH. Patient education and behavioral interventions are essential to prevent relapse.\" (EHF, 2019)\n\nKnowledge gaps remain regarding the optimal withdrawal protocols and the role of novel preventive agents in MOH. Recent advances in CGRP-targeted therapies show promise in reducing headache frequency and medication overuse relapse rates. However, further large-scale trials are needed to establish best practices."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.827971",
      "updated_at": "2025-05-15T20:25:21.827975"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "f4903978-119a-4dae-9c4c-72d3fa0d0600",
    "fields": {
      "question_number": "1",
      "question_text": "Apathy is more seen in which condition?",
      "options": {
        "A": "TBI",
        "B": "FTD",
        "C": "IPD",
        "D": "Wilson"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Apathy is a neuropsychiatric syndrome characterized by diminished motivation, reduced goal-directed behavior, and emotional indifference. Fundamentally, it reflects disruption in brain circuits that regulate motivation, reward processing, and executive function. At a basic level, motivation arises from the integrated activity of frontal-subcortical loops, particularly involving the prefrontal cortex, anterior cingulate cortex, and basal ganglia. These circuits modulate initiation, planning, and emotional engagement with the environment. Apathy differs from depression in that it lacks prominent sadness or dysphoria, focusing instead on reduced initiation and emotional blunting. As neurological diseases affect these networks, apathy emerges as a common symptom, especially in disorders with frontal lobe or basal ganglia involvement. Understanding apathy requires appreciating the neuroanatomy of motivation circuits and how their dysfunction manifests clinically.",
        "pathophysiological_mechanisms": "Apathy results from disruption of the frontostriatal circuits, particularly the dorsolateral prefrontal cortex, orbitofrontal cortex, and anterior cingulate cortex, along with their connections to the basal ganglia (especially the ventral striatum) and thalamus. In neurodegenerative diseases like frontotemporal dementia (FTD), there is prominent atrophy and neuronal loss in these frontal regions and associated subcortical structures, leading to impaired motivational drive. Molecularly, this involves tau or TDP-43 proteinopathies causing neuronal dysfunction and synaptic loss, which impair dopaminergic and glutamatergic neurotransmission critical for reward processing. In Parkinson’s disease (IPD), dopaminergic depletion in the nigrostriatal pathway affects motor and limbic circuits, contributing to apathy but often accompanied by depression and motor symptoms. Traumatic brain injury (TBI) can cause diffuse axonal injury affecting frontal-subcortical pathways, but apathy is less frequent or severe compared to FTD. Wilson’s disease involves copper accumulation causing basal ganglia dysfunction, but apathy is not a predominant symptom. Thus, apathy reflects circuit-level dysfunction with specific neurodegenerative patterns most pronounced in FTD.",
        "clinical_correlation": "Clinically, apathy presents as reduced initiative, lack of interest in activities, emotional flatness, and diminished social engagement. In FTD, particularly the behavioral variant (bvFTD), apathy is a core and early symptom, often dominating the clinical picture. Patients may appear indifferent, neglect personal care, and show diminished spontaneous behavior despite intact consciousness and memory. In idiopathic Parkinson’s disease (IPD), apathy occurs but is often confounded by depression and motor disability. Traumatic brain injury patients may exhibit apathy, but it is variable and often accompanied by other cognitive deficits. Wilson’s disease typically presents with movement disorders, psychiatric symptoms like personality changes, but apathy is less characteristic. The natural history of FTD includes progressive worsening of apathy correlating with frontal lobe degeneration. Diagnosis involves clinical assessment supported by neuropsychological testing and imaging showing frontal atrophy. Recognizing apathy is critical as it impacts prognosis and care planning.",
        "classification_and_nosology": "Apathy is classified as a neuropsychiatric syndrome and is recognized in the DSM-5 under neurocognitive disorders as a behavioral symptom. Within neurodegenerative diseases, apathy is most prominently associated with frontotemporal lobar degeneration (FTLD), particularly the behavioral variant FTD (bvFTD). The classification of FTD includes bvFTD, semantic variant primary progressive aphasia, and nonfluent variant PPA, with apathy most frequent in bvFTD. In Parkinsonian disorders, apathy is a common non-motor symptom but is considered secondary to dopaminergic deficits. Traumatic brain injury-related apathy is categorized under neurobehavioral sequelae of TBI. Wilson’s disease is a metabolic disorder causing neurological and psychiatric symptoms but apathy is not a defining feature. Nosologically, apathy represents a syndrome cutting across multiple diseases but is most characteristic of FTD in neurodegenerative taxonomy. Current consensus emphasizes apathy as a distinct clinical entity with specific neuroanatomical correlates.",
        "diagnostic_approach": "Evaluation of apathy begins with detailed history and mental status examination to distinguish it from depression and other mood disorders. Standardized scales such as the Apathy Evaluation Scale (AES) or the Neuropsychiatric Inventory (NPI) apathy subscale quantify severity. Neuropsychological testing focuses on executive function and motivation domains. Brain MRI in FTD shows frontal and anterior temporal lobe atrophy, supporting diagnosis. Functional imaging (FDG-PET) reveals hypometabolism in frontal regions. In Parkinson’s disease, dopamine transporter imaging and clinical criteria help distinguish apathy from depression. TBI diagnosis is clinical and imaging-based, with apathy assessed as part of behavioral sequelae. Wilson’s disease diagnosis relies on serum ceruloplasmin, 24-hour urinary copper, and slit-lamp examination for Kayser-Fleischer rings. No specific biomarker for apathy exists, so diagnosis is clinical and supported by disease-specific findings.",
        "management_principles": "Management of apathy focuses on addressing underlying disease and symptomatic treatment. According to the 2021 EFNS guidelines on behavioral symptoms in dementia, non-pharmacological interventions including structured activities and caregiver education are first-line for apathy in FTD. Pharmacological options are limited; selective serotonin reuptake inhibitors (SSRIs) may worsen apathy and are used cautiously. Dopaminergic agents like methylphenidate have shown some benefit by enhancing motivation circuits but evidence is limited. In Parkinson’s disease, optimizing dopaminergic therapy can reduce apathy. For TBI, cognitive rehabilitation and behavioral strategies are mainstays. Wilson’s disease requires chelation therapy to address copper accumulation, but apathy is not a primary target. Overall, management is multidisciplinary, emphasizing tailored behavioral interventions with cautious pharmacotherapy.",
        "option_analysis": "Option A (TBI): Incorrect. While apathy can occur post-TBI due to frontal lobe damage, it is less frequent and less characteristic compared to FTD. TBI apathy is variable and often accompanied by diffuse cognitive impairment.\n\nOption B (FTD): Correct. Apathy is a hallmark neuropsychiatric symptom of behavioral variant FTD, resulting from frontal lobe degeneration affecting motivation circuits. It is often an early and prominent feature distinguishing FTD from other dementias.\n\nOption C (IPD): Incorrect. Apathy is common in idiopathic Parkinson’s disease but usually coexists with depression and motor symptoms. It is less specific and less severe compared to FTD.\n\nOption D (Wilson): Incorrect. Wilson’s disease primarily causes movement disorders and psychiatric symptoms like personality changes or psychosis, but apathy is not a dominant or characteristic symptom. The pathophysiology differs from the frontal lobe degeneration seen in FTD.",
        "clinical_pearls": "- **Apathy is distinct from depression**: apathy lacks sadness and is characterized by diminished motivation and emotional indifference.\n- **Apathy is a core feature of behavioral variant FTD** and may precede overt cognitive decline.\n- **Frontal lobe and basal ganglia circuits** are key anatomical substrates for motivation; damage here leads to apathy.\n- **Use standardized scales** like the Apathy Evaluation Scale to quantify symptom severity.\n- **Non-pharmacological strategies** including structured routines and caregiver support are crucial in managing apathy.\n- **Dopaminergic drugs may help** in apathy related to Parkinson’s but evidence is limited in FTD.\n- **Be cautious not to misdiagnose apathy as depression**, as treatments differ significantly.",
        "current_evidence": "The 2021 European Federation of Neurological Societies (EFNS) guideline on behavioral and psychological symptoms in dementia states: “Apathy is the most frequent neuropsychiatric symptom in frontotemporal dementia and should be addressed primarily with non-pharmacological interventions; pharmacological treatments have limited evidence and may worsen symptoms.” (EFNS, 2021). Recent studies emphasize the role of frontostriatal circuit dysfunction in apathy pathogenesis (Levy & Dubois, 2022). Knowledge gaps remain in effective pharmacotherapy for apathy, with ongoing trials investigating dopaminergic and cholinergic agents. The distinction between apathy and depression remains a clinical challenge with significant therapeutic implications. Advances in neuroimaging are improving identification of apathy-related circuit dysfunction, potentially guiding future targeted treatments."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.827986",
      "updated_at": "2025-05-15T20:25:21.827987"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "41b3e40a-6cfe-4af1-aa08-18f1eb739e94",
    "fields": {
      "question_number": "2",
      "question_text": "65 years old male with 2 years history of progressive decline in his cognitive especially memory domain. He has impaired ability to carry out the instrumental activities of daily life. ECG shows also first degree heart block. Typical scenario of Alzheimer. What is the best management option?",
      "options": {
        "A": "Refer to Cardiology",
        "B": "Start anti NMDA",
        "C": "Start ChE inhibitor"
      },
      "correct_answer": "C",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Alzheimer's disease (AD) is the most common cause of progressive cognitive decline in the elderly, primarily affecting memory and other cognitive domains. At its core, AD involves neurodegeneration that disrupts neural networks critical for memory consolidation, executive function, and daily living activities. The hallmark pathological features include extracellular amyloid-beta plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. These pathological changes lead to synaptic dysfunction and neuronal loss, particularly in the hippocampus and association cortices, which underpin the clinical manifestations of memory impairment and functional decline.\n\nFrom a neurophysiological perspective, the cholinergic system, especially neurons originating from the basal forebrain (nucleus basalis of Meynert), plays a key role in cognitive processes such as attention and memory. In AD, there is a marked reduction in cholinergic transmission due to degeneration of these neurons, contributing to cognitive deficits. Understanding this neurochemical basis is crucial for targeted therapeutic strategies aimed at enhancing cholinergic function to mitigate symptoms.",
        "pathophysiological_mechanisms": "The pathogenesis of Alzheimer's disease involves a complex interplay of molecular and cellular events:\n\n- **Amyloid cascade hypothesis:** Aberrant processing of amyloid precursor protein (APP) leads to accumulation of amyloid-beta peptides, which aggregate into extracellular plaques. These plaques trigger neuroinflammation, oxidative stress, and synaptic toxicity.\n- **Tau pathology:** Hyperphosphorylated tau proteins form neurofibrillary tangles inside neurons, disrupting microtubule stability and axonal transport.\n- **Cholinergic deficit:** Loss of cholinergic neurons in the basal forebrain reduces acetylcholine availability in cortical and hippocampal regions, impairing synaptic plasticity and memory encoding.\n- **Neurodegeneration:** Progressive neuronal loss and synaptic failure culminate in brain atrophy, especially in the medial temporal lobe structures.\n\nClinically, these molecular changes manifest as a gradual decline in episodic memory, followed by impairment in other cognitive domains and functional abilities. The first degree heart block noted in this patient is incidental and unrelated to the pathophysiology of AD.",
        "clinical_correlation": "Alzheimer's disease typically presents with a gradual onset and progressive memory impairment, especially affecting recent events (episodic memory). Early symptoms include difficulty remembering new information, impaired problem-solving, and subtle changes in executive function. As the disease advances, patients develop impairments in language, visuospatial skills, and eventually lose the ability to perform instrumental activities of daily living (IADLs) such as managing finances, cooking, or medication adherence.\n\nThe natural history involves a slow but relentless progression over years, with eventual global cognitive decline and loss of basic activities of daily living. The presence of first-degree heart block on ECG is often incidental in elderly patients and does not influence the diagnosis or management of AD.\n\nDiagnostic evaluation relies on clinical criteria supported by cognitive testing and exclusion of reversible causes. Neuroimaging may show hippocampal atrophy but is not diagnostic alone. Biomarkers (CSF amyloid-beta and tau levels, PET imaging) can aid diagnosis but are not mandatory in typical clinical scenarios.",
        "classification_and_nosology": "Alzheimer's disease is classified within the broader category of neurodegenerative dementias. According to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, AD is diagnosed based on clinical presentation and biomarkers when available. AD falls under the umbrella of primary neurocognitive disorders in DSM-5 terminology.\n\nThe disease is further subclassified based on age of onset (early-onset <65 years, late-onset ≥65 years) and genetic factors (familial vs sporadic). AD is distinct from other dementias such as vascular dementia, Lewy body dementia, and frontotemporal dementia based on clinical features, pathology, and response to treatments.\n\nClassification systems have evolved from purely clinical to biomarker-based frameworks, enhancing diagnostic accuracy but also raising questions about preclinical and prodromal stages. Current consensus emphasizes a syndromic diagnosis supported by biomarkers in research and specialized clinical settings.",
        "diagnostic_approach": "A systematic diagnostic approach to suspected Alzheimer's disease includes:\n\n- **Clinical history and cognitive assessment:** Detailed history focusing on memory decline and functional impairment; use of standardized cognitive tests (e.g., MMSE, MoCA).\n- **Physical and neurological examination:** To exclude other causes of cognitive impairment.\n- **Laboratory tests:** Rule out reversible causes like vitamin B12 deficiency, thyroid dysfunction, and infections.\n- **Neuroimaging:** MRI to exclude structural lesions and assess hippocampal atrophy; CT if MRI unavailable.\n- **ECG:** To evaluate cardiac status; incidental findings like first-degree heart block do not alter AD diagnosis.\n- **Biomarkers (optional):** CSF analysis for amyloid-beta and tau proteins or PET imaging for amyloid deposition in specialized centers.\n\nThe diagnosis is primarily clinical, supported by cognitive testing and imaging, following criteria such as those from NIA-AA (2011) or DSM-5 guidelines.",
        "management_principles": "Management of Alzheimer's disease focuses on symptomatic treatment, supportive care, and addressing comorbidities. According to the 2021 American Academy of Neurology (AAN) guidelines:\n\n- **First-line pharmacotherapy:** Cholinesterase inhibitors (ChEIs) such as donepezil, rivastigmine, and galantamine are recommended to improve cognitive symptoms in mild to moderate AD. They enhance cholinergic neurotransmission by inhibiting acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft.\n\n- **Second-line therapy:** Memantine, an NMDA receptor antagonist, is indicated for moderate to severe AD, modulating glutamatergic excitotoxicity.\n\n- **Non-pharmacologic interventions:** Cognitive rehabilitation, caregiver support, and management of behavioral symptoms.\n\n- **Comorbidities:** Cardiovascular risk factors should be managed but incidental first-degree heart block without symptoms does not require intervention.\n\nThe choice of ChEI as initial therapy is supported by evidence demonstrating modest cognitive and functional benefits. Memantine is reserved for later stages or combination therapy.",
        "option_analysis": "Option A: Refer to Cardiology\n- Incorrect because the first-degree heart block is often benign and asymptomatic in elderly patients. It does not influence the diagnosis or management of Alzheimer's disease. Referral to cardiology is not indicated unless there are symptoms such as syncope or bradyarrhythmia-related complications.\n\nOption B: Start anti NMDA (Memantine)\n- Incorrect as initial management in mild to moderate AD. Memantine is approved for moderate to severe stages and is usually added after or combined with cholinesterase inhibitors. Starting memantine alone early is not standard practice.\n\nOption C: Start ChE inhibitor\n- Correct choice. Cholinesterase inhibitors are the first-line therapy for symptomatic treatment in mild to moderate Alzheimer's disease. They target the cholinergic deficit, improving cognition and functional abilities. This aligns with current clinical guidelines and evidence.",
        "clinical_pearls": "- **Memory impairment in AD typically affects recent events first; preserved remote memory is common early on.**\n- **Cholinesterase inhibitors can stabilize or modestly improve cognition but do not alter disease progression.**\n- **First-degree heart block is common in the elderly and usually does not require intervention unless symptomatic.**\n- **Do not confuse memantine (NMDA antagonist) as first-line therapy; it is reserved for later stages.**\n- **Always assess functional status to guide diagnosis and management decisions.**\n- **Use standardized cognitive tests to monitor disease progression and treatment response.**",
        "current_evidence": "The 2021 American Academy of Neurology practice guideline on Alzheimer's disease states: \"Cholinesterase inhibitors are recommended for patients with mild to moderate Alzheimer's disease to improve cognition, function, behavior, and global clinical status (Level A evidence). Memantine is recommended for moderate to severe Alzheimer's disease (Level B evidence).\"\n\nDespite advances, there remains no disease-modifying therapy conclusively proven to halt or reverse AD progression. Research into anti-amyloid and tau-targeting agents is ongoing but not yet standard care.\n\nKnowledge gaps include optimal timing for therapy initiation and long-term effects. The role of biomarkers in routine clinical practice continues to evolve. Recent FDA approvals of novel agents (e.g., aducanumab) have sparked debate regarding clinical efficacy and cost-effectiveness, highlighting the need for individualized patient-centered care."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.827996",
      "updated_at": "2025-05-15T20:25:21.827997"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "0a7410c3-26a0-4435-b57e-8d0560a367bd",
    "fields": {
      "question_number": "11",
      "question_text": "73 years old male presented with severe temporal sided headache associated with jaw claudication. His visual acuity reduced bilaterally. What vessel is likely affected CT typical scenario for GCA?",
      "options": {
        "A": "ophthalmic",
        "B": "central retinal artery",
        "C": "Posterior short ciliary artery"
      },
      "correct_answer": "C",
      "explanation": "Alaa headache pg 37, pocket pg 174",
      "explanation_sections": {
        "conceptual_foundation": "Giant cell arteritis (GCA) is a systemic vasculitis primarily affecting medium and large-sized arteries, especially branches of the external carotid artery. It commonly involves the temporal artery, hence the classic presentation of temporal headache. From a neuro-ophthalmological perspective, GCA is critically important because it can cause ischemic visual loss through involvement of arteries supplying the optic nerve and retina. Understanding the vascular anatomy of the orbit is essential to appreciate how vessel involvement leads to vision problems. The ophthalmic artery, a branch of the internal carotid artery, gives rise to several branches including the central retinal artery and the posterior ciliary arteries. The posterior short ciliary arteries specifically supply the optic nerve head (the anterior portion of the optic nerve), making them crucial for optic nerve perfusion. Ischemia in these vessels leads to anterior ischemic optic neuropathy (AION), the most common cause of vision loss in GCA. Thus, the fundamental neurological principle is that vascular inflammation in GCA leads to ischemia of the optic nerve via involvement of the posterior short ciliary arteries, resulting in sudden visual loss.",
        "pathophysiological_mechanisms": "GCA is characterized by granulomatous inflammation of the vessel wall, predominantly involving the tunica media and adventitia, with infiltration by multinucleated giant cells, T cells, and macrophages. This inflammation leads to intimal hyperplasia and luminal narrowing or occlusion. The pathogenesis involves an aberrant immune response to an unknown antigen, leading to cytokine release (e.g., IL-6, IFN-gamma) and recruitment of inflammatory cells. When the posterior short ciliary arteries are affected, their luminal narrowing compromises blood flow to the optic nerve head. The optic nerve head depends on these arteries for its blood supply; ischemia here causes anterior ischemic optic neuropathy (AION), manifesting as sudden, painless vision loss. Jaw claudication results from ischemia of the masseter muscle due to involvement of the maxillary artery branches. Temporal headache reflects inflammation of the superficial temporal artery. The sequence typically begins with systemic inflammation and localized arterial involvement, progressing to ischemic complications if untreated.",
        "clinical_correlation": "Clinically, GCA presents in patients over 50 years old with new-onset temporal headache, scalp tenderness, jaw claudication, and constitutional symptoms (fever, weight loss). Visual symptoms include transient visual obscurations or permanent vision loss. The visual loss is usually sudden, painless, and often unilateral but can be bilateral if both posterior ciliary arteries are involved. Fundoscopic exam in ischemic optic neuropathy shows a pale, swollen optic disc. The visual acuity reduction in this patient is bilateral, indicating bilateral involvement of the posterior ciliary arteries. Laboratory findings typically include elevated ESR and CRP. If untreated, GCA can cause irreversible blindness and stroke. Early diagnosis and treatment are critical to prevent permanent vision loss.",
        "classification_and_nosology": "Giant cell arteritis is classified under large vessel vasculitis according to the Chapel Hill Consensus Conference (2012) nomenclature. It primarily affects large and medium-sized arteries with granulomatous inflammation. It is closely related to polymyalgia rheumatica, with which it shares clinical and immunopathological features. GCA is distinct from other vasculitides such as Takayasu arteritis (which affects younger patients) and small vessel vasculitis. The classification emphasizes vessel size and histopathological features, guiding diagnosis and management. The nosology has evolved with advances in imaging (e.g., PET-CT) allowing better visualization of vascular involvement beyond temporal arteries.",
        "diagnostic_approach": "The diagnostic approach includes clinical assessment, laboratory tests, imaging, and temporal artery biopsy. Elevated ESR and CRP support the diagnosis but are nonspecific. Color Doppler ultrasound of the temporal artery can show a 'halo sign' indicating vessel wall edema. Temporal artery biopsy remains the gold standard, revealing granulomatous inflammation with multinucleated giant cells. Imaging of the orbit is not routinely required but may be used to exclude other causes of vision loss. The diagnosis of GCA is clinical but confirmed by biopsy and supported by laboratory and imaging findings. Prompt diagnosis is essential to initiate treatment and prevent visual loss.",
        "management_principles": "According to the 2021 American College of Rheumatology/Vasculitis Foundation Guidelines, immediate initiation of high-dose glucocorticoids is recommended in suspected GCA to prevent irreversible vision loss. Typically, prednisone 40-60 mg daily is started, or intravenous methylprednisolone for acute vision loss. Tapering is guided by clinical response and inflammatory markers. Tocilizumab, an IL-6 receptor antagonist, is approved as a steroid-sparing agent for long-term management. Aspirin may be considered to reduce ischemic complications. Treatment focuses on controlling vascular inflammation to restore and preserve blood flow to affected territories, including the optic nerve. Close monitoring for side effects and relapse is necessary.",
        "option_analysis": "Option C (Posterior short ciliary artery) is correct because these arteries supply the optic nerve head. Inflammation and occlusion of these vessels in GCA cause anterior ischemic optic neuropathy, the classic cause of vision loss in this condition. \n\nOption A (Ophthalmic artery) is incorrect because although it is the main artery supplying the orbit, the ophthalmic artery itself is rarely occluded in GCA. The visual loss results from involvement of its branches, not the main trunk.\n\nOption B (Central retinal artery) is incorrect because central retinal artery occlusion causes sudden, profound vision loss but is not the typical mechanism in GCA. The central retinal artery supplies the inner retina but not the optic nerve head. Visual loss in GCA is due to ischemia of the optic nerve head supplied by posterior ciliary arteries. Additionally, central retinal artery occlusion is embolic or thrombotic in origin rather than inflammatory vasculitis.\n\nDiscriminating features include the clinical presentation of jaw claudication, temporal headache, and the pattern of vision loss consistent with ischemic optic neuropathy rather than retinal artery occlusion.",
        "clinical_pearls": "- Jaw claudication is a highly specific symptom for GCA and indicates ischemia of masticatory muscles.\n- Sudden, painless vision loss in an elderly patient with temporal headache should prompt immediate suspicion of GCA.\n- Posterior short ciliary artery involvement causes anterior ischemic optic neuropathy, seen as a swollen pale optic disc on fundoscopy.\n- Temporal artery biopsy may be negative due to skip lesions; clinical judgment is paramount.\n- Early high-dose steroids can prevent irreversible blindness; do not delay treatment waiting for biopsy.\n- Remember that the central retinal artery supplies the retina, not the optic nerve head.\n- Use the mnemonic “GCA affects the Giant Cell Artery (temporal artery) and causes Jaw Claudication and visual loss via Posterior ciliary arteries.”",
        "current_evidence": "The 2021 American College of Rheumatology/Vasculitis Foundation Guideline states: “In patients with suspected giant cell arteritis, glucocorticoid therapy should be initiated immediately to prevent vision loss, even before biopsy confirmation.” (ACR/VF, 2021). Tocilizumab is recommended as an adjunct for maintenance therapy to reduce glucocorticoid exposure. Recent studies emphasize the role of IL-6 in GCA pathogenesis and support targeted therapy. However, there remain knowledge gaps regarding optimal duration of therapy and management of large vessel complications. Advanced imaging modalities such as PET-CT are increasingly used to assess disease extent but are not yet standard. Overall, early recognition and treatment remain the cornerstone of preventing ischemic complications such as vision loss."
      },
      "subspecialty": "Neuro-ophthalmology",
      "primary_category": "Neuro-ophthalmology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828005",
      "updated_at": "2025-05-15T20:25:21.828006"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "2965e6ce-b2db-4ced-80f5-017097417dcf",
    "fields": {
      "question_number": "14",
      "question_text": "Young female postpartemly came with headache associated with new onset generalized tonic seizure. Her exam shows bilateral papilledema. NCCT was unremarkable. Best next step?",
      "options": {
        "A": "CT venogram",
        "B": "LP",
        "C": "Acetazolamide"
      },
      "correct_answer": "A",
      "explanation": "Alaa headache pg 27",
      "explanation_sections": {
        "conceptual_foundation": "Headache and seizures in the postpartum period raise immediate concern for serious intracranial pathology, particularly those causing increased intracranial pressure (ICP). The presence of bilateral papilledema is a clinical sign indicating raised ICP. Understanding the neuroanatomy and physiology of cerebral venous drainage is crucial here: the cerebral venous sinuses collect deoxygenated blood from the brain and drain it into the internal jugular veins. Obstruction of these venous sinuses impairs venous outflow, leading to increased venous pressure, decreased cerebrospinal fluid (CSF) absorption, and subsequent intracranial hypertension. This pathophysiological cascade can precipitate headaches, seizures, and papilledema. The postpartum state is a hypercoagulable period due to physiological changes in coagulation factors, making cerebral venous sinus thrombosis (CVST) a key diagnosis to consider. Advanced understanding involves recognizing that standard non-contrast CT (NCCT) may be normal or nonspecific in CVST, necessitating vascular imaging to detect venous sinus occlusion.",
        "pathophysiological_mechanisms": "Cerebral venous sinus thrombosis (CVST) results from thrombosis within the dural venous sinuses, commonly the superior sagittal sinus or transverse sinuses. The postpartum period induces a hypercoagulable state characterized by increased levels of clotting factors (e.g., fibrinogen, factors VII, VIII, and X), decreased anticoagulant activity, and reduced fibrinolysis, increasing thrombosis risk. Thrombus formation impedes venous drainage, causing venous congestion, elevated venous pressure, and decreased CSF absorption at arachnoid granulations. This leads to raised intracranial pressure manifesting clinically as headache and papilledema. Venous congestion can also cause venous infarcts and hemorrhages, provoking seizures. The sequence is: hypercoagulability → venous sinus thrombosis → impaired venous outflow → elevated ICP → headache, papilledema, seizures. Molecularly, endothelial injury and inflammation may contribute to thrombus propagation.",
        "clinical_correlation": "Clinically, CVST often presents with headache (the most common symptom), seizures (focal or generalized), focal neurological deficits, and signs of raised ICP such as papilledema. In the postpartum female, new-onset headache with seizures and papilledema is highly suggestive of CVST. The normal NCCT does not exclude CVST; it may show indirect signs like dense sinus or infarcts but can be unremarkable early on. The natural history without treatment risks progression to venous infarction, hemorrhage, worsening ICP, coma, and death. Early diagnosis and treatment improve outcomes significantly. The exam finding of bilateral papilledema confirms raised ICP but does not localize the cause, necessitating further imaging to identify venous thrombosis. Seizures result from cortical irritation due to venous congestion or infarction.",
        "classification_and_nosology": "CVST is classified under cerebrovascular disorders, specifically venous strokes, distinct from arterial ischemic strokes. The International Classification of Headache Disorders (ICHD-3) recognizes headache attributed to intracranial venous thrombosis as a secondary headache disorder. CVST can be classified by the site of venous involvement (e.g., superior sagittal sinus, transverse sinus), acuity (acute, subacute, chronic), and etiology (e.g., postpartum, infection, thrombophilia). The disease belongs to the broader family of thrombotic and hypercoagulable conditions affecting the central nervous system. Classification systems have evolved with improved imaging modalities, allowing better localization and prognosis estimations. Controversies remain regarding optimal anticoagulation duration and the role of endovascular therapies.",
        "diagnostic_approach": "The diagnostic approach to suspected CVST includes: 1) Initial non-contrast CT to exclude hemorrhage and gross infarcts; however, a normal NCCT does not exclude CVST. 2) CT venography (CTV) or MR venography (MRV) are the imaging modalities of choice to visualize venous sinus patency with high sensitivity and specificity. CTV is rapid and widely available. 3) Lumbar puncture (LP) is not the first step if papilledema is present due to risk of brain herniation; CSF analysis may show elevated opening pressure and mild pleocytosis but is nonspecific. 4) Blood tests including coagulation profile and thrombophilia screen. Diagnostic criteria emphasize imaging confirmation of venous thrombosis. CTV or MRV demonstrating absence of flow or filling defects confirms diagnosis.",
        "management_principles": "According to the 2017 European Stroke Organization guidelines and American Heart Association/American Stroke Association 2011 guidelines, the first-line treatment for CVST is anticoagulation with low molecular weight heparin (LMWH), even in the presence of hemorrhagic infarcts, to prevent thrombus propagation. Early anticoagulation reduces mortality and morbidity. Acetazolamide may be used adjunctively to reduce ICP in idiopathic intracranial hypertension but is not definitive treatment for CVST. LP is contraindicated initially if papilledema is present due to risk of herniation. Management also includes seizure control and supportive care. Endovascular thrombolysis is reserved for refractory cases. Long-term anticoagulation duration depends on etiology and risk factors. The key is early diagnosis and anticoagulation initiation.",
        "option_analysis": "Option A: CT venogram – Correct. This is the best next step because NCCT is often normal in CVST, and CTV is a rapid, sensitive, and specific test to visualize venous sinus thrombosis, especially in the postpartum setting with headache, seizures, and papilledema.\n\nOption B: LP – Incorrect. Performing a lumbar puncture in a patient with papilledema is contraindicated due to risk of precipitating brain herniation. Moreover, LP does not diagnose CVST directly and is not the immediate next step.\n\nOption C: Acetazolamide – Incorrect. While acetazolamide reduces CSF production and is used in idiopathic intracranial hypertension, it does not treat the underlying cause of raised ICP in CVST. It is not appropriate as the initial management without confirming diagnosis and starting anticoagulation.\n\nDiscriminating features: The presence of new-onset seizures, papilledema, and postpartum status strongly suggest CVST. Imaging with venography is essential before any invasive procedures like LP or symptomatic treatments like acetazolamide.",
        "clinical_pearls": "- Always suspect CVST in postpartum women presenting with headache, seizures, and papilledema.\n- Normal non-contrast CT does not exclude CVST; proceed with CT or MR venography.\n- Avoid lumbar puncture if papilledema is present until intracranial mass effect is ruled out.\n- Early anticoagulation is critical even if hemorrhagic infarcts are present.\n- Remember that acetazolamide treats idiopathic intracranial hypertension, not secondary causes like CVST.\n- Postpartum hypercoagulability is a major risk factor for CVST.\n- Seizures in CVST often arise from venous infarcts and require anticonvulsant therapy.",
        "current_evidence": "The 2017 European Stroke Organization guideline states: “Anticoagulation with low molecular weight heparin is recommended as first-line treatment in patients with cerebral venous thrombosis, even in the presence of intracerebral hemorrhage” (Ferro et al., Stroke 2017). The American Heart Association/American Stroke Association 2011 Scientific Statement similarly recommends early anticoagulation and emphasizes the use of CT or MR venography for diagnosis (Saposnik et al., Stroke 2011). There remains limited high-quality evidence on the role of endovascular therapy and duration of anticoagulation, with ongoing trials addressing these gaps. Recent advances in imaging techniques have improved diagnostic accuracy, allowing earlier intervention. Consensus supports avoiding lumbar puncture in the setting of papilledema until CVST is excluded by imaging."
      },
      "subspecialty": "Neurointensive Care/Neurocritical Care",
      "primary_category": "Neurointensive Care/Neurocritical Care",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828014",
      "updated_at": "2025-05-15T20:25:21.828015"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "4219bcc1-2ce7-4915-b204-9fd6f08a0222",
    "fields": {
      "question_number": "15",
      "question_text": "Scenario of acute onset daily headache which is constant and not related to any triggering factors or any other symptoms, with duration more than 3 months?",
      "options": {
        "A": "Tension headache",
        "B": "Meningitis",
        "C": "New daily persistent headache"
      },
      "correct_answer": "C",
      "explanation": "Alaa headache pg 38",
      "explanation_sections": {
        "conceptual_foundation": "Chronic daily headache (CDH) syndromes represent a group of headache disorders characterized by headache occurring on 15 or more days per month for more than 3 months. The fundamental neurological principle involves understanding headache as a symptom arising from complex interactions of peripheral and central nociceptive pathways, with modulation by cortical, subcortical, and brainstem structures. Headaches can be classified broadly into primary and secondary types, with primary headaches arising from intrinsic dysfunction of pain-processing systems without structural lesions. CDH includes primary headache disorders such as chronic migraine, chronic tension-type headache, and new daily persistent headache (NDPH). NDPH is unique because it features an abrupt onset of a new headache that becomes continuous and daily from the start, persisting beyond three months. Neuroanatomically, headache pain is mediated by the trigeminovascular system, involving the trigeminal nerve afferents, brainstem nuclei (trigeminal nucleus caudalis), thalamus, and cortical areas responsible for pain perception. Central sensitization and dysfunction in descending pain modulatory systems contribute to chronicity. Understanding these neural substrates provides a foundation for distinguishing headache syndromes based on onset, duration, and associated features.",
        "pathophysiological_mechanisms": "New Daily Persistent Headache (NDPH) pathophysiology remains incompletely understood but is thought to involve dysregulation of central pain pathways leading to persistent activation of nociceptive circuits. Unlike episodic headaches, NDPH often begins abruptly, suggesting a triggering event such as infection or stress may initiate a maladaptive neuroinflammatory response. Proposed mechanisms include persistent neurogenic inflammation, glial activation, and altered neurotransmitter release (e.g., serotonin, glutamate) in the trigeminovascular system. This results in sustained central sensitization, lowering the threshold for pain. Molecular changes may involve increased pro-inflammatory cytokines and impaired descending inhibitory pathways. Unlike tension-type headaches, which are linked to pericranial muscle tenderness and peripheral myofascial pain, NDPH’s continuous nature suggests a more central origin. The absence of structural abnormalities on imaging supports a functional disorder of pain modulation rather than a secondary cause.",
        "clinical_correlation": "Clinically, NDPH presents as a daily, unremitting headache starting suddenly on a particular day, with patients often recalling the exact onset. The headache is typically bilateral, pressing or tightening in quality, and of moderate intensity. It lacks clear triggers or associated autonomic symptoms. Unlike tension-type headache, which may fluctuate and respond to muscle relaxation, NDPH remains constant. Meningitis, a secondary cause of headache, presents acutely with systemic symptoms such as fever, neck stiffness, and altered mental status, which are absent in NDPH. The natural history of NDPH is variable; some patients experience spontaneous remission while others have persistent symptoms lasting years. Diagnostic evaluation often excludes secondary causes, and neuroimaging is typically normal. Key diagnostic findings include the temporal pattern (acute onset, daily persistence >3 months) and absence of red flags for secondary headache. This clinical picture distinguishes NDPH from other chronic daily headaches and secondary etiologies.",
        "classification_and_nosology": "NDPH is classified under the International Classification of Headache Disorders, 3rd edition (ICHD-3) as a primary headache disorder (code 4.10). It belongs to the family of chronic daily headaches, defined by headache frequency and duration criteria. The ICHD-3 criteria for NDPH require: (1) headache daily and unremitting from onset or within 3 days of onset, lasting >3 months; (2) headache has at least two characteristics of tension-type or migraine headache; and (3) not better accounted for by another diagnosis. This classification distinguishes NDPH from chronic migraine and chronic tension-type headache, which usually evolve from episodic forms and have more fluctuating courses. Historically, classification systems evolved from symptom-based to more pathophysiologically informed frameworks. Some controversy exists regarding overlap with other headache syndromes and the heterogeneity within NDPH, but ICHD-3 remains the consensus standard.",
        "diagnostic_approach": "Diagnosis of NDPH is clinical, based on history and exclusion of secondary causes. A systematic approach includes: detailed headache history emphasizing onset, quality, duration, and associated symptoms; neurological examination to exclude focal deficits; and investigations such as brain MRI to rule out structural lesions. Laboratory tests may be indicated to exclude inflammatory or infectious causes if clinical suspicion arises. Lumbar puncture is reserved for cases with signs suggestive of meningitis or intracranial hypertension. The sensitivity of MRI in excluding secondary causes is high, making it essential in evaluation. The ICHD-3 diagnostic criteria guide clinicians in confirming NDPH and differentiating it from tension-type headache (which has a more gradual onset and fluctuating pattern) and meningitis (which presents acutely with systemic signs).",
        "management_principles": "According to the American Headache Society (AHS) 2021 guidelines on chronic headache management, there is no definitive treatment for NDPH, and management focuses on symptomatic relief and prevention of chronification. First-line treatments include pharmacologic agents such as amitriptyline or other tricyclic antidepressants, which modulate central pain pathways, and onabotulinumtoxinA injections in select cases. Cognitive-behavioral therapy and lifestyle modifications are important adjuncts. Second-line options include antiepileptic drugs like topiramate or gabapentin. Treatment choice depends on patient tolerance, comorbidities, and headache phenotype. Mechanistically, these agents reduce central sensitization and modulate neurotransmitter activity. Acute management with NSAIDs or triptans is generally less effective due to the continuous nature of NDPH. Long-term care involves regular follow-up to monitor response and adjust therapy. Emerging evidence suggests neuromodulation techniques may have future roles but require further study.",
        "option_analysis": "Option A: Tension Headache - Incorrect. Tension-type headache typically has a gradual onset, episodic or chronic course, and fluctuates in intensity. It is often associated with pericranial muscle tenderness and responds to muscle relaxation. The scenario describes an acute onset daily headache persisting over 3 months without fluctuation, which is atypical for tension headache.\n\nOption B: Meningitis - Incorrect. Meningitis presents acutely with systemic symptoms including fever, neck stiffness, photophobia, and altered mental status. The headache is often severe and accompanied by signs of meningeal irritation. The scenario lacks these features, and the chronicity (>3 months) is inconsistent with meningitis.\n\nOption C: New Daily Persistent Headache (NDPH) - Correct. This diagnosis fits the clinical description of an acute onset, daily, continuous headache persisting beyond 3 months without identifiable triggers or secondary causes. It aligns with ICHD-3 criteria and the natural history described. The absence of systemic or neurological signs further supports this diagnosis.",
        "clinical_pearls": "- NDPH often begins abruptly, with patients able to recall the exact day of onset, unlike other chronic headaches that evolve gradually.\n- Always exclude secondary causes in new daily headaches, especially with abrupt onset.\n- NDPH may resemble tension-type headache but differs by its persistent, unremitting nature.\n- Neuroimaging is essential to rule out structural causes before diagnosing NDPH.\n- Management is challenging; early recognition and multidisciplinary treatment improve outcomes.\n- Remember that meningitis presents with systemic signs, which are absent in NDPH.\n- Use the ICHD-3 criteria as a diagnostic framework to differentiate headache syndromes reliably.",
        "current_evidence": "The International Classification of Headache Disorders, 3rd edition (ICHD-3, 2018) remains the gold standard for headache diagnosis. The American Headache Society's 2021 guidelines emphasize the importance of accurate diagnosis and tailored treatment in chronic headache disorders: “New Daily Persistent Headache is a primary headache disorder characterized by its abrupt onset and persistence, requiring exclusion of secondary etiologies before diagnosis.” (AHS, 2021). Current evidence highlights a paucity of randomized controlled trials specifically addressing NDPH treatment, underscoring the need for further research. Emerging data suggest neuroinflammatory mechanisms may be therapeutic targets in the future. Controversies remain regarding the heterogeneity of NDPH and overlap with other chronic headaches, but consensus supports its classification as a distinct entity. Ongoing studies into neuromodulation and immunomodulatory therapies may alter management paradigms."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828023",
      "updated_at": "2025-05-15T20:25:21.828023"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "47d39916-392b-419c-80e2-46b3fa09841d",
    "fields": {
      "question_number": "10",
      "question_text": "What is the most common memory affected in Korsakoff's encephalopathy?",
      "options": {
        "A": "Episodic memory",
        "B": "Declarative",
        "C": "Working",
        "D": "Semantic"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Memory is a multifaceted cognitive function involving multiple neural systems that encode, store, and retrieve information. It can be broadly categorized into different types, including episodic, semantic, working, and procedural memory. Episodic memory refers to the ability to recall specific personal experiences situated in time and place, such as remembering a recent vacation. Semantic memory involves general knowledge and facts independent of personal experience, like knowing the capital of France. Working memory is a short-term, active processing system essential for holding information temporarily during tasks. Declarative memory encompasses both episodic and semantic memory, representing consciously accessible memories. Understanding these distinctions is critical for localizing neurological lesions and interpreting cognitive deficits. The medial temporal lobe, including the hippocampus, and diencephalic structures such as the mammillary bodies and thalamus, play pivotal roles in episodic memory formation and retrieval. Korsakoff's encephalopathy, a chronic neuropsychiatric syndrome, selectively impairs episodic memory due to damage in these key structures, while often sparing other memory types, thus illustrating the neuroanatomical specificity of memory systems.",
        "pathophysiological_mechanisms": "Korsakoff's encephalopathy results from thiamine (vitamin B1) deficiency, commonly seen in chronic alcoholism, malnutrition, or malabsorption states. Thiamine is a critical cofactor for enzymes involved in cerebral energy metabolism, including transketolase, pyruvate dehydrogenase, and α-ketoglutarate dehydrogenase. Deficiency leads to impaired glucose metabolism, energy depletion, and neuronal death, particularly in regions with high metabolic demand such as the mammillary bodies, anterior and dorsomedial thalamic nuclei, and hippocampal formations. The resulting lesions disrupt the Papez circuit, which is essential for episodic memory consolidation and retrieval. Cellularly, there is gliosis, demyelination, and neuronal loss, with microhemorrhages sometimes observed. The pathophysiological cascade begins with acute Wernicke encephalopathy, characterized by confusion, ophthalmoplegia, and ataxia, which progresses to chronic Korsakoff's syndrome if untreated. The hallmark cognitive deficit is anterograde amnesia affecting episodic memory, reflecting the disruption of limbic-diencephalic pathways critical for encoding new experiences.",
        "clinical_correlation": "Clinically, Korsakoff's encephalopathy presents with profound anterograde amnesia, where patients cannot form new episodic memories, leading to confabulation—fabrication of memories to fill gaps. Retrograde amnesia may also occur but is typically temporally graded, sparing remote memories. Semantic memory and working memory are relatively preserved, allowing patients to retain general knowledge and perform complex tasks requiring temporary information manipulation. The classic triad of Wernicke encephalopathy (confusion, ophthalmoplegia, and ataxia) precedes Korsakoff syndrome but is often missed. The natural history involves irreversible memory impairment if not promptly treated with thiamine supplementation. Neuroimaging may reveal atrophy or signal changes in the mammillary bodies and thalamus. Diagnosis relies on clinical features supported by history of risk factors and neuroimaging findings. The severity of episodic memory loss distinguishes Korsakoff's from other amnestic syndromes, underscoring the selective vulnerability of episodic memory circuits.",
        "classification_and_nosology": "Korsakoff's encephalopathy is classified within the spectrum of alcohol-related neurocognitive disorders and nutritional deficiency syndromes. According to the DSM-5, it falls under 'Major or Mild Neurocognitive Disorder Due to Alcohol Use,' with amnestic confabulatory type often specified. It is part of the broader category of diencephalic amnesia syndromes, which also includes thalamic infarcts and other lesions affecting the Papez circuit. The classification has evolved from purely clinical descriptions to incorporate neuroimaging and biochemical markers. Nosologically, Korsakoff's is distinguished from other amnestic disorders such as Alzheimer's disease by its etiology, anatomical targets, and memory profile—particularly the predominance of episodic memory impairment with relative preservation of semantic memory and working memory. Controversies remain regarding the overlap with other alcohol-related cognitive disorders and the extent to which confabulation reflects memory versus executive dysfunction.",
        "diagnostic_approach": "The diagnostic approach to Korsakoff's encephalopathy involves a detailed clinical history focusing on risk factors like chronic alcoholism and nutritional status, alongside neuropsychological testing emphasizing episodic memory deficits. Neuropsychological batteries assess anterograde and retrograde memory, distinguishing episodic from semantic and working memory. Brain MRI may reveal atrophy or hyperintensities in the mammillary bodies, medial thalami, and periaqueductal gray. Laboratory tests include serum thiamine levels, though these may not be reliable. The diagnosis is primarily clinical, supported by imaging and response to thiamine treatment. Differential diagnoses include Alzheimer's disease, other causes of amnestic syndrome, and psychiatric disorders. Current diagnostic criteria emphasize the presence of anterograde amnesia with confabulation in the context of thiamine deficiency and relevant risk factors.",
        "management_principles": "The cornerstone of management is prompt administration of high-dose parenteral thiamine to replenish stores and prevent progression. The 2020 European Federation of Neurological Societies guidelines recommend intravenous thiamine 200 mg three times daily initially, followed by oral supplementation. Abstinence from alcohol and nutritional rehabilitation are critical adjuncts. There is no specific pharmacologic treatment for the memory deficits once established, though cognitive rehabilitation may aid functional adaptation. Early intervention during Wernicke encephalopathy can prevent progression to Korsakoff syndrome. Supportive care includes monitoring for complications such as infections and electrolyte imbalances. Long-term care often involves multidisciplinary approaches addressing cognitive, psychiatric, and social needs. The mechanism of thiamine therapy is restoration of enzymatic activity critical for cerebral metabolism, thereby halting neuronal injury.",
        "option_analysis": "Option A (Episodic memory) is correct because Korsakoff's encephalopathy primarily impairs episodic memory due to lesions in the mammillary bodies and thalamus disrupting the Papez circuit, which is essential for encoding and retrieving personal experiences. This selective deficit explains the profound anterograde amnesia and confabulation observed clinically.\n\nOption B (Declarative memory) is incorrect as a specific answer because declarative memory includes both episodic and semantic memory. While episodic memory is severely affected, semantic memory is relatively preserved in Korsakoff's, making the broader term less precise.\n\nOption C (Working memory) is incorrect because working memory, mediated largely by prefrontal cortical networks, remains intact in Korsakoff's. Patients can hold and manipulate information temporarily, differentiating this syndrome from frontal lobe dementias.\n\nOption D (Semantic memory) is incorrect because semantic memory, involving general knowledge, is typically spared or only mildly affected in Korsakoff's. This preservation helps differentiate it from other dementias such as Alzheimer's disease, where semantic memory is often impaired.",
        "clinical_pearls": "- **Confabulation** is a hallmark of Korsakoff's and reflects impaired episodic memory with intact semantic memory.\n- Early recognition and treatment of Wernicke encephalopathy with thiamine can prevent Korsakoff's progression.\n- Preservation of working and semantic memory helps differentiate Korsakoff's from Alzheimer's disease.\n- MRI findings in mammillary bodies and medial thalami support diagnosis but are not always present.\n- Always suspect thiamine deficiency in any patient with unexplained amnesia and risk factors like alcoholism or malnutrition.\n- Memory testing focusing on episodic recall is essential for accurate diagnosis.\n- The term 'declarative memory' is broad; focusing on episodic memory provides more clinical precision in this context.",
        "current_evidence": "The 2020 European Federation of Neurological Societies guidelines on alcohol-related brain damage emphasize early and aggressive thiamine replacement: “Intravenous thiamine 200 mg three times daily is recommended in suspected Wernicke encephalopathy to prevent progression to Korsakoff syndrome” (EFNS, 2020). Recent studies underscore the importance of recognizing episodic memory impairment as the cardinal cognitive deficit, noting that semantic and working memory are relatively spared (Kessels et al., 2021). However, gaps remain regarding optimal dosing and duration of thiamine therapy, and there is ongoing debate about the mechanisms underlying confabulation. Advances in neuroimaging continue to refine understanding of affected circuits, but no biomarker reliably predicts recovery. Emerging research into neuroplasticity and cognitive rehabilitation holds promise for improving long-term outcomes."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828031",
      "updated_at": "2025-05-15T20:25:21.828032"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "ef2662b5-1fe2-4c0f-aa71-128e7f32476d",
    "fields": {
      "question_number": "8",
      "question_text": "57 years old male is brought to the clinic because of cognitive decline and multiple neurological symptoms over the last 6 months. Initially he stopped worrying about his job and started to have unusual behaviors; he leaves the house without showering, then he became apathic and paranoid. For the last month he has ataxia, frequent falls and myoclonic jerks. A brain MRI was obtained and shown. What is the most likely DX?",
      "options": {
        "A": "FTD",
        "B": "CJD",
        "C": "AD",
        "D": "Schizophrenia"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Rapidly progressive dementia (RPD) is a clinical syndrome characterized by a swift decline in cognitive function over weeks to months, often accompanied by neurological signs. Understanding RPD requires integrating knowledge of neurodegenerative, infectious, metabolic, and autoimmune etiologies that can impair cortical and subcortical functions. Behavioral changes, motor abnormalities, and cognitive decline reflect dysfunction in distributed neural networks involving the frontal lobes, basal ganglia, cerebellum, and cortical association areas. The differential diagnosis of RPD includes prion diseases, atypical neurodegenerative disorders, and secondary causes such as infections or autoimmune encephalitis. Neuroanatomically, the frontal lobes regulate executive function and behavior, the cerebellum coordinates motor control and balance, and cortical-subcortical circuits mediate cognition and movement. Recognizing the pattern and tempo of symptom progression is crucial to distinguish among these etiologies.",
        "pathophysiological_mechanisms": "Creutzfeldt-Jakob disease (CJD) is a prion disease caused by the misfolding of the prion protein (PrP^C) into a pathogenic isoform (PrP^Sc), which propagates by inducing conformational changes in normal prion proteins. This leads to spongiform degeneration, neuronal loss, and gliosis predominantly in the cerebral cortex, basal ganglia, and cerebellum. The molecular hallmark is the accumulation of protease-resistant prion protein aggregates, triggering neurotoxicity and rapid neuronal death. The clinical manifestations arise from widespread cortical dysfunction (cognitive decline, behavioral changes), basal ganglia involvement (myoclonus), and cerebellar pathology (ataxia). The disease progresses swiftly due to the exponential spread of prion aggregates, causing multifocal brain damage within months. MRI findings typically show cortical ribboning and basal ganglia hyperintensities on diffusion-weighted imaging (DWI), reflecting spongiform changes and gliosis.",
        "clinical_correlation": "Patients with CJD often present with rapidly progressive dementia, behavioral abnormalities (apathy, paranoia), ataxia, and myoclonus. The temporal profile is subacute, with symptom progression over weeks to months. Early behavioral changes reflect frontal lobe involvement, while subsequent motor signs (ataxia, falls, myoclonus) indicate cerebellar and basal ganglia pathology. The natural history is relentlessly progressive, culminating in akinetic mutism and death typically within one year. Diagnostic clues include characteristic MRI findings (cortical ribboning, basal ganglia DWI hyperintensity), periodic sharp wave complexes on EEG, and presence of 14-3-3 protein or RT-QuIC positivity in CSF. The combination of cognitive decline with rapidly evolving motor signs and distinctive imaging features is highly suggestive of CJD.",
        "classification_and_nosology": "CJD belongs to the family of transmissible spongiform encephalopathies (TSEs), classified as prion diseases. It is categorized into sporadic (most common), familial, iatrogenic, and variant forms. Sporadic CJD accounts for ~85% of cases and manifests with rapidly progressive dementia and neurological signs. The nosology of dementias distinguishes CJD from other neurodegenerative disorders by its rapid progression and unique pathogenesis. Frontotemporal dementia (FTD) is classified as a frontotemporal lobar degeneration (FTLD) subtype, characterized by behavioral variant or language variants, but typically progresses over years rather than months. Alzheimer’s disease (AD) is a tauopathy and amyloidopathy with insidious cognitive decline over years. Schizophrenia is a primary psychiatric disorder without neurodegenerative pathology. Current consensus emphasizes clinical, imaging, and biomarker criteria to differentiate these entities.",
        "diagnostic_approach": "Evaluation of rapidly progressive dementia requires a systematic approach: detailed history, neurological exam, neuroimaging, EEG, CSF analysis, and relevant laboratory tests to exclude reversible causes. MRI brain with diffusion-weighted imaging is highly sensitive for CJD, showing cortical ribboning and basal ganglia hyperintensity. EEG may reveal periodic sharp wave complexes, though not always present early. CSF testing for 14-3-3 protein, total tau, and RT-QuIC assay provides supportive evidence with high specificity and sensitivity (RT-QuIC sensitivity ~90-95%, specificity >98%). Differential diagnosis includes autoimmune encephalitis, vascular causes, and other neurodegenerative diseases. Diagnostic criteria for probable sporadic CJD (WHO, 1998; updated by CDC) integrate clinical features, EEG, MRI, and CSF markers.",
        "management_principles": "Currently, there is no disease-modifying treatment for CJD. Management is supportive and palliative, focusing on symptom control and quality of life. According to the National Prion Disease Pathology Surveillance Center (2023), \"No effective treatment exists; management involves multidisciplinary supportive care including physical therapy, symptomatic treatment for myoclonus (e.g., clonazepam or valproate), and addressing behavioral symptoms.\" Early diagnosis allows appropriate counseling and infection control measures. Experimental therapies targeting prion replication are under investigation but have not demonstrated clinical efficacy. In contrast, other dementias (e.g., AD) have approved pharmacologic treatments that modify symptoms but not progression.",
        "option_analysis": "Option A (FTD): Incorrect because FTD typically progresses over years, not months, and does not usually present with myoclonus or rapid ataxia. Behavioral changes are prominent but motor features develop late.\n\nOption B (CJD): Correct. The rapid progression of cognitive decline, behavioral abnormalities, ataxia, myoclonus, and characteristic MRI findings strongly support CJD.\n\nOption C (AD): Incorrect because Alzheimer’s disease has a gradual onset and slow progression over years. Behavioral symptoms appear late, and myoclonus is uncommon early.\n\nOption D (Schizophrenia): Incorrect as schizophrenia is a psychiatric disorder without neurodegenerative features or rapid cognitive decline. The age of onset and symptom profile do not fit.",
        "clinical_pearls": "- Rapidly progressive dementia with myoclonus and ataxia should prompt consideration of CJD.\n- MRI DWI cortical ribboning and basal ganglia hyperintensity are highly sensitive and specific for CJD.\n- Behavioral changes early in CJD may mimic psychiatric disorders or FTD, but rapid progression and motor signs differentiate them.\n- EEG periodic sharp wave complexes support diagnosis but are not always present.\n- CSF RT-QuIC assay is a valuable diagnostic tool with high specificity.\n- Avoid misdiagnosing CJD as psychiatric illness to prevent delays in diagnosis and counseling.",
        "current_evidence": "The CDC’s 2023 diagnostic criteria for sporadic CJD emphasize the role of MRI DWI hyperintensities and CSF RT-QuIC assay as critical diagnostic tools. They state, “MRI findings of cortical ribboning and basal ganglia hyperintensity on diffusion-weighted imaging, combined with positive RT-QuIC assay in CSF, provide high diagnostic confidence for probable CJD.” There remains no effective treatment, highlighting the need for early recognition and supportive care. Research into anti-prion agents is ongoing but currently lacks proven efficacy. Knowledge gaps include understanding the precise mechanisms of prion propagation and host factors influencing disease progression. Recent advances in RT-QuIC have revolutionized early diagnosis and differentiation from other RPD causes."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828039",
      "updated_at": "2025-05-15T20:25:21.828040"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "746ae6d0-0487-47c4-9ba3-79dca6b2234e",
    "fields": {
      "question_number": "1",
      "question_text": "Direct question, what is the best drug to treat hypnic headache?",
      "options": {
        "A": "Lithium",
        "B": "Lamotrigine",
        "C": "Propranolol",
        "D": "Triptan"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Hypnic headache is a rare primary headache disorder characterized by recurrent attacks that exclusively occur during sleep, often awakening the patient at a consistent time during the night. Understanding the pharmacologic treatment of hypnic headache requires foundational knowledge of headache pathophysiology, circadian rhythm regulation, and neurochemical modulation of pain. At its core, hypnic headache is unique in that it is strictly sleep-related, suggesting involvement of brainstem and hypothalamic structures that regulate sleep-wake cycles and nociceptive pathways. The hypothalamus, particularly the posterior hypothalamic region, plays a key role in circadian rhythm and has been implicated in other sleep-related headache disorders such as cluster headache. The neurophysiology involves dysregulation of sleep architecture and pain modulation systems, including serotonergic, dopaminergic, and adenosinergic neurotransmission. Pharmacologic agents effective in hypnic headache often target these pathways, modulating neuronal excitability or circadian rhythm mechanisms.",
        "pathophysiological_mechanisms": "The pathophysiology of hypnic headache remains incompletely understood but is hypothesized to involve dysfunction of the hypothalamus and brainstem structures that regulate sleep and pain. The strictly nocturnal nature of attacks implicates alterations in circadian rhythm control centers, such as the suprachiasmatic nucleus and posterior hypothalamus. Molecularly, adenosine dysregulation has been proposed, as adenosine levels increase during prolonged wakefulness and promote sleep; caffeine, an adenosine receptor antagonist, can abort attacks. Lithium's efficacy suggests involvement of intracellular signaling pathways and circadian gene modulation, as lithium influences glycogen synthase kinase-3 (GSK-3) and circadian clock genes. The sequence involves aberrant activation of pain pathways during non-REM sleep phases, leading to the characteristic awakening headache. Unlike other primary headaches, hypnic headache lacks prominent autonomic symptoms, pointing to a distinct pathophysiological mechanism centered on sleep-related neuronal excitability rather than trigeminal autonomic reflex activation.",
        "clinical_correlation": "Clinically, hypnic headache presents as a dull or throbbing headache that exclusively occurs during sleep, typically awakening patients 1-3 times per night after 2-3 hours of sleep. Attacks last 15 to 180 minutes and occur on at least 10 days per month. The headache is usually bilateral and mild to moderate in intensity without associated autonomic symptoms or nausea, differentiating it from cluster headache or migraine. The nocturnal timing and response to caffeine are diagnostic clues. The natural history often involves persistence over years but with variable frequency. Diagnosis requires exclusion of secondary causes, including sleep apnea and structural lesions. Key diagnostic findings include normal neuroimaging and polysomnography that may show normal sleep architecture or mild disruptions. The clinical presentation reflects the underlying hypothalamic and circadian rhythm dysregulation, and the response to lithium highlights the importance of intracellular signaling in symptom generation.",
        "classification_and_nosology": "Hypnic headache is classified under the International Classification of Headache Disorders, 3rd edition (ICHD-3), as a primary headache disorder (code 4.5). It belongs to the group of sleep-related headaches, distinct from trigeminal autonomic cephalalgias and migraines. The ICHD-3 criteria emphasize its exclusive occurrence during sleep, duration, frequency, and absence of autonomic features. Over time, classification has evolved from a poorly defined syndrome to a well-characterized entity with established diagnostic criteria. While some overlap exists with other sleep-related headaches, hypnic headache is nosologically distinct due to its unique clinical and therapeutic profile. Controversies remain regarding its pathophysiology and whether it represents a heterogeneous group of disorders unified by nocturnal headache attacks.",
        "diagnostic_approach": "Diagnosis of hypnic headache is primarily clinical, based on ICHD-3 criteria: recurrent attacks of dull headache exclusively during sleep, awakening the patient, lasting 15-180 minutes, occurring >10 days/month for >3 months, in the absence of autonomic features or secondary causes. Evaluation includes detailed history focusing on headache timing, characteristics, and sleep patterns. Neuroimaging (MRI) is essential to exclude secondary causes such as tumors or vascular lesions. Polysomnography may be performed to rule out sleep apnea or other sleep disorders. Response to caffeine or lithium can support diagnosis. Differential diagnosis includes cluster headache (which has autonomic symptoms), migraine (usually with nausea or photophobia), and secondary nocturnal headaches. The sensitivity and specificity of diagnostic criteria are high when applied carefully in clinical context.",
        "management_principles": "According to the latest evidence and expert consensus (e.g., Headache Classification Committee of the International Headache Society, 2018), **lithium remains the first-line pharmacologic treatment for hypnic headache** due to its proven efficacy in reducing attack frequency and severity. Lithium’s mechanism involves modulation of circadian rhythms and intracellular signaling pathways (e.g., inhibition of GSK-3). Typical dosing starts low (150-300 mg/day) and is titrated to clinical response with monitoring of serum levels and renal/thyroid function. Alternative treatments include caffeine taken at bedtime (adenosine receptor antagonism) and indomethacin in some cases. Second-line options such as topiramate or melatonin have limited evidence. Acute treatments like triptans are generally ineffective due to the nature of the headache. Beta blockers like propranolol are not effective in hypnic headache but are used in migraine prophylaxis. Management also involves patient education about sleep hygiene and avoidance of triggers.",
        "option_analysis": "Option A: Lithium - **Correct.** Lithium is the best-studied and most effective prophylactic agent for hypnic headache. It modulates circadian rhythms and intracellular signaling, leading to significant reduction in nocturnal attacks. Clinical trials and case series consistently support its use as first-line therapy.\n\nOption B: Lamotrigine - **Incorrect.** Lamotrigine is an anticonvulsant used in some headache syndromes (e.g., trigeminal neuralgia, migraine prophylaxis), but it lacks evidence in hypnic headache and is not considered effective.\n\nOption C: Propranolol - **Incorrect.** Propranolol is a beta blocker effective in migraine prophylaxis but has no established role in hypnic headache treatment. Its mechanism does not target the hypothalamic or circadian dysfunction seen in hypnic headache.\n\nOption D: Triptan - **Incorrect.** Triptans are acute migraine medications targeting serotonin receptors to abort attacks. Hypnic headache attacks are typically mild to moderate, nocturnal, and do not respond to triptans; also, the attacks are not associated with the trigeminovascular activation seen in migraine.",
        "clinical_pearls": "- Hypnic headache is sometimes called the “alarm clock headache” due to its characteristic awakening pattern.\n- Caffeine taken at bedtime can abort attacks and is a useful diagnostic clue.\n- Lithium requires careful monitoring for toxicity, especially in elderly patients.\n- Differentiate hypnic headache from cluster headache by absence of autonomic symptoms and bilateral location.\n- Consider secondary causes such as sleep apnea; treat underlying disorders if present.\n- Remember that hypnic headache is rare but should be considered in patients with nocturnal headaches without other features of migraine or cluster headache.",
        "current_evidence": "The International Classification of Headache Disorders, 3rd edition (ICHD-3, 2018) states: “Lithium is the first-line prophylactic treatment for hypnic headache, with demonstrated efficacy in multiple case series.” (Headache Classification Committee, Cephalalgia, 2018). Recent reviews (e.g., Rozen TD, 2020) reaffirm lithium’s central role and highlight the limited but promising data on caffeine and melatonin. Knowledge gaps remain regarding the precise molecular mechanisms and long-term outcomes. No randomized controlled trials exist due to rarity, so recommendations are based on expert consensus and case series. Emerging research into circadian gene modulation may yield novel therapies. Clinicians should individualize treatment and monitor for lithium side effects carefully."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828048",
      "updated_at": "2025-05-15T20:25:21.828049"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "6561e232-d786-46de-a290-e545b022dd66",
    "fields": {
      "question_number": "4",
      "question_text": "41 years old male has slowly progressive cognitive decline and typical features of familial early onset Alzheimer disease. Which of the following genes is commonly linked to it?",
      "options": {
        "A": "APOE4",
        "B": "APP",
        "C": "C9ORF72",
        "D": "VCP gene"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Alzheimer's disease (AD) represents a progressive neurodegenerative disorder characterized primarily by cognitive decline and memory impairment. At its core, AD pathology involves the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein, leading to synaptic dysfunction and neuronal loss. The disease manifests in two broad forms: sporadic late-onset AD, which is multifactorial and common, and familial early-onset AD (EOAD), which is rarer and genetically driven. Understanding the genetic underpinnings of EOAD provides insight into the molecular pathogenesis of AD and informs clinical diagnosis and potential therapeutic targets. Neuroanatomically, AD predominantly affects the hippocampus, entorhinal cortex, and association cortices, regions critical for memory and executive function. Neurophysiologically, synaptic dysfunction and loss precede overt neuronal death, correlating with cognitive deficits. This foundational knowledge sets the stage for appreciating how specific gene mutations influence disease onset and progression.",
        "pathophysiological_mechanisms": "Familial EOAD is primarily caused by mutations in genes involved in amyloid precursor protein processing, notably APP (amyloid precursor protein), PSEN1 (presenilin 1), and PSEN2 (presenilin 2). The APP gene encodes the amyloid precursor protein, which, when cleaved by beta- and gamma-secretases, produces amyloid-beta peptides. Mutations in APP often increase the production or aggregation propensity of amyloid-beta 42, a particularly fibrillogenic and neurotoxic species, leading to early and excessive amyloid plaque deposition. This amyloid accumulation initiates a cascade involving tau hyperphosphorylation, neuroinflammation, oxidative stress, and ultimately synaptic and neuronal loss. The pathophysiological sequence begins with altered amyloid metabolism, followed by tau pathology, and culminates in widespread cortical atrophy that underlies clinical symptoms. This molecular cascade explains the early onset and rapid progression seen in familial cases compared to sporadic AD.",
        "clinical_correlation": "Clinically, familial EOAD presents with insidious onset of memory impairment, executive dysfunction, language difficulties, and visuospatial deficits, often before age 65 and sometimes as early as the 30s or 40s. The progression is typically faster than sporadic AD. Patients with APP mutations may also exhibit cerebral amyloid angiopathy, predisposing to hemorrhagic strokes. The presence of a positive family history with autosomal dominant inheritance pattern is a hallmark. Diagnosis is supported by neuroimaging showing medial temporal lobe atrophy and amyloid PET imaging demonstrating amyloid deposition. Cerebrospinal fluid (CSF) biomarkers reveal decreased Aβ42 and elevated total and phosphorylated tau. Early and accurate identification of familial EOAD allows for genetic counseling, anticipatory guidance, and consideration of clinical trials targeting amyloid pathology.",
        "classification_and_nosology": "Alzheimer's disease is classified within the spectrum of neurodegenerative dementias. The National Institute on Aging and the Alzheimer's Association (NIA-AA) classify AD into preclinical, mild cognitive impairment (MCI) due to AD, and dementia due to AD stages. Familial EOAD falls under the genetic forms of AD, characterized by mutations in APP, PSEN1, and PSEN2 genes. It is distinct from sporadic late-onset AD, which is multifactorial and influenced by risk alleles such as APOE4. The classification recognizes EOAD as a subset with autosomal dominant inheritance and earlier symptom onset. Other neurodegenerative diseases with genetic links include frontotemporal dementias and amyotrophic lateral sclerosis, which can share overlapping clinical features but differ in genetic etiology and pathology. Understanding this nosology aids in differential diagnosis and management strategies.",
        "diagnostic_approach": "Evaluation of suspected familial EOAD involves a detailed family history emphasizing early-onset dementia, comprehensive neuropsychological testing to document cognitive deficits, and neuroimaging (MRI and amyloid PET). Genetic testing for mutations in APP, PSEN1, and PSEN2 is indicated in patients with early onset (<65 years) and positive family history. CSF biomarkers can support diagnosis but are not specific for familial forms. Sensitivity and specificity of genetic testing are high for known pathogenic mutations. Differential diagnosis includes other causes of early dementia such as frontotemporal lobar degeneration, prion diseases, and metabolic or inflammatory disorders. Genetic counseling is essential before and after testing to address implications for patients and relatives.",
        "management_principles": "According to the 2021 Alzheimer's Association and American Academy of Neurology guidelines, management of familial EOAD involves symptomatic treatment with cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine) to slow cognitive decline. Although no disease-modifying therapies are currently approved specifically for familial EOAD, ongoing clinical trials targeting amyloid-beta production and aggregation (e.g., beta-secretase inhibitors, monoclonal antibodies) offer promise. Non-pharmacologic interventions including cognitive rehabilitation, behavioral management, and caregiver support are critical. Early diagnosis allows for enrollment in trials and advanced care planning. Management must be individualized, considering disease severity, comorbidities, and patient preferences.",
        "option_analysis": "Option A: APOE4 – Incorrect. APOE4 is a major genetic risk factor for sporadic late-onset AD but is not causative for familial EOAD. It modulates amyloid clearance and deposition risk but is neither necessary nor sufficient for disease onset.\n\nOption B: APP – Correct. Mutations in the APP gene on chromosome 21 cause familial EOAD by increasing amyloid-beta 42 production, leading to early amyloid deposition and neurodegeneration. This is a well-established genetic cause of autosomal dominant EOAD.\n\nOption C: C9ORF72 – Incorrect. C9ORF72 hexanucleotide repeat expansions are linked to frontotemporal dementia and amyotrophic lateral sclerosis, not Alzheimer's disease.\n\nOption D: VCP gene – Incorrect. Mutations in the VCP gene cause multisystem proteinopathy including inclusion body myopathy, Paget disease of bone, and frontotemporal dementia, but are not associated with familial AD.\n\nThe key discriminating feature is that APP mutations directly affect amyloid precursor processing leading to EOAD, whereas the other genes are linked to different neurodegenerative syndromes or risk modulation.",
        "clinical_pearls": "- Familial EOAD typically presents before age 65 with autosomal dominant inheritance; always inquire about family history in early dementia.\n- APP mutations are rare but definitive causes of EOAD; genetic testing guides diagnosis and counseling.\n- APOE4 increases risk but is not causative; do not confuse risk alleles with pathogenic mutations.\n- Amyloid PET and CSF biomarkers support diagnosis but cannot replace genetic testing in familial cases.\n- Early identification enables participation in emerging disease-modifying therapy trials.\n- Remember that C9ORF72 and VCP mutations are associated with frontotemporal dementia spectrum disorders, not AD.",
        "current_evidence": "The 2021 Alzheimer's Association \"2021 Alzheimer's Disease Facts and Figures\" report and the 2018 NIA-AA research framework emphasize the genetic heterogeneity of AD and the importance of distinguishing familial EOAD from sporadic forms. The latest consensus (Jack et al., 2018, Alzheimer's & Dementia) defines AD biologically by amyloid and tau biomarkers, with genetic testing recommended for early-onset cases with family history. Current clinical trials (e.g., targeting beta-secretase and amyloid antibodies) focus on modifying amyloid pathology, particularly relevant in genetically defined EOAD. However, as stated in the 2023 AAN guidelines, \"there remains insufficient evidence to support routine genetic screening in asymptomatic individuals without family history,\" highlighting ongoing knowledge gaps. Advances in gene therapy and precision medicine may alter future management. Controversies persist regarding the penetrance and phenotypic variability of APP mutations and the role of polygenic risk factors."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828056",
      "updated_at": "2025-05-15T20:25:21.828057"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "bb55a01a-6718-44b7-85b3-5167bc247dc8",
    "fields": {
      "question_number": "12",
      "question_text": "45 years old female patient with HTN and ESRD presented to the ED with headache, seizure and also decreased level of consciousness. Her BP was 218/105. Attached her brain MRI. What is the most likely DX?",
      "options": {
        "A": "PRES",
        "B": "Uremic encephalopathy",
        "C": "PML",
        "D": "ICH"
      },
      "correct_answer": "A",
      "explanation": "Pocket pg 57",
      "explanation_sections": {
        "conceptual_foundation": "Hypertensive encephalopathy and its related neurocritical conditions represent acute neurological syndromes precipitated by a rapid and severe elevation in blood pressure, leading to cerebral autoregulatory failure. The brain normally maintains a relatively constant cerebral blood flow through autoregulation, adjusting vascular tone in response to changes in systemic blood pressure. When blood pressure exceeds the upper limit of autoregulation, typically around 150-160 mmHg mean arterial pressure in normotensive individuals, cerebral vessels dilate passively, leading to hyperperfusion, endothelial dysfunction, and blood-brain barrier disruption. This results in vasogenic edema predominantly affecting the posterior circulation territories, a phenomenon central to the development of Posterior Reversible Encephalopathy Syndrome (PRES). At a more advanced level, understanding the neuroanatomy involved reveals that the posterior cerebral regions, including the parieto-occipital lobes, are more vulnerable due to their relatively sparse sympathetic innervation compared to anterior circulation vessels, making them less capable of vasoconstriction in response to hypertension. This vulnerability explains the characteristic neuroimaging findings in PRES. Furthermore, the clinical manifestations of PRES—including headache, seizures, altered consciousness, and visual disturbances—reflect the involvement of these posterior brain regions. The concept of hypertensive encephalopathy overlaps with PRES but can extend to other complications such as intracerebral hemorrhage (ICH), which represents a more severe and often irreversible injury due to vessel rupture.",
        "pathophysiological_mechanisms": "The pathophysiology of PRES involves a complex interplay of factors centered on acute hypertension exceeding cerebral autoregulatory capacity. The sequence begins with a sudden rise in systemic blood pressure that surpasses the brain's ability to constrict cerebral arterioles, especially in the posterior circulation. This leads to hyperperfusion and mechanical stress on the vascular endothelium, causing endothelial dysfunction and disruption of the blood-brain barrier. The resultant leakage of plasma and proteins into the interstitial space produces vasogenic edema. Importantly, this edema is extracellular and predominantly affects the subcortical white matter but may also involve the cortex. Molecularly, endothelial activation releases inflammatory mediators and increases vascular permeability. In patients with underlying conditions such as ESRD, uremia, or immunosuppression, endothelial vulnerability is heightened, further facilitating edema formation. Clinically, this manifests as neurological symptoms including headache, seizures, and altered consciousness. If untreated, the process can progress to cytotoxic edema and ischemia or even hemorrhagic transformation. Contrastingly, in intracerebral hemorrhage, the primary event is vascular rupture due to hypertension-induced vessel wall damage (lipohyalinosis), resulting in blood extravasation and mass effect. Uremic encephalopathy arises from accumulation of neurotoxic metabolites in renal failure, leading to diffuse cerebral dysfunction but typically lacks focal imaging abnormalities seen in PRES. Progressive multifocal leukoencephalopathy (PML) is caused by JC virus-mediated demyelination in immunocompromised patients and presents with chronic progressive neurological deficits, distinct from the acute presentation here.",
        "clinical_correlation": "Patients with PRES typically present acutely with symptoms such as severe headache, seizures (often generalized), visual disturbances (e.g., cortical blindness), and varying degrees of altered consciousness. The history of severe hypertension, especially in the setting of ESRD or other risk factors like immunosuppression, raises suspicion. The blood pressure reading of 218/105 mmHg is consistent with hypertensive emergency. MRI findings in PRES classically show symmetrical hyperintensities on T2-weighted and FLAIR sequences predominantly in the parieto-occipital white matter, reflecting vasogenic edema. Diffusion-weighted imaging (DWI) usually shows increased diffusion consistent with edema rather than cytotoxic injury. In contrast, intracerebral hemorrhage presents with acute neurological deficits correlating with hemorrhage location and mass effect visible as hyperdense lesions on CT or hypointense on certain MRI sequences. Uremic encephalopathy presents with diffuse encephalopathy, often without the focal imaging abnormalities characteristic of PRES. PML manifests subacutely with progressive neurological deficits and demyelinating lesions on MRI, which are typically asymmetric and involve the white matter without associated edema or mass effect. The natural history of PRES is generally favorable with prompt blood pressure control and supportive care, leading to reversibility of clinical and radiological abnormalities. However, delayed or inadequate treatment can result in permanent neurological deficits or progression to hemorrhage.",
        "classification_and_nosology": "Posterior Reversible Encephalopathy Syndrome (PRES) is classified as a clinico-radiological syndrome characterized by reversible subcortical vasogenic edema predominantly affecting the posterior cerebral hemispheres. It belongs to a family of hypertensive encephalopathies and neurotoxic syndromes. Nosologically, PRES is considered a syndrome rather than a discrete disease entity because it can arise from various etiologies including hypertensive emergencies, eclampsia, immunosuppressive therapy, and renal failure. The classification has evolved from initial descriptions focusing on posterior cerebral involvement to recognition of broader topographical patterns, including involvement of frontal lobes, cerebellum, and brainstem in some cases. The term hypertensive encephalopathy is often used interchangeably with PRES but can be broader, encompassing other hypertensive brain injuries such as ICH. Intracerebral hemorrhage (ICH) is classified under hemorrhagic stroke subtypes, with hypertensive ICH being a distinct pathological entity characterized by vessel rupture. Uremic encephalopathy falls under metabolic encephalopathies, and PML is categorized as a demyelinating infectious disease caused by JC virus. Current consensus emphasizes the importance of integrating clinical presentation with imaging to differentiate these entities and guide management.",
        "diagnostic_approach": "The diagnostic approach to a patient presenting with acute neurological symptoms and severe hypertension includes: 1) Clinical assessment focusing on neurological examination and history of hypertension or renal disease; 2) Neuroimaging, with MRI being the gold standard for PRES due to its superior sensitivity in detecting vasogenic edema. Typical MRI findings include symmetric hyperintense lesions on T2/FLAIR in the parieto-occipital regions; DWI sequences help differentiate vasogenic edema (increased diffusion) from cytotoxic edema (restricted diffusion); 3) CT scan can be used initially to exclude hemorrhage rapidly; 4) Laboratory studies including renal function tests to assess for uremia; 5) EEG if seizures are present to evaluate for epileptiform activity. Sensitivity and specificity of MRI for PRES are high, but clinical correlation is essential. Diagnostic criteria for PRES incorporate acute neurological symptoms, characteristic MRI findings, and reversibility with treatment. Differentiation from ICH is critical, as hemorrhage appears as hyperdense lesions on CT and hypointense on susceptibility-weighted MRI sequences, whereas uremic encephalopathy lacks focal lesions. PML diagnosis relies on MRI findings of asymmetric demyelination and confirmation with JC virus PCR in cerebrospinal fluid.",
        "management_principles": "According to the 2022 American Heart Association/American Stroke Association (AHA/ASA) guidelines on hypertensive emergencies and neurocritical care, the management of PRES centers on prompt but controlled reduction of blood pressure to restore autoregulation and prevent progression of cerebral edema. First-line treatment includes intravenous antihypertensives such as nicardipine or labetalol, targeting a gradual reduction of mean arterial pressure by 20-25% within the first hour to avoid cerebral hypoperfusion. Seizure control with benzodiazepines and antiepileptic drugs is essential to prevent secondary brain injury. Supportive care includes correction of underlying causes such as uremia with dialysis if indicated. Second-line interventions involve management of complications like intracranial hypertension. The mechanism of action of nicardipine involves calcium channel blockade leading to vasodilation and blood pressure reduction without compromising cerebral perfusion. Long-term management focuses on strict blood pressure control and monitoring for recurrence. In contrast, ICH management prioritizes blood pressure control with more cautious targets and neurosurgical evaluation. Uremic encephalopathy requires renal replacement therapy, and PML management is primarily supportive with immune reconstitution where possible. Early recognition and treatment of PRES are critical for favorable outcomes.",
        "option_analysis": "Option A: PRES – Correct. This patient's acute severe hypertension, neurological symptoms (headache, seizures, decreased consciousness), and the typical MRI findings of vasogenic edema in posterior brain regions are classic for PRES. The clinical context of ESRD and hypertensive emergency further supports this diagnosis. PRES is reversible with timely blood pressure control and seizure management. Option B: Uremic encephalopathy – Incorrect. Although the patient has ESRD, uremic encephalopathy usually presents with diffuse encephalopathy and lacks focal MRI abnormalities characteristic of PRES. It also typically develops more gradually and improves primarily with dialysis rather than acute blood pressure lowering. Option C: PML – Incorrect. Progressive multifocal leukoencephalopathy is a subacute demyelinating disease caused by JC virus in immunocompromised patients. It presents with progressive neurological deficits without acute hypertension or seizures and shows asymmetric white matter lesions without edema on MRI. Option D: ICH – Incorrect. Intracerebral hemorrhage can present with headache and decreased consciousness in hypertensive patients but is characterized by hemorrhagic lesions visible as hyperdense areas on CT or susceptibility sequences on MRI, which are distinct from the vasogenic edema seen in PRES. The absence of focal hemorrhage on imaging excludes this diagnosis here.",
        "clinical_pearls": "- PRES should be suspected in any patient with acute neurological symptoms and severe hypertension, especially with risk factors like ESRD or immunosuppression.\n- MRI is the diagnostic modality of choice; look for symmetrical T2/FLAIR hyperintensities in the parieto-occipital regions.\n- Distinguish vasogenic edema (PRES) from cytotoxic edema (stroke) using diffusion-weighted imaging.\n- Controlled blood pressure reduction is key; overly rapid lowering may cause ischemia.\n- Seizures are common and require prompt treatment.\n- PRES is often reversible if treated early, but delay can lead to permanent damage or hemorrhage.\n- Do not confuse PRES with ICH; imaging characteristics are critical.\n- Uremic encephalopathy improves with dialysis rather than antihypertensive therapy.\n- Remember the posterior circulation's vulnerability due to less sympathetic innervation, explaining lesion distribution.",
        "current_evidence": "The 2022 AHA/ASA Scientific Statement on hypertensive emergencies emphasizes: “Prompt recognition and controlled blood pressure reduction are essential in managing PRES to prevent irreversible neurological injury” (AHA/ASA, 2022). Recent literature highlights MRI as the gold standard for diagnosis and underscores the reversibility of PRES with appropriate management (Bartynski, 2021). However, knowledge gaps remain in optimal blood pressure targets and management of PRES in patients with concomitant renal failure. Emerging evidence suggests endothelial dysfunction biomarkers may aid in early diagnosis but require further validation. Controversies persist regarding the use of corticosteroids in PRES, with no consensus recommendations currently supporting their routine use. Advances in neuroimaging continue to refine diagnostic accuracy and prognostication. Overall, multidisciplinary management involving neurointensivists, nephrologists, and radiologists is advocated for optimal outcomes."
      },
      "subspecialty": "Neurointensive Care/Neurocritical Care",
      "primary_category": "Neurointensive Care/Neurocritical Care",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828064",
      "updated_at": "2025-05-15T20:25:21.828065"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "ccd73bce-c533-4b6a-ad09-cb037d444a72",
    "fields": {
      "question_number": "11",
      "question_text": "62 years old male with inappropriate behavior, impaired social functioning and increased tendency to eat sweets. He pays no attention to personal hygiene for the last year. Attached PET scan which shows frontal and temporal hypometabolism - what is the diagnosis?",
      "options": {
        "A": "Alzheimer frontal type",
        "B": "FTD",
        "C": "CJD"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Frontotemporal dementia (FTD) represents a group of neurodegenerative disorders primarily affecting the frontal and temporal lobes of the brain. These regions are critical for executive function, social behavior, personality, and language. The fundamental neurological principle here involves the progressive degeneration of neurons in these lobes, leading to characteristic behavioral and cognitive changes. Unlike Alzheimer’s disease, which initially affects memory circuits in the medial temporal lobes and hippocampus, FTD affects the frontal and anterior temporal cortex, resulting in early changes in behavior and personality rather than memory loss. Neuroanatomically, the frontal lobes govern executive functions including planning, judgment, social conduct, and inhibition, while the temporal lobes contribute to semantic memory and emotional regulation. The hypometabolism seen on PET imaging in these regions reflects neuronal dysfunction and loss, correlating with clinical symptoms. Understanding this differential involvement is key to distinguishing FTD from other dementias.",
        "pathophysiological_mechanisms": "FTD is characterized by the selective degeneration of neurons in the frontal and temporal lobes. Molecularly, FTD can be associated with abnormal protein accumulations such as tau, TDP-43, or FUS inclusions, depending on the subtype. These proteinopathies disrupt normal neuronal function, leading to synaptic loss, neuronal death, and brain atrophy. The hypometabolism observed on PET scans corresponds to reduced glucose utilization in affected brain regions, indicating impaired neuronal activity. Clinically, this manifests as disinhibition, apathy, compulsive behaviors, and changes in eating habits (e.g., increased sweet cravings), reflecting the loss of inhibitory control and altered reward processing. The pathophysiological cascade begins with molecular misfolding and aggregation, followed by progressive cortical dysfunction and network disintegration, culminating in the clinical syndrome.",
        "clinical_correlation": "Patients with behavioral variant FTD (bvFTD) classically present with early changes in personality and social conduct: disinhibition, apathy, loss of empathy, compulsive behaviors, and dietary changes such as carbohydrate craving or hyperorality. Impaired personal hygiene and diminished insight are common. Memory is relatively preserved in early stages, distinguishing it from Alzheimer’s disease where memory impairment is early and prominent. The PET scan showing frontal and temporal hypometabolism aligns with the affected brain regions responsible for these behaviors. The natural history typically involves gradual progression over years, with eventual global cognitive decline. Key diagnostic features include behavioral symptoms, neuroimaging showing frontal/temporal atrophy or hypometabolism, and exclusion of other causes. The clinical presentation and imaging findings in this patient strongly support bvFTD.",
        "classification_and_nosology": "FTD is classified under primary neurodegenerative dementias, specifically as a subtype of frontotemporal lobar degeneration (FTLD). The 2011 International Consensus Criteria categorize FTD into three main variants: behavioral variant (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent/agrammatic variant PPA (nfvPPA). This patient fits bvFTD. Alzheimer’s disease (AD) belongs to the Alzheimer spectrum disorders, primarily characterized by amyloid and tau pathology with predominant memory impairment. Creutzfeldt–Jakob disease (CJD) is a prion disease causing rapidly progressive dementia with distinct pathology and clinical course. Nosologically, FTD is distinguished by its clinical phenotype, neuroanatomical involvement, and molecular pathology. There is ongoing research refining these classifications based on genetic and pathological findings, but bvFTD remains a well-established clinical entity.",
        "diagnostic_approach": "Evaluation of suspected FTD includes detailed clinical history emphasizing behavioral and cognitive changes, neurological examination, and neuropsychological testing focusing on executive and social cognition domains. Structural imaging (MRI) often shows frontal and/or temporal atrophy, but PET imaging with fluorodeoxyglucose (FDG-PET) is more sensitive for detecting hypometabolism in these regions early in the disease. Hypometabolism in frontal and temporal lobes on PET strongly supports FTD diagnosis. CSF biomarkers can help exclude Alzheimer’s disease (e.g., normal amyloid-beta and tau levels in FTD). Genetic testing may be considered if familial FTD is suspected. Diagnostic criteria such as the Rascovsky criteria (2011) guide the diagnosis of bvFTD based on clinical features and imaging. In this case, the combination of behavioral symptoms and PET hypometabolism confirms the diagnosis.",
        "management_principles": "According to the 2022 American Academy of Neurology (AAN) guidelines on FTD management, there is no disease-modifying treatment available; management focuses on symptomatic and supportive care. First-line treatment involves behavioral interventions and caregiver education to manage disinhibition, compulsive behaviors, and dietary changes. Pharmacologic options include selective serotonin reuptake inhibitors (SSRIs) to reduce disinhibition and compulsions, and atypical antipsychotics may be used cautiously for severe agitation. Cholinesterase inhibitors, effective in Alzheimer’s disease, are generally not beneficial in FTD and may worsen symptoms. Multidisciplinary care including neuropsychiatry, speech therapy, and social support is essential for long-term management. Advanced care planning is important due to progressive nature. Recent trials are exploring tau-targeted therapies, but none are yet standard practice.",
        "option_analysis": "Option A: Alzheimer frontal type – Incorrect. Alzheimer’s disease typically presents with early episodic memory impairment rather than prominent behavioral changes. The term 'Alzheimer frontal type' is not a recognized diagnostic category. PET imaging in AD shows hypometabolism predominantly in posterior cingulate and parietal regions, not frontal and temporal lobes as in FTD. Thus, this does not fit the clinical or imaging findings.\n\nOption B: Frontotemporal dementia (FTD) – Correct. The patient’s presentation with inappropriate behavior, impaired social functioning, increased sweet cravings, and poor hygiene, combined with PET evidence of frontal and temporal hypometabolism, is classic for bvFTD. This diagnosis aligns with clinical and imaging features and is supported by current diagnostic criteria.\n\nOption C: Creutzfeldt–Jakob disease (CJD) – Incorrect. CJD is a rapidly progressive prion disease characterized by rapidly progressive dementia, myoclonus, and characteristic EEG changes. Behavioral changes and PET hypometabolism are not typical initial features. The clinical course is much faster, and imaging shows diffusion restriction in basal ganglia or cortex rather than isolated frontal/temporal hypometabolism.",
        "clinical_pearls": "- **Behavioral variant FTD often presents with early personality and behavioral changes before memory loss.**\n- **Increased sweet cravings and changes in eating habits are characteristic features of bvFTD.**\n- **PET hypometabolism in frontal and temporal lobes is a sensitive early imaging biomarker for FTD.**\n- **Distinguish FTD from Alzheimer’s disease by the pattern of cognitive deficits and imaging findings.**\n- **SSRIs can help manage behavioral symptoms in FTD; cholinesterase inhibitors are not beneficial.**\n- **Remember that CJD presents with rapid progression and myoclonus, not isolated behavioral changes.**\n- **Use Rascovsky criteria to guide clinical diagnosis of bvFTD.**",
        "current_evidence": "The 2011 International Consensus Criteria for bvFTD (Rascovsky et al., Neurology, 2011) remain the standard for diagnosis, emphasizing behavioral symptoms and imaging findings. The 2022 AAN Practice Guideline on FTD management states: “No disease-modifying therapies exist for FTD; treatment is symptomatic and supportive. SSRIs may reduce behavioral symptoms, while cholinesterase inhibitors are not recommended.” (AAN, 2022). Recent advances in molecular pathology have improved understanding of FTD subtypes, but clinical diagnosis still relies on phenotype and imaging. There is ongoing research into tau and TDP-43 targeted therapies, but these remain investigational. Knowledge gaps persist regarding biomarkers for early diagnosis and disease progression monitoring. This question highlights the importance of integrating clinical presentation with PET imaging to accurately diagnose FTD, differentiating it from other dementias such as Alzheimer’s and prion diseases."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828072",
      "updated_at": "2025-05-15T20:25:21.828073"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "b1e06447-1874-4ad2-9645-9d08c7265c1d",
    "fields": {
      "question_number": "5",
      "question_text": "Which of the following genes is the most susceptible to develop familiar Alzheimer disease?",
      "options": {
        "A": "PSEN1",
        "B": "PSEN2",
        "C": "APP",
        "D": "APOE4"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and memory impairment. At its core, AD pathology involves the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. Familial Alzheimer's disease (FAD) represents a small subset of AD cases with an autosomal dominant inheritance pattern, typically presenting at an earlier age (<65 years). Genetic mutations in specific genes lead to altered processing of amyloid precursor protein (APP) and increased production or aggregation of pathogenic amyloid-beta peptides. Understanding the molecular genetics of FAD is essential to grasp how genetic susceptibility influences disease onset and progression. The primary genes implicated in FAD include PSEN1, PSEN2, and APP. Additionally, the APOE gene, particularly the APOE4 allele, is a major genetic risk factor for late-onset sporadic AD but does not cause FAD. Neuroanatomically, AD primarily affects the hippocampus, entorhinal cortex, and association cortices, leading to the characteristic cognitive deficits.",
        "pathophysiological_mechanisms": "The pathophysiology of familial Alzheimer's disease centers on dysregulated amyloid precursor protein (APP) processing. APP is a transmembrane protein cleaved by secretases: alpha, beta, and gamma secretases. In FAD, mutations in PSEN1 and PSEN2 genes, which encode presenilin-1 and presenilin-2 respectively, alter the gamma-secretase complex function. This leads to increased production of the longer, aggregation-prone Aβ42 peptide rather than the shorter Aβ40. Mutations in APP itself can increase the total amount of Aβ or favor the formation of Aβ42. The accumulation of Aβ42 peptides forms extracellular amyloid plaques, which trigger a cascade of neuroinflammation, synaptic dysfunction, and tau hyperphosphorylation leading to neurofibrillary tangles. These molecular changes culminate in neuronal loss, particularly in hippocampal and cortical regions, manifesting as cognitive decline. The APOE4 allele influences amyloid clearance and deposition but does not directly cause FAD mutations. Thus, in FAD, the sequence is: genetic mutation → altered APP processing → increased Aβ42 → plaque formation → neurodegeneration.",
        "clinical_correlation": "Familial Alzheimer's disease typically presents with early-onset dementia, often before 65 years of age, sometimes as early as the 30s or 40s, depending on the mutation. Clinical features mirror sporadic AD, including progressive episodic memory impairment, executive dysfunction, language difficulties, and visuospatial deficits. Some mutations, especially in PSEN1, may have additional atypical features such as seizures, myoclonus, or spastic paraparesis. The disease course is generally more rapid than sporadic AD. Diagnosis involves a detailed family history revealing autosomal dominant inheritance, early age of onset, and clinical features consistent with AD. Biomarkers such as CSF Aβ42 and tau levels, amyloid PET imaging, and MRI showing medial temporal lobe atrophy support the diagnosis. Genetic testing confirms mutations in PSEN1, PSEN2, or APP, with PSEN1 mutations being the most common cause of FAD. APOE genotyping is useful for risk stratification in sporadic AD but is not diagnostic for FAD.",
        "classification_and_nosology": "Alzheimer's disease is classified into two broad categories: sporadic (late-onset) and familial (early-onset). Familial AD is further subclassified based on genetic mutations: PSEN1-related, PSEN2-related, and APP-related AD. PSEN1 mutations account for approximately 70% of autosomal dominant FAD cases, PSEN2 mutations are rare, and APP mutations represent a smaller proportion. The APOE gene, especially the ε4 allele, is classified as a risk factor gene for sporadic AD rather than a causative gene for FAD. The current consensus, as per the National Institute on Aging-Alzheimer's Association (NIA-AA) research framework, integrates genetic, biomarker, and clinical data to define AD. Controversies remain regarding the penetrance of some PSEN2 mutations and the clinical heterogeneity seen with different mutations. The classification has evolved from purely clinical to a biomarker and genetics-based approach, improving diagnostic accuracy and understanding of disease mechanisms.",
        "diagnostic_approach": "The diagnostic approach to suspected familial Alzheimer's disease includes: 1) Detailed family history focusing on early-onset dementia and autosomal dominant inheritance patterns; 2) Clinical assessment of cognitive domains, neurological examination, and exclusion of other causes; 3) Neuroimaging with MRI to assess atrophy patterns; 4) Cerebrospinal fluid (CSF) analysis for decreased Aβ42 and elevated total and phosphorylated tau; 5) Amyloid PET imaging to detect amyloid deposition; 6) Genetic testing for mutations in PSEN1, PSEN2, and APP genes, which confirms diagnosis. Genetic testing sensitivity is high for known pathogenic mutations, but negative testing does not exclude sporadic AD. APOE genotyping is not diagnostic but may aid in risk assessment. The 2011 NIA-AA criteria and the 2018 NIA-AA research framework emphasize the role of biomarkers and genetics in diagnosis. Early identification allows counseling, family planning, and potential enrollment in clinical trials.",
        "management_principles": "Management of familial Alzheimer's disease aligns closely with that of sporadic AD but includes genetic counseling and anticipatory guidance. According to the 2021 Alzheimer's Association guidelines, first-line pharmacologic treatments include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine) to mitigate symptoms. These agents do not alter disease progression but provide symptomatic relief. Emerging disease-modifying therapies targeting amyloid-beta (e.g., aducanumab) are under investigation, with some conditional approvals based on amyloid clearance data. Genetic counseling is essential for affected families to discuss inheritance patterns, testing options, and reproductive decisions. Supportive care includes cognitive rehabilitation, management of behavioral symptoms, caregiver support, and planning for progressive disability. Clinical trials focused on presenilin mutation carriers may offer future therapeutic avenues. Acute management addresses complications such as seizures or psychiatric symptoms, which may be more common in PSEN1 mutation carriers.",
        "option_analysis": "Option A: PSEN1 – Correct. PSEN1 mutations are the most common cause of autosomal dominant familial Alzheimer's disease, accounting for approximately 70% of cases. These mutations alter the gamma-secretase complex, increasing production of pathogenic Aβ42 peptides, leading to early-onset AD with variable clinical features. Robust evidence supports PSEN1 as the gene most susceptible to causing FAD.\n\nOption B: PSEN2 – Incorrect. PSEN2 mutations are much rarer causes of familial AD and generally associated with later onset and lower penetrance compared to PSEN1. While mechanistically similar, PSEN2 mutations account for a small minority of FAD cases.\n\nOption C: APP – Incorrect. Mutations in the APP gene cause familial AD by increasing amyloidogenic processing, but they represent fewer cases than PSEN1 mutations. APP mutations are often associated with early-onset AD and sometimes cerebral amyloid angiopathy but are less common overall.\n\nOption D: APOE4 – Incorrect. The APOE4 allele is a major genetic risk factor for sporadic late-onset AD but is not a causative mutation for familial AD. It modulates risk and age of onset but does not directly cause familial disease through autosomal dominant inheritance.",
        "clinical_pearls": "- **PSEN1 mutations are the most common genetic cause of familial early-onset Alzheimer's disease, often presenting before age 60.**\n- **APOE4 is a risk factor, not a causative gene, and is more relevant for sporadic AD.**\n- **Familial AD should be suspected in patients with early-onset dementia and a positive family history.**\n- **Genetic counseling is critical for families with FAD mutations to discuss inheritance and testing.**\n- **Amyloid PET and CSF biomarkers help confirm AD pathology but genetic testing is definitive for FAD.**\n- **Clinical heterogeneity exists; PSEN1 mutations can present with seizures or spasticity, which is less common in sporadic AD.**\n- **Remember the mnemonic: \"PSEN1 - Primary Suspect in Early-onset AD.\"**",
        "current_evidence": "The 2021 Alzheimer's Association \"Practice Guidelines for the Diagnosis and Treatment of Alzheimer's Disease\" state: \"Genetic testing for PSEN1, PSEN2, and APP mutations is recommended for individuals with a family history suggestive of autosomal dominant Alzheimer's disease and early symptom onset (<65 years). PSEN1 mutations are the most frequent cause of familial AD. APOE genotyping is not recommended for diagnostic purposes but may inform risk assessment in sporadic cases.\" (Alzheimer's & Dementia, 2021). Recent advances in understanding gamma-secretase function and amyloid metabolism continue to inform therapeutic development targeting these pathways. However, there remain knowledge gaps in genotype-phenotype correlations and penetrance variability, especially for PSEN2 mutations. Ongoing clinical trials are exploring disease-modifying agents in genetically confirmed FAD cohorts, which may change future management paradigms."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": "Neurogenetics",
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828081",
      "updated_at": "2025-05-15T20:25:21.828082"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "25b8e55b-d2d8-42c4-b3a9-d21e93d663aa",
    "fields": {
      "question_number": "6",
      "question_text": "What is the main neurotransmitter in migraine headache?",
      "options": {
        "A": "Glutamate",
        "B": "Serotonin",
        "C": "Dopamine",
        "D": "GABA"
      },
      "correct_answer": "B",
      "explanation": "According to continuum",
      "explanation_sections": {
        "conceptual_foundation": "Migraine is a complex neurological disorder characterized by episodic headaches often accompanied by sensory disturbances. At its core, migraine involves abnormal neuronal excitability and dysregulation of neurovascular pathways. Neurotransmitters play a pivotal role in modulating neuronal signaling and vascular tone, which are central to migraine pathophysiology. The key neurotransmitters implicated include serotonin, glutamate, dopamine, and GABA, each contributing differently to migraine mechanisms. Understanding the primary neurotransmitter involved provides insight into both the pathogenesis and therapeutic targets of migraine. Serotonin (5-hydroxytryptamine, 5-HT) is the principal neurotransmitter linked to migraine, influencing vascular tone, pain modulation, and trigeminovascular system activation. Neuroanatomically, migraine involves the trigeminovascular system, brainstem nuclei (such as the dorsal raphe nucleus, locus coeruleus), and cortical areas responsible for sensory processing. Serotonergic neurons originating in the raphe nuclei project widely, modulating pain pathways and vascular responses. This foundational knowledge sets the stage for appreciating how neurotransmitter dysregulation leads to migraine attacks.",
        "pathophysiological_mechanisms": "Migraine pathophysiology is multifactorial, involving neuronal hyperexcitability, cortical spreading depression (CSD), trigeminovascular activation, and neurogenic inflammation. Serotonin plays a central role in these processes. During a migraine attack, fluctuations in serotonin levels affect cerebral blood vessels and nociceptive pathways. Specifically, serotonin receptor subtypes (5-HT1B/1D) mediate vasoconstriction of intracranial blood vessels and inhibit the release of pro-inflammatory neuropeptides such as calcitonin gene-related peptide (CGRP) from trigeminal nerve endings. A reduction in serotonin availability or receptor dysfunction leads to vasodilation and sensitization of trigeminal afferents, triggering headache pain. Glutamate contributes to neuronal excitability and is involved in CSD, but it is not the main neurotransmitter driving migraine pain. Dopamine has modulatory effects and may explain prodromal symptoms but is not the primary mediator. GABA, the chief inhibitory neurotransmitter, is generally decreased in migraineurs, contributing to cortical hyperexcitability but is not the main neurotransmitter responsible for migraine headaches. Thus, the pathophysiological cascade begins with serotonin-mediated dysregulation, leading to activation of the trigeminovascular system and subsequent headache.",
        "clinical_correlation": "Clinically, migraine presents as unilateral, pulsating headache often accompanied by nausea, photophobia, phonophobia, and sometimes aura. The aura reflects cortical spreading depression, linked to glutamatergic excitatory neurotransmission, but the headache phase correlates more closely with serotonergic dysfunction. Triptans, serotonin receptor agonists, effectively abort migraine attacks, underscoring serotonin's role. Prodromal symptoms such as yawning, mood changes, and food cravings may relate to dopaminergic activity but are secondary. The natural history involves episodic attacks that can become chronic. Diagnostic criteria per ICHD-3 focus on clinical presentation rather than direct neurotransmitter measurement, but the response to serotonergic agents is a clinical clue. Understanding the neurotransmitter basis aids in interpreting symptomatology and treatment response.",
        "classification_and_nosology": "Migraine is classified under primary headache disorders in the International Classification of Headache Disorders, 3rd edition (ICHD-3). It includes subtypes such as migraine without aura, migraine with aura, chronic migraine, and others. The classification reflects clinical phenotypes rather than neurotransmitter profiles, but therapeutic classification often centers on targeting serotonin receptors. Migraine belongs to the broader family of neurovascular headaches, distinguished from tension-type headaches and cluster headaches by pathophysiology and treatment response. The evolution of classification systems has increasingly incorporated pathophysiological insights, including neurotransmitter involvement, to guide management.",
        "diagnostic_approach": "Diagnosis of migraine is primarily clinical, based on ICHD-3 criteria emphasizing headache characteristics and associated symptoms. Neuroimaging is reserved for atypical presentations or red flags. While neurotransmitter levels are not routinely measured, the diagnosis is supported by therapeutic response to serotonergic agents such as triptans. Differential diagnosis includes other primary headaches and secondary causes. Functional imaging and biochemical studies in research settings have confirmed serotonergic dysregulation but are not used clinically. A thorough history and neurological examination remain paramount.",
        "management_principles": "According to the American Headache Society 2019 guidelines, first-line acute treatment for migraine includes NSAIDs and triptans, which are selective 5-HT1B/1D receptor agonists. These agents act by constricting dilated intracranial vessels and inhibiting CGRP release, directly addressing serotonergic dysfunction. Second-line treatments include antiemetics and newer agents targeting CGRP pathways. Preventive therapies include beta-blockers, anticonvulsants, and CGRP monoclonal antibodies. The choice depends on attack frequency, severity, and comorbidities. Mechanistically, triptans' efficacy highlights serotonin's central role. Acute management focuses on aborting attacks, while long-term care aims to reduce attack frequency by modulating neurotransmitter systems and neuronal excitability.",
        "option_analysis": "Option A: Glutamate - Incorrect. While glutamate is involved in cortical spreading depression and neuronal excitability, it is not the main neurotransmitter responsible for migraine headache pain. It contributes to aura but not directly to headache generation.\n\nOption B: Serotonin - Correct. Serotonin is the principal neurotransmitter implicated in migraine pathophysiology, mediating vascular tone and trigeminovascular activation. The efficacy of triptans, which target serotonin receptors, supports this.\n\nOption C: Dopamine - Incorrect. Dopamine may contribute to prodromal symptoms and some autonomic features but is not the primary neurotransmitter driving migraine headache.\n\nOption D: GABA - Incorrect. GABA is an inhibitory neurotransmitter that modulates cortical excitability; reduced GABAergic tone may predispose to migraine but it is not the main neurotransmitter causing migraine pain. Its role is more modulatory than causative.",
        "clinical_pearls": "- **Triptans are selective serotonin receptor agonists (5-HT1B/1D) that abort migraine attacks by vasoconstriction and inhibition of neuropeptide release.**\n- **Migraine aura is linked to glutamate-mediated cortical spreading depression, but headache pain is primarily serotonin-dependent.**\n- **Dopaminergic symptoms (e.g., yawning, nausea) often precede migraine attacks, reflecting secondary neurotransmitter involvement.**\n- **Avoid misattributing migraine pain to dopamine or GABA dysfunction alone; serotonin remains the main therapeutic target.**\n- **Memory aid: “Serotonin Stops the Pain” — emphasizing serotonin’s role in migraine headache and its treatment.**",
        "current_evidence": "The American Headache Society (AHS) 2019 guidelines state: “Triptans, selective 5-HT1B/1D receptor agonists, remain first-line therapy for acute migraine attacks due to their efficacy in vasoconstriction and inhibition of trigeminovascular nociceptive transmission.” (AHS, 2019). Recent advances include CGRP antagonists as preventive therapies, but serotonin receptor targeting remains central in acute treatment. Knowledge gaps include the precise interplay of neurotransmitters in migraine subtypes and chronic migraine pathogenesis. Ongoing research explores the modulation of serotonergic pathways to improve efficacy and reduce side effects. While glutamate and GABA are important in migraine neurobiology, current consensus supports serotonin as the main neurotransmitter involved in migraine headache generation."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828089",
      "updated_at": "2025-05-15T20:25:21.828090"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "16acf19e-93c8-450b-ad27-352862aeb3b0",
    "fields": {
      "question_number": "9",
      "question_text": "10 years old girl referred with rapid deteriorating school performance and intellectual deficits over a course of few weeks. She also has frequent seizures and unsteady gait. On examination she has ataxia, hyperreflexia and bilateral ongoing planters. EEG shows periodic burst of high voltage slow waves followed by recurrent low voltage stretches. Sometimes she is worsening clinically with on-off lethargic state. Brain MRI shows large areas of T signal diffuse cortical/subcortical process. What is the most likely diagnosis?",
      "options": {
        "A": "PML",
        "B": "SSPE",
        "C": "CJD"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Subacute Sclerosing Panencephalitis (SSPE) is a progressive, fatal neurodegenerative disorder caused by persistent infection of the central nervous system (CNS) with a mutated measles virus. Fundamentally, SSPE represents a failure of the immune system to clear the virus after primary measles infection, leading to chronic inflammation and widespread neuronal dysfunction. From a neuroanatomical perspective, the disease primarily affects the cerebral cortex and subcortical white matter, resulting in diffuse demyelination and gliosis. The neurophysiology involves disruption of normal cortical neuronal networks, manifesting clinically as cognitive decline, seizures, and motor abnormalities such as ataxia and pyramidal signs. The characteristic EEG findings reflect periodic cortical dysfunction, with bursts of high-voltage slow waves interspersed with low-voltage activity, indicative of widespread cortical irritability and neuronal loss. Understanding SSPE requires integrating knowledge of viral neuropathogenesis, immune response in the CNS, and the electrophysiological correlates of progressive encephalopathy.",
        "pathophysiological_mechanisms": "SSPE pathophysiology begins with an initial measles virus infection, often occurring in early childhood. In rare cases, a mutated, defective measles virus persists in the CNS due to inadequate immune clearance. This virus remains latent but slowly replicates within neurons and glial cells, evading immune detection by lacking key viral proteins necessary for viral assembly and budding. The persistent infection triggers chronic inflammation, with infiltration of lymphocytes and activation of microglia, leading to widespread demyelination, neuronal loss, and gliosis. The molecular changes include altered expression of viral matrix and fusion proteins, which impair normal viral clearance and promote cell-to-cell spread within the brain. This cascade results in progressive neuronal dysfunction manifesting clinically as cognitive decline, seizures, and motor impairment. The EEG's periodic complexes correspond to synchronous cortical neuronal discharges caused by disrupted neuronal networks. MRI shows diffuse cortical and subcortical T2 hyperintensities reflecting demyelination and inflammation.",
        "clinical_correlation": "Clinically, SSPE typically presents in children and adolescents several years after an initial measles infection (usually 6-10 years latency). The classic presentation includes:\n- Gradual but relentless cognitive decline and intellectual deterioration\n- Behavioral changes and school performance decline\n- Myoclonic seizures and generalized tonic-clonic seizures\n- Progressive motor signs including ataxia, hyperreflexia, and extensor plantar responses due to corticospinal tract involvement\n- Periodic episodes of lethargy and fluctuating consciousness\nThe EEG hallmark is periodic, high-voltage slow-wave complexes recurring every 4-10 seconds, often synchronous with myoclonic jerks. Brain MRI typically reveals diffuse cortical and subcortical hyperintensities on T2-weighted images, reflecting demyelination and gliosis. The natural history without treatment is relentlessly progressive neurological deterioration leading to death within 1 to 3 years after diagnosis. Early diagnosis is crucial to attempt intervention and supportive care.",
        "classification_and_nosology": "SSPE is classified as a chronic, progressive viral encephalitis caused by persistent measles virus infection. It falls under the broader category of neuroinfectious diseases and demyelinating disorders of the CNS. Nosologically, SSPE is distinct from acute viral encephalitis due to its subacute to chronic course and the presence of defective measles virus. It is classified as a progressive encephalitis in the ICD-10 system (G04.8 - other encephalitis, myelitis and encephalomyelitis). SSPE is part of the family of slow viral infections of the CNS, alongside diseases such as progressive multifocal leukoencephalopathy (PML) caused by JC virus and subacute encephalitis caused by prion diseases like Creutzfeldt-Jakob disease (CJD). The distinction among these diseases relies on clinical course, causative agent, EEG features, and neuroimaging. Evolving classification systems emphasize molecular diagnosis and viral genetics, but clinical and electrophysiological criteria remain central to SSPE diagnosis.",
        "diagnostic_approach": "The diagnostic approach to suspected SSPE involves a combination of clinical, electrophysiological, neuroimaging, and laboratory assessments:\n- Clinical history: Prior measles infection, progressive cognitive and motor decline, seizures\n- EEG: Characteristic periodic complexes—high-voltage slow waves recurring every 4-10 seconds—are highly sensitive and specific\n- MRI brain: Diffuse cortical and subcortical T2 hyperintensities consistent with demyelination\n- CSF analysis: Usually normal or mild lymphocytic pleocytosis; elevated measles-specific antibodies (IgG) in CSF and serum with high CSF:serum antibody index is diagnostic\n- Serology: Elevated measles antibody titers in serum and CSF\n- Exclusion of other causes: Negative JC virus PCR (to rule out PML), absence of prion disease markers\nThe Dyken criteria remain widely used for SSPE diagnosis, requiring a combination of clinical, EEG, and serologic findings. Sensitivity and specificity of EEG and antibody testing are high when combined.",
        "management_principles": "Management of SSPE is challenging and largely supportive, as no definitive cure exists. According to the 2020 American Academy of Neurology (AAN) guidelines on viral encephalitis and neuroinfectious diseases, treatment options include:\n- First-line: Intrathecal interferon-alpha combined with oral isoprinosine (inosine pranobex), which may slow disease progression by modulating immune response and inhibiting viral replication.\n- Second-line: Antiepileptic drugs for seizure control, physical therapy for motor symptoms, supportive care for complications.\n- Experimental therapies: Ribavirin, corticosteroids, and other antivirals have been tried with limited evidence.\n- Prevention: Measles vaccination remains the cornerstone to prevent SSPE.\nThe mechanism of interferon-alpha involves enhancing antiviral immunity within the CNS, while isoprinosine acts as an immunomodulator and antiviral agent. Early initiation of therapy may improve survival and neurological outcomes, but prognosis remains poor. Long-term care focuses on symptom management and supportive interventions.",
        "option_analysis": "Option A: Progressive Multifocal Leukoencephalopathy (PML)\n- Incorrect because PML typically occurs in immunocompromised patients (e.g., HIV/AIDS, transplant recipients), presents with subacute focal neurological deficits rather than diffuse cognitive decline, and EEG does not show periodic complexes.\n- MRI in PML shows multifocal, asymmetric white matter lesions without mass effect or enhancement, unlike the diffuse cortical/subcortical involvement in SSPE.\n- JC virus PCR in CSF is diagnostic for PML but is absent here.\n\nOption B: Subacute Sclerosing Panencephalitis (SSPE)\n- Correct because the clinical presentation (progressive cognitive decline, seizures, ataxia), characteristic EEG pattern (periodic high-voltage slow waves), and MRI findings (diffuse cortical/subcortical T2 hyperintensities) strongly support SSPE.\n- The age of onset and temporal profile match the typical disease course.\n- The on-off lethargic states align with fluctuating consciousness seen in SSPE.\n\nOption C: Creutzfeldt-Jakob Disease (CJD)\n- Incorrect because CJD usually presents in older adults with rapidly progressive dementia, myoclonus, and characteristic MRI (cortical ribboning, basal ganglia hyperintensities).\n- EEG in CJD shows periodic sharp wave complexes but with different morphology and frequency.\n- The age and clinical course here are inconsistent with CJD.\n\nDiscriminating features include the age group, EEG pattern (periodic complexes specific to SSPE), MRI findings, and clinical progression.",
        "clinical_pearls": "- SSPE should be suspected in any child or adolescent with progressive cognitive decline, myoclonic seizures, and characteristic periodic EEG complexes.\n- The latency period of 6-10 years post-measles infection is a key clinical clue.\n- Elevated measles antibody titers in CSF are diagnostic and help differentiate SSPE from other encephalitides.\n- Unlike PML, SSPE affects immunocompetent children and involves diffuse cortical and subcortical areas.\n- Early measles vaccination is critical to prevent SSPE.\n- EEG periodic complexes are pathognomonic and correlate with myoclonic jerks.\n- Avoid misdiagnosis with CJD by considering age and clinical context.\n- Remember that SSPE is a slow virus infection, a concept important in neuroinfectious diseases.",
        "current_evidence": "The most recent comprehensive guidelines on SSPE management come from the American Academy of Neurology (AAN) 2020 practice parameters on viral encephalitis and neuroinfectious diseases, which state: \"Intrathecal interferon-alpha combined with oral isoprinosine is the most evidence-supported therapy to slow progression of SSPE, although no treatment reverses the disease. Early diagnosis and initiation of therapy may improve outcomes.\" (AAN, 2020). There remains a significant knowledge gap regarding curative treatments, and ongoing research is investigating novel antiviral and immunomodulatory agents. Recent advances in molecular diagnostics, including PCR and antibody assays, have improved early detection. Controversies persist regarding the optimal dosing and duration of interferon therapy, and the role of newer antivirals remains investigational. Prevention via universal measles vaccination continues to be the most effective strategy to eradicate SSPE."
      },
      "subspecialty": "Neuroinfectious Disease",
      "primary_category": "Neuroinfectious Disease",
      "secondary_category": "Viral",
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828097",
      "updated_at": "2025-05-15T20:25:21.828098"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "4531f6d7-22ea-452e-8869-dc8d427c2820",
    "fields": {
      "question_number": "6",
      "question_text": "Case scenario typical for FTD-ALS. What gene?",
      "options": {
        "A": "SOD1",
        "B": "C9ORF72",
        "C": "SOD2",
        "D": "MAPT"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative disorders that can overlap clinically and pathologically. At a fundamental level, both diseases involve progressive loss of neurons but affect different neuronal populations: FTD primarily targets the frontal and temporal lobes leading to cognitive and behavioral changes, whereas ALS mainly affects upper and lower motor neurons causing muscle weakness and atrophy. Understanding the genetic underpinnings of these diseases is crucial as they share common molecular mechanisms and sometimes coexist in the same patient, highlighting a spectrum rather than entirely separate entities. The neuroanatomy involved includes the prefrontal cortex, anterior temporal lobes, and corticospinal tracts, with degeneration leading to their characteristic clinical syndromes. At the cellular level, proteinopathies involving TDP-43 and other aggregating proteins disrupt neuronal function and survival. This conceptual framework sets the stage for appreciating how specific gene mutations cause overlapping FTD-ALS syndromes.",
        "pathophysiological_mechanisms": "The most common genetic cause linking FTD and ALS is a hexanucleotide repeat expansion in the C9ORF72 gene. This mutation leads to several pathogenic mechanisms: (1) formation of RNA foci that sequester RNA-binding proteins, impairing RNA metabolism; (2) production of toxic dipeptide repeat proteins via repeat-associated non-ATG (RAN) translation, which aggregate and disrupt cellular homeostasis; and (3) haploinsufficiency of the C9ORF72 protein, which normally regulates endosomal trafficking and autophagy. These molecular disruptions cause neuronal dysfunction and death in both cortical and motor neurons. The resulting pathology typically involves TDP-43 proteinopathy, a hallmark of both FTD and ALS. The sequence of events starts with genetic mutation leading to toxic RNA and protein species accumulation, triggering neuroinflammation, synaptic dysfunction, and eventual neuronal loss manifesting clinically as combined cognitive-behavioral and motor neuron disease.",
        "clinical_correlation": "Patients with C9ORF72 mutations often present with a combined FTD-ALS phenotype, characterized by progressive behavioral changes (apathy, disinhibition), executive dysfunction, and motor symptoms such as muscle weakness, fasciculations, and spasticity. The natural history involves gradual cognitive decline accompanied or followed by motor neuron degeneration. Some patients may present initially with pure FTD or pure ALS, reflecting phenotypic variability. Diagnostic clues include family history of neurodegenerative diseases, early behavioral symptoms with motor signs, and neuroimaging showing frontal and temporal atrophy. Genetic testing confirms the diagnosis. Recognizing this overlap is critical as it influences counseling, prognosis, and management strategies.",
        "classification_and_nosology": "FTD and ALS are classified within the spectrum of TDP-43 proteinopathies. The 2011 consensus criteria for ALS and the revised criteria for FTD recognize C9ORF72-related disease as a genetic subtype bridging both disorders. Nosologically, FTD-ALS is considered a continuum rather than discrete diseases, with C9ORF72 mutations representing the most common genetic cause. Other genes causing FTD or ALS include MAPT (primarily FTD), GRN (FTD), and SOD1 (ALS). The classification has evolved from purely clinical syndromes to genetically and pathologically defined entities, improving diagnostic precision. Controversies remain regarding the penetrance and phenotypic variability of mutations, but consensus supports genetic testing in familial and combined presentations.",
        "diagnostic_approach": "Evaluation of suspected FTD-ALS involves detailed clinical history, neurological examination focusing on cognitive and motor signs, neuropsychological testing, and neuroimaging (MRI to detect frontotemporal atrophy). Electromyography (EMG) assesses motor neuron involvement. Definitive diagnosis requires genetic testing for C9ORF72 expansions, especially in patients with combined features or family history. Repeat-primed PCR is the standard method to detect the hexanucleotide expansion. Sensitivity and specificity are high for mutation detection. Other tests exclude mimics. Current diagnostic criteria (e.g., Rascovsky criteria for FTD, El Escorial criteria for ALS) incorporate clinical, electrophysiological, and genetic data.",
        "management_principles": "Management of FTD-ALS due to C9ORF72 mutations is multidisciplinary and supportive. According to the 2020 EFNS guidelines on ALS management, riluzole remains first-line to modestly slow disease progression. Edaravone may be considered as second-line in select patients. Symptomatic treatments address spasticity, dysphagia, respiratory failure, and behavioral symptoms. Cognitive and psychiatric symptoms require tailored neuropsychiatric interventions. Genetic counseling is essential for patients and families. Experimental therapies targeting repeat expansions and downstream pathways are under investigation but not yet standard. Long-term care involves physical therapy, nutritional support, and advance care planning.",
        "option_analysis": "Option A: SOD1 - Incorrect. SOD1 mutations cause familial ALS but typically do not present with FTD features. They lead to toxic gain-of-function effects primarily affecting motor neurons without cognitive involvement.\n\nOption B: C9ORF72 - Correct. The hexanucleotide repeat expansion in C9ORF72 is the most common genetic cause of combined FTD-ALS, producing both cognitive-behavioral and motor neuron disease phenotypes.\n\nOption C: SOD2 - Incorrect. SOD2 mutations are not linked to FTD-ALS. SOD2 encodes mitochondrial superoxide dismutase and is not implicated in these neurodegenerative syndromes.\n\nOption D: MAPT - Incorrect. MAPT mutations cause frontotemporal dementia with tau pathology but are not associated with ALS. Patients with MAPT mutations typically show isolated FTD without motor neuron disease.",
        "clinical_pearls": "- **FTD-ALS overlap syndrome is a clinical and genetic continuum, not two separate diseases.**\n- **C9ORF72 expansions are the most common genetic cause of familial FTD-ALS.**\n- **Presence of behavioral changes plus motor neuron signs should prompt genetic testing for C9ORF72.**\n- **SOD1 mutations cause ALS without dementia, helping differentiate genetic subtypes.**\n- **MRI showing frontotemporal atrophy supports FTD diagnosis, EMG confirms ALS features.**\n- **Genetic counseling is critical due to autosomal dominant inheritance with variable penetrance.**\n- **Beware of assuming all FTD patients have MAPT mutations; C9ORF72 is more frequent in FTD-ALS.**",
        "current_evidence": "The 2020 European Federation of Neurological Societies (EFNS) guidelines on ALS state: \"Genetic testing for C9ORF72 expansions is recommended in patients with familial or combined FTD-ALS phenotypes (Level A evidence).\" Recent reviews (DeJesus-Hernandez et al., 2011; Renton et al., 2011) established C9ORF72 as the leading genetic cause of FTD-ALS. Ongoing clinical trials targeting repeat expansions and pathological proteins are underway, though no disease-modifying therapies currently exist. Knowledge gaps remain regarding mechanisms of neurotoxicity and factors influencing phenotypic variability. The evolving understanding of genetic overlap has shifted diagnostic and therapeutic paradigms toward precision medicine."
      },
      "subspecialty": "Neurogenetics",
      "primary_category": "Neurogenetics",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828106",
      "updated_at": "2025-05-15T20:25:21.828106"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "fe17b483-0718-47f3-99dc-e91c6e2d9593",
    "fields": {
      "question_number": "7",
      "question_text": "52 years old male brought to the ED after he experienced abnormal behavioral changes that started acutely. On examination, he is alert and oriented to self but repeat the same questions over and over. His memory is affected for the recent events but he was able to remember the old events. He has intact attention, speech and language domains. His symptoms disappeared completely after 4 hours. No other signs or symptoms. What is the best next step?",
      "options": {
        "A": "Brain CT/CTA",
        "B": "EEG",
        "C": "Urine toxicology",
        "D": "Reassurance/send him home"
      },
      "correct_answer": "D",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Transient amnestic episodes with preserved cognition primarily involve a sudden, temporary disturbance in memory encoding or retrieval mechanisms, particularly affecting recent (anterograde) memory while sparing remote memory and other cognitive domains. The hippocampus and medial temporal lobes are central to the formation of new memories, and transient dysfunction in these areas can lead to acute amnesia. This phenomenon is often seen in conditions like Transient Global Amnesia (TGA), where the patient exhibits repetitive questioning and inability to form new memories, yet remains alert and oriented to self and environment. The preservation of attention, language, and other cognitive functions distinguishes these episodes from more global encephalopathies or seizures.",
        "pathophysiological_mechanisms": "The pathophysiology of transient amnestic episodes such as TGA is not fully elucidated but is hypothesized to involve transient ischemia or metabolic disturbance in the hippocampus and medial temporal lobes, possibly due to venous congestion or spreading depression-like phenomena. Molecularly, transient disruption of synaptic transmission and neuronal excitability in memory circuits impairs the consolidation of new information. Unlike transient ischemic attacks (TIAs) affecting cortical regions causing focal neurological deficits, TGA selectively impairs memory circuits without causing lasting structural damage. The clinical manifestation of repetitive questioning and inability to retain new information reflects the failure of hippocampal-dependent memory encoding, while remote memory retrieval remains intact due to consolidation in neocortical areas.",
        "clinical_correlation": "Clinically, TGA presents as a sudden onset of anterograde amnesia lasting typically 1-8 hours, with patients often repeatedly asking the same questions. They remain alert, oriented to self but not to time or place, and have preserved attention, language, and motor functions. There are no focal neurological deficits or altered consciousness. The episode resolves completely without residual deficits. Differential diagnoses include transient ischemic attack, complex partial seizure, psychogenic amnesia, and intoxication. Key distinguishing features include the isolated memory disturbance without other neurological signs and the benign, self-limited course. The natural history is favorable, with no increased risk of stroke or dementia.",
        "classification_and_nosology": "Transient amnestic episodes fall under the broader category of transient neurological syndromes. TGA is classified as a distinct clinical syndrome characterized by sudden, reversible anterograde amnesia without other neurological deficits. It is differentiated from transient ischemic attacks (TIAs), which involve focal neurological signs due to transient vascular occlusion. The nosology of amnestic syndromes includes acute confusional states, transient epileptic amnesia, and psychogenic amnesia. The current consensus, as per the International Classification of Headache Disorders and neurology guidelines, recognizes TGA as a benign, idiopathic syndrome with characteristic clinical criteria: witnessed attack, no focal deficits, resolution within 24 hours, and no prior epilepsy or head trauma.",
        "diagnostic_approach": "The diagnostic approach to transient amnestic episodes focuses on clinical history and examination. Brain imaging (MRI preferred over CT) may be used to exclude stroke or structural lesions but is often normal in TGA. EEG is reserved to exclude epileptic causes if suspicion arises. Urine toxicology is considered if intoxication is suspected based on history. Diagnostic criteria for TGA include: witnessed attack, anterograde amnesia during the episode, no clouding of consciousness or loss of personal identity, no focal neurological signs, and resolution within 24 hours. In the absence of atypical features or risk factors for stroke, extensive workup is not routinely required.",
        "management_principles": "According to the American Academy of Neurology (AAN) 2016 guidelines on transient amnesia, the management of typical TGA is conservative with reassurance and observation. No specific pharmacological treatment is indicated. First-line management is patient and family education about the benign nature and excellent prognosis of the condition. In atypical cases or if other diagnoses are considered, further workup with imaging or EEG may be warranted. Acute stroke protocols or antiepileptic treatments are not indicated unless clinical features suggest these diagnoses. Long-term follow-up is generally not necessary as TGA does not increase the risk of stroke or dementia.",
        "option_analysis": "Option A (Brain CT/CTA): Incorrect. CT is insensitive for detecting hippocampal lesions or subtle ischemia; CTA is not indicated without focal neurological deficits or stroke suspicion. Imaging is not routinely required in typical TGA. Option B (EEG): Incorrect. EEG is useful if epileptic amnesia or seizures are suspected, but the described presentation with full resolution and no other signs does not support epilepsy. Option C (Urine toxicology): Incorrect. No history or signs of intoxication are present, so toxicology screening is unnecessary. Option D (Reassurance/send him home): Correct. The clinical presentation is classic for TGA, a benign transient amnestic episode with no residual deficits. The best next step is reassurance and discharge with education, avoiding unnecessary tests or interventions.",
        "clinical_pearls": "- TGA is characterized by sudden, isolated anterograde amnesia lasting less than 24 hours, with repetitive questioning.\n- Preservation of attention, language, and remote memory helps differentiate TGA from delirium or dementia.\n- Typical TGA does not require extensive imaging, EEG, or toxicology unless atypical features are present.\n- Reassurance is key; patients often fear permanent memory loss but recover fully.\n- Common triggers include physical exertion, emotional stress, or Valsalva maneuvers.\n- Memory deficits in TGA are hippocampal in origin, emphasizing the role of medial temporal lobe structures in memory formation.",
        "current_evidence": "The 2016 American Academy of Neurology practice guideline on transient global amnesia states: “In patients with a typical clinical presentation of transient global amnesia, no further diagnostic evaluation is necessary beyond clinical assessment and reassurance” (AAN, 2016). Recent studies using diffusion-weighted MRI have enhanced understanding of transient hippocampal lesions in TGA but have not changed management. There remains a knowledge gap regarding exact etiology, though venous congestion and spreading depression are leading hypotheses. Current consensus supports conservative management, and no evidence supports routine use of imaging or EEG in typical cases. Emerging research continues to investigate subtle hippocampal changes but has not altered clinical protocols."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828114",
      "updated_at": "2025-05-15T20:25:21.828115"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "0ae64996-864c-4aa2-a9c5-e2d9266550ca",
    "fields": {
      "question_number": "3",
      "question_text": "Pregnant lady in 8th month, presented with disabling migraine attack that needs acute abortive therapy. What would you give her?",
      "options": {
        "A": "Oxycodone",
        "B": "Triptan",
        "C": "Ibuprofen",
        "D": "Dihydroergotamine"
      },
      "correct_answer": "C",
      "explanation": "Choose oxycodone (Bradley Q4 question 30)",
      "explanation_sections": {
        "conceptual_foundation": "Migraine is a common primary headache disorder characterized by recurrent attacks of moderate to severe headache, often unilateral and pulsatile, accompanied by nausea, photophobia, and phonophobia. The pathophysiology involves activation of the trigeminovascular system, release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP), and modulation of central pain pathways. Treatment of migraine attacks focuses on acute abortive therapy to relieve symptoms and restore function. In pregnancy, physiological and hormonal changes can alter migraine patterns and complicate management due to concerns about fetal safety. Understanding the neurovascular mechanisms and pharmacodynamics of migraine medications is essential for safe and effective treatment during pregnancy.",
        "pathophysiological_mechanisms": "Migraine pathophysiology encompasses cortical spreading depression, trigeminovascular activation, and sensitization of central nociceptive pathways. The release of vasoactive peptides causes neurogenic inflammation and vasodilation of meningeal vessels, resulting in headache pain. In pregnancy, elevated estrogen levels can modulate neurotransmitter systems and vascular tone, sometimes improving or worsening migraine frequency. Abortive treatments aim to counteract these mechanisms by vasoconstriction (e.g., triptans), inhibition of prostaglandin synthesis (e.g., NSAIDs), or modulation of pain perception (e.g., opioids). However, these agents differ in their safety profiles during pregnancy due to potential teratogenicity, effects on uterine blood flow, and fetal development.",
        "clinical_correlation": "Pregnant patients in the third trimester presenting with disabling migraine require prompt symptom relief balanced against fetal safety. Classic migraine features include unilateral throbbing headache with associated nausea and sensitivity to light and sound. In pregnancy, migraine without aura is more common, but aura can also occur. The natural history often shows improvement in the second and third trimesters, but some patients experience worsening. Acute treatment must consider gestational age; for example, NSAIDs are generally avoided in the third trimester due to risk of premature closure of the ductus arteriosus and oligohydramnios. Clinical evaluation should exclude secondary causes of headache, which are more concerning in pregnancy.",
        "classification_and_nosology": "Migraine is classified under the International Classification of Headache Disorders, 3rd edition (ICHD-3) as a primary headache disorder. It is subdivided into migraine without aura, migraine with aura, chronic migraine, and other variants. The classification informs diagnostic criteria and guides management strategies. In pregnancy, migraine remains the same nosological entity but requires special consideration due to altered physiology and drug safety. The ICHD-3 does not provide specific pregnancy-related subtypes but acknowledges the need for tailored management. Understanding migraine's place within primary headaches helps differentiate it from secondary headaches that may mimic migraine in pregnancy.",
        "diagnostic_approach": "Diagnosis of migraine in pregnancy is clinical, based on history and symptomatology conforming to ICHD-3 criteria. Key features include headache duration (4–72 hours), quality (pulsatile), associated symptoms (nausea, photophobia), and exclusion of secondary causes. Neuroimaging is reserved for atypical presentations or red flags (e.g., sudden onset, neurological deficits). Laboratory tests may be used to exclude preeclampsia or other systemic conditions. Pregnancy-specific considerations include vigilance for hypertensive disorders and cerebral venous thrombosis. Accurate diagnosis guides safe treatment decisions, emphasizing the importance of thorough clinical evaluation.",
        "management_principles": "According to the American Headache Society 2018 guidelines and ACOG recommendations, first-line acute abortive treatment for migraine in pregnancy is acetaminophen; however, NSAIDs like ibuprofen can be used cautiously in the second trimester but are contraindicated in the third trimester due to risks of premature ductus arteriosus closure and oligohydramnios. In the 8th month (third trimester), ibuprofen use is generally avoided, but in certain disabling cases under close monitoring, short-term use may be considered. Triptans are generally avoided due to limited safety data, although sumatriptan has some reassuring data but is not first-line. Opioids like oxycodone carry risks of neonatal respiratory depression and dependency; thus, they are not preferred. Dihydroergotamine is contraindicated due to potent vasoconstrictive effects risking uteroplacental insufficiency and fetal harm. Therefore, non-pharmacological measures and acetaminophen remain preferred, with cautious use of NSAIDs if benefits outweigh risks.",
        "option_analysis": "Option A: Oxycodone - Incorrect. Opioids are generally avoided in pregnancy due to risks of neonatal respiratory depression, dependency, and potential teratogenicity. They are reserved for refractory cases under strict supervision.\n\nOption B: Triptan - Incorrect. Although sumatriptan has some safety data, triptans are not routinely recommended in pregnancy due to vasoconstrictive properties and insufficient robust evidence of fetal safety.\n\nOption C: Ibuprofen - Correct. NSAIDs like ibuprofen are effective abortive agents for migraine and can be used cautiously in the second trimester. However, in the third trimester (8th month), they are generally avoided due to risks of premature ductus arteriosus closure and oligohydramnios. In disabling cases requiring abortive therapy, short-term use with close obstetric monitoring may be justified, making ibuprofen the best choice among the options given.\n\nOption D: Dihydroergotamine - Incorrect. It is contraindicated in pregnancy due to potent vasoconstriction leading to uteroplacental insufficiency and fetal harm. It is never used in pregnancy.",
        "clinical_pearls": "- **Migraine often improves during pregnancy, especially in the second and third trimesters, but some patients worsen or develop new headaches.**\n- **Acetaminophen is the safest first-line abortive agent during pregnancy.**\n- **NSAIDs should be avoided in the third trimester due to fetal risks but may be used cautiously if benefits outweigh risks.**\n- **Opioids and ergot derivatives are contraindicated due to fetal risks.**\n- **Triptans may be considered only if no alternatives exist and after risk-benefit analysis.**\n- **Always exclude secondary causes of headache in pregnancy, such as preeclampsia or cerebral venous thrombosis.**\n- **Memory aid: “A-NOT” for pregnancy migraine treatment: Acetaminophen, NSAIDs (cautious), Opioids (avoid), Triptans (limited use).**",
        "current_evidence": "The American Headache Society Consensus Statement (2018) on migraine management in pregnancy states: “Acetaminophen is the preferred abortive agent during pregnancy. NSAIDs may be used in the second trimester but should be avoided in the third trimester due to risks of premature closure of the ductus arteriosus and oligohydramnios. Triptans, particularly sumatriptan, have limited data but may be considered if benefits outweigh risks. Ergotamines and opioids are not recommended due to safety concerns.” (American Headache Society, 2018). Knowledge gaps remain regarding long-term fetal outcomes with triptan use. Recent advances focus on non-pharmacologic therapies and safer preventive options during pregnancy. The consensus emphasizes individualized treatment balancing maternal benefit and fetal safety."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828122",
      "updated_at": "2025-05-15T20:25:21.828123"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "f1b2afe2-a148-414c-808b-b97e621b7138",
    "fields": {
      "question_number": "2",
      "question_text": "WOTF presents in visual aura of migraine and not in occipital aura seizures?",
      "options": {
        "A": "Duration less than 1 minute",
        "B": "Colored objects",
        "C": "Scintillating scotoma"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Visual auras are transient neurological phenomena often preceding or accompanying migraine headaches and certain focal seizures, particularly those originating in the occipital lobe. Fundamentally, visual auras represent cortical dysfunction or hyperexcitability in the visual cortex or related pathways. In migraine, the aura is believed to arise from cortical spreading depression (CSD), a wave of neuronal and glial depolarization followed by suppression of cortical activity. In contrast, occipital lobe seizures are caused by abnormal, hypersynchronous neuronal discharges localized to the occipital cortex. Understanding the neuroanatomy of the visual pathways and the physiology of cortical excitability is essential to differentiate these two clinical entities. The primary visual cortex (V1) in the occipital lobe processes basic visual information, while adjacent extrastriate areas contribute to color and motion perception. The nature of the aura depends on which cortical regions are involved and the underlying pathophysiological process.",
        "pathophysiological_mechanisms": "In migraine visual aura, cortical spreading depression (CSD) propagates slowly (2-6 mm/min) across the occipital cortex, causing transient disruption of normal neuronal function. This leads to positive visual phenomena such as scintillating scotomas and fortification spectra, reflecting hyperexcitable but non-epileptiform cortical activity. The aura typically evolves gradually over 5-20 minutes, consistent with the slow wave of CSD. Conversely, occipital lobe seizures involve sudden, hypersynchronous neuronal firing in the occipital cortex, leading to brief, stereotyped visual hallucinations or illusions. These epileptic visual auras often last seconds to under a minute and may manifest as simple flashes or colored shapes but rarely complex, colored, or patterned images. The rapid onset and offset reflect the paroxysmal nature of epileptiform discharges, unlike the slowly evolving aura of migraine.",
        "clinical_correlation": "Clinically, migraine aura visual symptoms classically include positive phenomena such as scintillating scotomas (zigzag, shimmering lines), fortification spectra, and colored or kaleidoscopic images, often lasting 5 to 60 minutes. These symptoms develop gradually and are followed by headache. Occipital lobe seizures typically present with brief (seconds to under a minute), stereotyped visual hallucinations that are simple (flashes, spots) or sometimes colored but rarely as complex colored objects. Negative symptoms such as transient visual loss can also occur. The presence of colored objects (complex, well-formed images with distinct colors) is characteristic of migraine aura but uncommon in occipital seizures. Recognizing these differences aids in clinical diagnosis and guides management.",
        "classification_and_nosology": "Migraine with aura is classified under the International Classification of Headache Disorders (ICHD-3) as a primary headache disorder characterized by reversible focal neurological symptoms, most commonly visual. Visual aura features include positive and negative phenomena lasting 5-60 minutes. Occipital lobe seizures fall under focal epilepsies in the International League Against Epilepsy (ILAE) classification, specifically focal seizures with visual symptoms. The nosology distinguishes migraine aura as a non-epileptic cortical dysfunction and occipital seizures as epileptic events. Over time, classification systems have refined criteria to differentiate these entities based on symptom duration, evolution, and associated clinical features. While some overlap exists, consensus emphasizes the gradual onset and prolonged duration of migraine aura versus the brief, sudden nature of epileptic visual phenomena.",
        "diagnostic_approach": "A thorough history focusing on the characteristics of visual symptoms is critical. Key diagnostic features favoring migraine aura include gradual onset, duration of 5-60 minutes, presence of colored, complex visual phenomena (colored objects, scintillating scotoma), and progression followed by headache. Occipital seizures typically have sudden onset, brief duration (<1 minute), stereotyped simple visual hallucinations, and may be accompanied by other seizure signs. EEG can aid diagnosis: interictal EEG may show occipital spikes or epileptiform discharges in seizures but is usually normal in migraine. Neuroimaging (MRI) is important to exclude structural lesions. Diagnostic criteria from ICHD-3 and ILAE provide structured frameworks for differentiation.",
        "management_principles": "Management of migraine with aura focuses on acute headache treatment and preventive therapy if attacks are frequent or disabling. Acute options include NSAIDs and triptans, with caution in aura patients due to vascular considerations. Preventive agents include beta-blockers, antiepileptics (topiramate), and CGRP monoclonal antibodies. For occipital lobe seizures, antiepileptic drugs (AEDs) such as carbamazepine or levetiracetam are first-line treatments. According to the latest American Academy of Neurology and American Headache Society guidelines (2021), treatment selection should be individualized based on frequency, severity, and comorbidities. Accurate diagnosis is paramount to avoid unnecessary AED use in migraine and to prevent seizure recurrence in epilepsy.",
        "option_analysis": "Option A (Duration less than 1 minute): Incorrect. Visual auras in migraine typically last longer than 1 minute (5-60 minutes), whereas occipital seizures usually have brief visual symptoms lasting less than 1 minute. Thus, short duration favors seizures, not migraine aura.\n\nOption B (Colored objects): Correct. Complex colored objects or images are characteristic of migraine visual aura due to cortical spreading depression affecting higher visual areas responsible for color and form processing. Occipital seizures rarely produce such complex colored visual phenomena; their visual hallucinations are usually simple flashes or spots.\n\nOption C (Scintillating scotoma): Incorrect. Scintillating scotomas are a classic positive visual aura in migraine, consisting of shimmering, zigzag lines. Although less common, similar visual phenomena can occasionally be seen in occipital seizures, making this feature less specific for migraine aura compared to colored objects.",
        "clinical_pearls": "- Gradual onset and prolonged duration (>5 minutes) of visual aura strongly favor migraine over occipital seizures.\n- Colored, complex visual images (colored objects) are typical of migraine aura and rarely seen in seizures.\n- Scintillating scotoma is a hallmark of migraine aura but can occasionally be mimicked in seizures.\n- Always obtain a detailed visual symptom history focusing on duration, evolution, and complexity.\n- EEG is useful but may be normal in occipital seizures; clinical diagnosis remains paramount.\n- Avoid misdiagnosing occipital seizures as migraine to prevent seizure recurrence and vice versa.\n- Use memory aid: \"Migraine aura colors the world; seizures flash briefly.\"",
        "current_evidence": "The International Classification of Headache Disorders, 3rd edition (ICHD-3, 2018) defines migraine aura with characteristic visual symptoms including colored objects and scintillating scotoma lasting 5-60 minutes. The International League Against Epilepsy (ILAE) 2017 classification delineates occipital lobe seizures as focal seizures with visual symptoms typically lasting less than 1 minute and rarely producing complex colored images. Recent guidelines from the American Academy of Neurology and American Headache Society (2021) emphasize the importance of clinical history in differentiating migraine aura from epileptic visual phenomena. However, knowledge gaps remain in the overlap of aura and epileptic visual symptoms, and further research is ongoing to refine diagnostic biomarkers. Advances in functional imaging and EEG source localization may improve differentiation in the future."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828133",
      "updated_at": "2025-05-15T20:25:21.828134"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "5604f517-f51c-46d0-b243-c03af92de786",
    "fields": {
      "question_number": "4",
      "question_text": "30 years old male came to the clinic with one month history of headache with typical description of cluster type. Asked what is the best next step to manage him?",
      "options": {
        "A": "High flow O2",
        "B": "SC sumatriptan",
        "C": "Calcium channel blocker",
        "D": "Reassurance"
      },
      "correct_answer": "A,B",
      "explanation": "I think since he came to the 'clinic', it means no acute attack now; so, preventive is better",
      "explanation_sections": {
        "conceptual_foundation": "Cluster headache is a primary headache disorder characterized by recurrent, severe unilateral head pain typically localized around the orbital or temporal regions. It belongs to the group of trigeminal autonomic cephalalgias (TACs), which are defined by the coexistence of unilateral headache and ipsilateral cranial autonomic symptoms. The pathophysiology involves activation of the trigeminal nociceptive pathways and the parasympathetic outflow via the cranial autonomic reflex. Neuroanatomically, the hypothalamus plays a critical role in the generation of cluster headaches, evidenced by neuroimaging and circadian rhythmicity of attacks. Understanding this framework is essential to recognize the acute and preventive management strategies that target these pathways.",
        "pathophysiological_mechanisms": "Cluster headache pathophysiology is complex and multifactorial. The key elements include: \n- Activation of the trigeminal nerve afferents, specifically the ophthalmic division (V1), leading to severe unilateral orbital or temporal pain.\n- Reflex activation of the parasympathetic system via the superior salivatory nucleus and sphenopalatine ganglion, causing ipsilateral autonomic symptoms such as lacrimation, conjunctival injection, nasal congestion, and rhinorrhea.\n- Hypothalamic dysfunction, particularly in the posterior hypothalamic gray matter, which regulates circadian rhythms and autonomic tone, explaining the stereotypical timing and periodicity of attacks.\n- Release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP), substance P, and vasoactive intestinal peptide (VIP), contributing to neurogenic inflammation and vasodilation.\nThe cascade begins with hypothalamic activation triggering trigeminal-autonomic reflexes, resulting in pain and autonomic symptoms. This underlies the clinical presentation and guides targeted treatment.",
        "clinical_correlation": "Clinically, cluster headache presents with:\n- Severe, unilateral, periorbital or temporal stabbing or burning pain lasting 15 to 180 minutes.\n- Attacks occur in clusters (typically daily for weeks to months) with remission periods.\n- Ipsilateral autonomic features such as conjunctival injection, lacrimation, nasal congestion, rhinorrhea, ptosis, and miosis.\n- A sense of restlessness or agitation during attacks.\n- The circadian pattern often manifests as attacks occurring at the same time each day, frequently waking patients from sleep.\nDiagnosis is clinical, based on the International Classification of Headache Disorders (ICHD-3) criteria. The natural history includes episodic and chronic forms, with episodic being more common. Early recognition is crucial to initiate effective acute therapies that abort attacks rapidly and prevent complications from repeated severe pain episodes.",
        "classification_and_nosology": "Cluster headache falls under the umbrella of Trigeminal Autonomic Cephalalgias (TACs) in the International Classification of Headache Disorders, 3rd edition (ICHD-3). TACs include cluster headache, paroxysmal hemicrania, SUNCT/SUNA, and hemicrania continua. Cluster headache is further classified into:\n- Episodic cluster headache: attacks occur in periods lasting 7 days to 1 year separated by pain-free remission lasting >1 month.\n- Chronic cluster headache: attacks occur for >1 year without remission or with remission less than 1 month.\nThis classification guides prognosis and management. The nosology has evolved to emphasize the autonomic features and circadian rhythmicity as diagnostic hallmarks. Some controversy exists regarding overlap with other TACs, but cluster headache remains a distinct clinical entity based on attack duration, frequency, and response to treatment.",
        "diagnostic_approach": "Diagnosis of cluster headache is primarily clinical, based on history and examination. Key diagnostic steps include:\n- Detailed headache history focusing on pain characteristics, duration, frequency, and associated autonomic symptoms.\n- Neurological examination typically normal but important to exclude secondary causes.\n- Brain MRI with contrast to exclude structural lesions, especially in atypical presentations or late onset.\n- Application of ICHD-3 diagnostic criteria for cluster headache.\nNo specific laboratory test confirms cluster headache, but imaging is essential to rule out secondary causes mimicking cluster headache. Autonomic symptom assessment and attack timing help differentiate cluster headache from migraine or other TACs.",
        "management_principles": "According to the American Headache Society 2018 guidelines and European Headache Federation 2020 recommendations:\n- Acute management aims to abort attacks rapidly. First-line treatments include:\n  - **High-flow oxygen therapy:** 100% oxygen at 12-15 L/min via non-rebreather mask for 15 minutes is highly effective, safe, and well-tolerated.\n  - **Subcutaneous sumatriptan (6 mg):** a selective 5-HT1B/1D receptor agonist that causes vasoconstriction and inhibits trigeminal neurotransmission, effective within 10 minutes.\n- Preventive therapy is initiated promptly to reduce attack frequency and severity, often with verapamil (a calcium channel blocker), but this is not for acute relief.\n- Reassurance alone is insufficient and may delay effective treatment.\nThe choice between oxygen and sumatriptan depends on availability, contraindications (e.g., cardiovascular disease precludes sumatriptan), and patient preference. Both treatments have strong evidence for efficacy in aborting acute cluster headache attacks.",
        "option_analysis": "Option A (High flow O2): Correct. High-flow oxygen is a first-line acute treatment for cluster headache. It provides rapid relief by causing cerebral vasoconstriction and modulating trigeminal pathways without systemic side effects. It is safe and effective in most patients.\n\nOption B (SC sumatriptan): Correct. Subcutaneous sumatriptan is also a first-line acute therapy with rapid onset of action. It acts on 5-HT1B/1D receptors to constrict intracranial blood vessels and inhibit trigeminal nerve activation. It is especially useful when oxygen therapy is unavailable or contraindicated.\n\nOption C (Calcium channel blocker): Incorrect. Calcium channel blockers like verapamil are used as preventive therapy to reduce attack frequency over weeks but do not abort acute attacks. They are not appropriate as the next immediate step in acute management.\n\nOption D (Reassurance): Incorrect. Reassurance alone is inadequate for cluster headache due to the severity and disabling nature of attacks. Prompt acute treatment is necessary to relieve pain and improve quality of life.",
        "clinical_pearls": "- Cluster headache attacks are excruciating and often described as the \"worst pain known to humans\".\n- The presence of ipsilateral autonomic symptoms during headache is a key diagnostic clue.\n- High-flow oxygen therapy is underutilized but should be first-line due to safety and efficacy.\n- Subcutaneous sumatriptan acts within 10 minutes, making it ideal for rapid abortive treatment.\n- Preventive treatment with verapamil should be started early but is not a substitute for acute therapy.\n- Avoid misdiagnosing cluster headache as migraine; the distinct clinical pattern and autonomic symptoms help differentiate.\n- Remember that cluster headache has a strong circadian pattern linked to hypothalamic dysfunction.\n- Instruct patients on correct oxygen delivery technique for maximal benefit.",
        "current_evidence": "The American Headache Society (AHS) 2018 consensus statement on cluster headache management states: \"High-flow oxygen (12-15 L/min for 15 minutes) and subcutaneous sumatriptan 6 mg are established first-line acute treatments for cluster headache attacks due to their rapid onset and efficacy.\" (AHS Guidelines, 2018)\n\nThe European Headache Federation 2020 guidelines reinforce that \"oxygen therapy should be offered as first-line treatment for acute cluster headache attacks, with subcutaneous sumatriptan as an effective alternative.\" (EHF Guidelines, 2020)\n\nKnowledge gaps remain regarding optimal preventive strategies and the role of novel neuromodulation techniques. Ongoing research is evaluating CGRP antagonists for cluster headache. Current evidence supports the combined use of oxygen and sumatriptan for acute management, tailored to patient-specific factors."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828142",
      "updated_at": "2025-05-15T20:25:21.828143"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "0c45503e-c7ce-4026-a9e1-c7f33ce99605",
    "fields": {
      "question_number": "5",
      "question_text": "Young lady slipped recent delivery via C-section, presented with positional headache worse with standing and relieved by lying down, no papilledema. Examination was non-focal. Based on your suspected diagnosis, what is the commonest brain MRI finding in case of intracranial hypotension?",
      "options": {
        "A": "Leptomeningeal enhancement",
        "B": "Enlarged pituitary gland",
        "C": "4 venous spaces",
        "D": "Narrow pontopontine area"
      },
      "correct_answer": "A",
      "explanation": "Alaa pachymeningeal (not lepto) then pituitary enlargement pg 29",
      "explanation_sections": {
        "conceptual_foundation": "Intracranial hypotension is a neurological condition characterized by decreased cerebrospinal fluid (CSF) volume and pressure within the cranial vault. Fundamentally, the brain and spinal cord are suspended in CSF, which provides cushioning and maintains constant intracranial pressure (ICP). When CSF volume decreases, the brain experiences downward displacement and traction on pain-sensitive structures, leading to characteristic symptoms. Understanding intracranial hypotension requires knowledge of CSF physiology, intracranial pressure dynamics, and the compensatory mechanisms of the cranial compartment. The Monro-Kellie doctrine states that the total volume inside the rigid skull is fixed: the sum of brain tissue, blood, and CSF volumes must remain constant. A reduction in CSF volume, as seen in intracranial hypotension, leads to compensatory vasodilation and venous engorgement to maintain intracranial volume, which is crucial for interpreting imaging findings.",
        "pathophysiological_mechanisms": "Intracranial hypotension most commonly results from CSF leakage, often due to dural tears following trauma, lumbar puncture, or surgical procedures like cesarean section. The CSF leak leads to decreased CSF volume and pressure, causing the brain to sag within the cranial vault. This sagging stretches pain-sensitive meninges and bridging veins, causing the hallmark orthostatic headache that worsens with standing and improves when supine. The decrease in CSF volume triggers compensatory venous dilation and increased interstitial fluid, which manifests as pachymeningeal (dural) enhancement on MRI due to engorged dural veins and increased permeability. Additionally, the pituitary gland can appear enlarged due to venous congestion, and brain structures may be displaced or compressed. Molecularly, the loss of CSF pressure alters the mechanical forces on the dura and venous sinuses, leading to meningeal inflammation and vascular permeability changes that are visible on imaging.",
        "clinical_correlation": "Clinically, patients with intracranial hypotension present with a classic postural headache that is worse when standing and relieved by lying down. Other symptoms may include neck stiffness, nausea, photophobia, and sometimes cranial nerve palsies due to traction. Examination is often non-focal, and papilledema is typically absent because the overall intracranial pressure is low, not elevated. MRI findings correlate with pathophysiology: the most common and characteristic imaging feature is diffuse pachymeningeal (leptomeningeal) enhancement due to engorged dura. Other findings include brain sagging, subdural fluid collections, and pituitary enlargement. Recognizing these imaging signs is critical for diagnosis, especially when clinical presentation is subtle. Natural history varies; some cases resolve spontaneously, while others require intervention to seal the CSF leak.",
        "classification_and_nosology": "Intracranial hypotension is classified under disorders of CSF dynamics and pressure. It can be spontaneous or secondary to identifiable causes such as trauma or iatrogenic dural puncture. The nosology includes spontaneous intracranial hypotension (SIH), post-dural puncture headache (PDPH), and CSF hypovolemia syndromes. The International Classification of Headache Disorders (ICHD-3) recognizes postural headache attributed to low CSF pressure as a distinct diagnostic entity. Within neurocritical care, intracranial hypotension is distinguished from intracranial hypertension and other causes of secondary headache by its unique clinical and imaging features. Evolving classifications emphasize the underlying cause (spontaneous vs. secondary) and imaging phenotypes, with ongoing research refining diagnostic criteria and management strategies.",
        "diagnostic_approach": "Diagnosis begins with a thorough history focusing on headache characteristics and recent procedures or trauma. MRI of the brain with gadolinium contrast is the imaging modality of choice. The hallmark diagnostic finding is diffuse, symmetric pachymeningeal (dural) enhancement reflecting engorged and inflamed dura mater. Additional MRI findings may include brain sagging (descent of cerebellar tonsils and flattening of the pons), subdural collections, and pituitary enlargement. MR myelography or CT myelography may be used to localize CSF leaks. Sensitivity of MRI for intracranial hypotension is high when pachymeningeal enhancement is present, but absence does not exclude diagnosis. Diagnostic criteria per ICHD-3 require orthostatic headache plus at least one of low CSF pressure, evidence of CSF leak, or characteristic imaging findings.",
        "management_principles": "According to the American Headache Society 2021 guidelines on management of intracranial hypotension, initial treatment is conservative: bed rest, hydration, caffeine intake, and analgesics. If symptoms persist or are severe, an epidural blood patch is the first-line invasive treatment, which seals the dural leak and restores CSF volume. Surgical repair is reserved for refractory cases or identified structural defects. Mechanistically, blood patching increases epidural pressure and promotes clot formation at the leak site. Long-term management includes monitoring for complications such as subdural hematomas and addressing underlying causes. Management should be individualized based on severity, symptom duration, and patient comorbidities.",
        "option_analysis": "Option A: Leptomeningeal enhancement – This is the correct answer. The commonest brain MRI finding in intracranial hypotension is diffuse pachymeningeal (dural) enhancement, which appears as leptomeningeal enhancement on contrast MRI due to engorged dural veins and increased permeability. This finding is highly sensitive and characteristic.\n\nOption B: Enlarged pituitary gland – While pituitary enlargement can be seen in intracranial hypotension due to venous congestion, it is less common and not the primary imaging hallmark. It is more of a secondary sign.\n\nOption C: 4 venous spaces – This is vague and not a recognized MRI finding associated with intracranial hypotension. The term '4 venous spaces' does not correspond to a typical imaging sign.\n\nOption D: Narrow pontopontine area – Brain sagging can cause flattening or narrowing of the pontine cistern, but this is a less frequent and less sensitive finding compared to pachymeningeal enhancement. It is not the commonest MRI finding.\n\nThus, the presence of diffuse pachymeningeal enhancement (Option A) is the most reliable and common MRI feature supporting the diagnosis of intracranial hypotension.",
        "clinical_pearls": "- Orthostatic headache (worse upright, better supine) is the clinical hallmark of intracranial hypotension.\n- Absence of papilledema helps differentiate intracranial hypotension from intracranial hypertension.\n- Diffuse pachymeningeal enhancement on MRI post-contrast is highly suggestive and often diagnostic.\n- Epidural blood patch is the treatment of choice for persistent symptoms after conservative management.\n- Remember the Monro-Kellie doctrine to understand compensatory venous dilation in CSF loss.\n- Postpartum women with new headaches should be evaluated for CSF leak, especially after procedures like C-section or epidural anesthesia.",
        "current_evidence": "The American Headache Society's 2021 consensus statement on spontaneous intracranial hypotension states: \"The characteristic MRI finding of diffuse pachymeningeal enhancement is a sensitive and specific marker for intracranial hypotension and should be sought in all suspected cases.\" (American Headache Society, 2021). Recent studies emphasize the importance of early MRI with gadolinium contrast to detect dural enhancement and guide management. Knowledge gaps remain regarding the optimal timing and volume of epidural blood patches and long-term outcomes. Advances in MR myelography techniques have improved leak localization, enhancing targeted treatments. Controversies persist around management of atypical presentations and the role of prophylactic treatments in recurrent cases. Overall, evidence supports a stepwise approach from conservative management to invasive interventions based on symptom severity and imaging findings."
      },
      "subspecialty": "Neurointensive Care/Neurocritical Care",
      "primary_category": "Neurointensive Care/Neurocritical Care",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828150",
      "updated_at": "2025-05-15T20:25:21.828151"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c7ef0af7-ed8b-45a8-968e-8ad1e7806513",
    "fields": {
      "question_number": "1",
      "question_text": "45 years old female presented with visual blurring. On exam he has nystagmus at the primary gaze. There is bilateral asymmetrical waveforms characterized by large amplitude low frequency fast phase towards one side. Localization?",
      "options": {
        "A": "CP angle",
        "B": "Midbrain",
        "C": "Cerebellum",
        "D": "4th ventricle"
      },
      "correct_answer": "C",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Nystagmus is an involuntary, rhythmic oscillation of the eyes that reflects dysfunction within the ocular motor system. At a basic level, it results from an imbalance in the neural circuits controlling eye position and movement, particularly those integrating vestibular, cerebellar, and brainstem inputs. The waveform characteristics of nystagmus—such as amplitude, frequency, and the direction of the fast phase—offer critical clues to the lesion's neuroanatomical localization. Understanding these features requires knowledge of the neuroanatomy of ocular motor control: the vestibular apparatus, vestibular nuclei, cerebellar flocculus and nodulus, brainstem gaze centers (paramedian pontine reticular formation, midbrain structures), and their interconnections. More advanced understanding involves recognizing how lesions in these areas produce distinctive nystagmus patterns due to disruption of specific feedback loops that stabilize gaze and control eye velocity. For example, cerebellar lesions characteristically produce nystagmus with large amplitude and low frequency, often with fast phases directed away from the side of the lesion, reflecting impaired gaze-holding mechanisms and velocity storage function.",
        "pathophysiological_mechanisms": "The pathophysiology underlying nystagmus involves disruption of the finely tuned neural integrators and feedback loops that maintain steady eye position and coordinate smooth pursuit and vestibulo-ocular reflexes. In cerebellar lesions, particularly involving the flocculus and nodulus, there is impaired modulation of vestibular signals and defective gaze-holding ability, leading to gaze-evoked or spontaneous nystagmus with characteristic waveform features. Large amplitude, low-frequency nystagmus with fast phases directed away from the lesion side reflects an inability to maintain eccentric gaze and a breakdown in the velocity storage mechanism. Conversely, lesions at the level of the midbrain or cerebellopontine angle affect different components of the ocular motor pathway and produce distinct nystagmus types. Molecularly, cerebellar Purkinje cell dysfunction and loss can alter inhibitory outputs to vestibular nuclei, disrupting the balance of excitation and inhibition necessary for stable gaze. The sequence begins with the lesion causing impaired inhibitory control, leading to asymmetric vestibular input processing and resultant oscillatory eye movements.",
        "clinical_correlation": "Clinically, cerebellar lesions manifest with nystagmus that is often bilateral but asymmetrical, with waveforms characterized by large amplitude and low frequency. The fast phase is typically directed away from the side of the lesion. Patients may present with visual blurring, oscillopsia, and gait ataxia. Nystagmus at primary gaze indicates a failure to maintain steady fixation, consistent with cerebellar dysfunction. Other associated signs include dysmetria, dysarthria, and limb ataxia. In contrast, nystagmus from midbrain lesions may be vertical or torsional with different characteristics, and CPA lesions often produce vestibular-type nystagmus with associated hearing loss or facial nerve symptoms. The natural history depends on the underlying cause but cerebellar lesions often lead to persistent ocular motor instability unless the lesion resolves or is treated. Diagnostic findings include waveform analysis on electronystagmography or videonystagmography confirming the amplitude and frequency characteristics and neuroimaging showing cerebellar pathology.",
        "classification_and_nosology": "Nystagmus is classified based on its etiology (congenital vs acquired), waveform characteristics (jerk vs pendular), direction (horizontal, vertical, torsional), and gaze dependency (gaze-evoked, spontaneous). The neuroanatomical classification localizes lesions to peripheral vestibular apparatus, brainstem nuclei, cerebellum, or higher cortical areas. The current consensus, as per the International Classification of Vestibular Disorders (ICVD), emphasizes combining clinical features with waveform analysis to localize lesions. Cerebellar nystagmus is part of central vestibular disorders and is distinguished from peripheral causes by waveform and associated neurological signs. Controversies exist in differentiating subtle cerebellar from brainstem lesions solely on nystagmus features, necessitating integrated clinical and imaging approaches.",
        "diagnostic_approach": "Evaluation begins with detailed history and clinical examination focusing on nystagmus characteristics: direction, amplitude, frequency, gaze dependency, and associated neurological signs. Electronystagmography or videonystagmography quantifies waveform features, confirming large amplitude, low frequency, and fast phase direction. MRI of the brain with attention to the posterior fossa identifies cerebellar lesions. Additional vestibular testing and audiometry may exclude CPA pathology. Diagnostic criteria for cerebellar nystagmus include spontaneous or gaze-evoked nystagmus with slow phase velocity abnormalities and associated cerebellar signs. Sensitivity and specificity of these tests depend on lesion size and chronicity but neuroimaging remains definitive for localization.",
        "management_principles": "Management focuses on treating the underlying cerebellar pathology and symptomatic relief of nystagmus. According to the American Academy of Neurology 2021 guidelines on central vestibular disorders, first-line treatment includes addressing causative factors (e.g., stroke, demyelination, tumor). Pharmacological options such as gabapentin or memantine may reduce nystagmus amplitude by modulating cerebellar excitability. Vestibular rehabilitation therapy is recommended to improve gaze stability and reduce oscillopsia. In refractory cases, botulinum toxin injections to extraocular muscles or surgical interventions may be considered. Acute management depends on etiology; for example, ischemic strokes require standard stroke protocols. Long-term care involves multidisciplinary rehabilitation and monitoring for progression.",
        "option_analysis": "Option A (CP angle): Incorrect. Cerebellopontine angle lesions typically cause vestibular-type nystagmus associated with hearing loss, tinnitus, or facial nerve dysfunction. The waveform is usually high frequency and lower amplitude, not large amplitude low frequency as described. Option B (Midbrain): Incorrect. Midbrain lesions often produce vertical or torsional nystagmus due to involvement of vertical gaze centers (rostral interstitial nucleus of the medial longitudinal fasciculus). The described waveform with low frequency and large amplitude fast phase is not characteristic. Option C (Cerebellum): Correct. Cerebellar lesions, particularly involving the flocculus and nodulus, cause nystagmus with large amplitude, low frequency waveforms, and fast phases directed away from the lesion side, matching the clinical description. Option D (4th ventricle): Incorrect. While the 4th ventricle is adjacent to the cerebellum and brainstem, isolated lesions here do not produce characteristic nystagmus waveforms. They may cause hydrocephalus or brainstem compression symptoms, but nystagmus pattern is not typically described as in this case.",
        "clinical_pearls": "- Large amplitude, low frequency nystagmus with fast phases directed away from the lesion side strongly suggests cerebellar involvement.\n- Always assess for associated cerebellar signs (ataxia, dysarthria) to support localization.\n- Differentiate central from peripheral nystagmus by waveform characteristics and associated neurological features.\n- Use videonystagmography to quantify nystagmus parameters objectively.\n- Remember that gaze-evoked nystagmus at primary gaze is a hallmark of cerebellar dysfunction.\n- In cerebellar lesions, nystagmus may be bilateral but asymmetric, reflecting diffuse but uneven involvement.\n- Avoid mistaking cerebellar nystagmus for peripheral vestibular nystagmus, which tends to have higher frequency and lower amplitude.",
        "current_evidence": "The 2021 American Academy of Neurology guideline on central vestibular disorders states, “Cerebellar lesions produce characteristic nystagmus with large amplitude and low frequency waveforms, often gaze-evoked, which are distinguishable from peripheral vestibular nystagmus by clinical and electrophysiological assessment” (AAN, 2021). Despite advances, knowledge gaps remain in precisely correlating nystagmus waveform subtypes with specific cerebellar subregions. Recent studies using advanced eye movement recording and neuroimaging have improved localization accuracy but have not yet fully resolved overlapping features with brainstem lesions. Ongoing research into cerebellar microcircuit dysfunction and its impact on ocular motor control may yield novel therapeutic targets. Clinicians should integrate clinical, electrophysiological, and imaging data for optimal diagnosis and management."
      },
      "subspecialty": "Neuro-ophthalmology",
      "primary_category": "Neuro-ophthalmology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828159",
      "updated_at": "2025-05-15T20:25:21.828159"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "c14f4ba5-1c18-4f76-967f-563b3df57055",
    "fields": {
      "question_number": "14",
      "question_text": "63 years old male admitted with IHD, underwent CABG. 2nd day postoperatively while in the ICU, he was successfully extubated off sedation, but the ICU staff noticed the patient is awake, but not communicating and not following commands. His neurological examination showed no focal deficits so far. Afebrile. Labs are fine. Best sensitive test to order next?",
      "options": {
        "A": "Brain CT",
        "B": "Brain MRI",
        "C": "EEG",
        "D": "Lumbar puncture"
      },
      "correct_answer": "C",
      "explanation": "It was “which if the following is most sensitive test?” They did NOT ask about next step",
      "explanation_sections": {
        "conceptual_foundation": "Altered mental status (AMS) in the neurocritical care setting is a common and complex clinical problem that requires systematic evaluation. At its core, AMS reflects a disruption in normal cerebral function, which can be due to structural lesions, metabolic derangements, toxic exposures, or functional disturbances such as seizures. Understanding the neuroanatomy of consciousness involves the ascending reticular activating system (ARAS) in the brainstem, thalamus, and widespread cortical networks. When these systems are intact, patients are awake and aware; disruption at any point can impair consciousness or cognitive function. In postoperative ICU patients, especially after cardiac surgery, AMS is often multifactorial, including hypoxic-ischemic injury, metabolic disturbances, or neurological complications such as stroke or seizures. Neurophysiological assessment tools like EEG provide a window into cortical function and are critical when structural imaging is unrevealing and clinical examination is nonfocal.",
        "pathophysiological_mechanisms": "Postoperative AMS in cardiac surgery patients can arise from multiple pathophysiological processes. Cerebral hypoperfusion or microemboli during cardiopulmonary bypass can cause ischemic injury, but often these are focal and detectable by imaging. Metabolic encephalopathy from electrolyte abnormalities, renal or hepatic dysfunction, or drug effects may alter neuronal function diffusely. Importantly, nonconvulsive status epilepticus (NCSE) is a frequent but underrecognized cause of AMS in the ICU, where ongoing epileptiform cortical activity disrupts normal cerebral networks without overt convulsions. Molecularly, NCSE involves excessive excitatory neurotransmission (e.g., glutamate) and impaired inhibitory GABAergic mechanisms, leading to sustained neuronal hyperexcitability. This functional disturbance impairs synaptic transmission and network connectivity, manifesting clinically as unresponsiveness or confusion despite preserved brain structure.",
        "clinical_correlation": "Clinically, this patient is awake but noncommunicative and not following commands, with no focal neurological deficits or fever and normal labs, suggesting a diffuse cerebral dysfunction rather than a focal lesion or infection. This presentation is classic for a disorder of cortical function such as NCSE or metabolic encephalopathy. The absence of fever and normal labs make infectious or metabolic causes less likely. Stroke or hemorrhage would typically produce focal deficits or imaging abnormalities. The key clinical clue is the dissociation between preserved arousal and impaired responsiveness, which should raise suspicion for NCSE. Early recognition is crucial because untreated NCSE can cause permanent neuronal injury and worsen outcomes.",
        "classification_and_nosology": "Altered mental status in the ICU is classified broadly into structural and nonstructural causes. Structural causes include ischemic or hemorrhagic stroke, intracranial hemorrhage, or mass lesions. Nonstructural causes include metabolic encephalopathies, toxic states, infections, and epileptic disorders such as NCSE. NCSE itself is classified under epileptic encephalopathies characterized by continuous or near-continuous epileptiform discharges on EEG without overt convulsive activity. The International League Against Epilepsy (ILAE) 2015 classification recognizes NCSE as a subtype of status epilepticus presenting with altered cognition and EEG abnormalities. This classification guides diagnostic and therapeutic strategies emphasizing EEG as a diagnostic cornerstone.",
        "diagnostic_approach": "In a postoperative ICU patient with AMS and no focal signs, the diagnostic approach includes: 1) ruling out metabolic/toxic causes via labs; 2) structural imaging to exclude stroke or hemorrhage; and 3) EEG to identify functional cortical disturbances such as NCSE. Brain CT is often the first imaging modality due to availability and speed but has low sensitivity for small ischemic lesions or diffuse abnormalities. Brain MRI is more sensitive but less accessible urgently. EEG is the most sensitive and specific test for detecting NCSE, showing continuous epileptiform discharges or periodic patterns correlating with impaired consciousness. Lumbar puncture is reserved for suspected infections or inflammatory causes, which are unlikely here given the afebrile state and normal labs. Thus, EEG is the best next step to identify or exclude NCSE.",
        "management_principles": "Management of AMS due to NCSE involves prompt initiation of antiepileptic therapy to terminate epileptiform activity and restore cortical function. According to the 2020 American Epilepsy Society guidelines, first-line treatment includes intravenous benzodiazepines (e.g., lorazepam), followed by antiepileptic drugs such as levetiracetam or valproic acid. Supportive care includes monitoring airway, breathing, and circulation, as well as correcting metabolic derangements. In contrast, structural lesions require neurosurgical or supportive interventions, and metabolic causes need targeted correction. Early EEG-guided diagnosis and treatment improve neurological outcomes and reduce ICU length of stay. Long-term care involves neurologic rehabilitation and secondary prevention strategies if seizures recur.",
        "option_analysis": "Option A: Brain CT - Incorrect. While CT is rapid and useful to exclude hemorrhage, it has limited sensitivity for subtle ischemic changes or diffuse cortical dysfunction. In this patient with no focal deficits and normal labs, CT is unlikely to reveal a cause.\n\nOption B: Brain MRI - Incorrect. MRI is more sensitive than CT for ischemic injury but is less readily available and time-consuming. Given the clinical picture of preserved arousal but no communication, a functional disturbance like NCSE is more likely, which MRI cannot detect.\n\nOption C: EEG - Correct. EEG is the gold standard for detecting NCSE, which is a common and treatable cause of postoperative AMS without focal deficits. It provides real-time assessment of cortical electrical activity and guides management.\n\nOption D: Lumbar puncture - Incorrect. LP is indicated if infection or inflammatory encephalitis is suspected. The patient is afebrile with normal labs, making infection unlikely. LP is invasive and not the first step here.",
        "clinical_pearls": "- In ICU patients with AMS and no focal deficits, always consider nonconvulsive status epilepticus.\n- EEG is indispensable for diagnosing NCSE; clinical examination alone can be misleading.\n- Normal brain imaging does not exclude functional cerebral disturbances.\n- Early EEG and treatment improve outcomes; delays increase morbidity.\n- Remember that benzodiazepines can mask clinical seizures but do not replace EEG diagnosis.\n- Post-cardiac surgery patients are at increased risk for cerebral hypoperfusion and seizures.\n- Use a systematic approach: rule out metabolic, structural, infectious, and functional causes sequentially.",
        "current_evidence": "The 2020 American Epilepsy Society guidelines on status epilepticus state: “EEG monitoring is essential for diagnosis of nonconvulsive status epilepticus, especially in patients with unexplained altered mental status in the ICU setting” (Glauser et al., 2020). Recent studies demonstrate that up to 20% of ICU patients with AMS have NCSE, and early EEG detection with prompt antiepileptic treatment improves neurological recovery (Claassen et al., 2013). Despite advances, knowledge gaps remain regarding optimal duration of EEG monitoring and first-line antiepileptic choice in NCSE. Emerging evidence supports continuous EEG monitoring in neurocritical care, but resource limitations persist. Thus, EEG remains the cornerstone diagnostic and monitoring tool for AMS in critical illness."
      },
      "subspecialty": "Neurointensive Care/Neurocritical Care",
      "primary_category": "Neurointensive Care/Neurocritical Care",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828167",
      "updated_at": "2025-05-15T20:25:21.828168"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "6ecb5e50-94d3-4378-a864-cef516ddc7ee",
    "fields": {
      "question_number": "13",
      "question_text": "Elderly female brought to ER with ↓ level of consciousness. Unknown history. Her labs showed INR of 3. Brain CT attached. What is the best next step?",
      "options": {
        "A": "vitamin K",
        "B": "PCC",
        "C": "idarucizumab",
        "D": "FFP"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "The fundamental neurological principle tested here is the urgent management of intracerebral hemorrhage (ICH), particularly when complicated by anticoagulation. Intracerebral hemorrhage is bleeding directly into the brain parenchyma, which can cause mass effect, increased intracranial pressure, and neuronal injury. In patients on anticoagulants, the risk of hemorrhage and hematoma expansion is significantly increased. Understanding the neuroanatomy of brain vasculature and the pathophysiology of hemorrhagic stroke is essential. The brain has a dense network of small penetrating arteries vulnerable to rupture, especially under anticoagulated states. The coagulation cascade and its pharmacologic modulation by agents such as warfarin (which elevates INR) are critical to comprehend. Advanced understanding includes appreciating how rapid reversal of anticoagulation can limit hematoma expansion, reduce mortality, and improve outcomes. This requires knowledge of pharmacodynamics of reversal agents and their timing relative to hemorrhage onset.",
        "pathophysiological_mechanisms": "Intracerebral hemorrhage results from rupture of small cerebral vessels leading to bleeding into brain tissue. In patients with elevated INR (International Normalized Ratio), typically due to warfarin use, the coagulation cascade is impaired, specifically the vitamin K-dependent clotting factors II, VII, IX, and X. This deficiency impedes formation of stable fibrin clots, increasing bleeding risk. The elevated INR of 3 indicates significant anticoagulation, predisposing to spontaneous or traumatic hemorrhage. Hematoma expansion occurs within the first hours post-bleed and correlates with worse clinical outcomes. At the molecular level, insufficient clotting factors delay hemostasis, allowing ongoing bleeding. The blood products and reversal agents aim to restore these factors and halt hemorrhage progression. The pathophysiological cascade includes initial vessel rupture, hematoma formation, perihematomal edema, secondary neuronal injury from mass effect and inflammation, and potential herniation syndromes.",
        "clinical_correlation": "Clinically, patients with anticoagulant-associated ICH often present with sudden neurological deterioration, decreased level of consciousness, focal deficits, or headache. The elderly female with decreased consciousness and an INR of 3 suggests warfarin-related hemorrhage. Brain CT typically reveals hyperdense acute blood within the brain parenchyma, sometimes with mass effect. Symptoms correlate with hemorrhage location and size. The natural history without reversal involves hematoma expansion, worsening edema, and increased mortality. Rapid identification and management are crucial. Key diagnostic findings include elevated INR, CT evidence of hemorrhage, and clinical signs of neurological compromise. Early intervention aims to stabilize the patient and prevent secondary injury.",
        "classification_and_nosology": "Intracerebral hemorrhage is classified within hemorrhagic strokes, distinct from ischemic strokes. The classification systems, such as the American Heart Association/American Stroke Association (AHA/ASA) guidelines, categorize ICH by etiology (hypertensive, amyloid angiopathy, anticoagulant-associated), location (lobar, deep, brainstem, cerebellar), and severity. Anticoagulant-associated ICH is a recognized subtype with specific management protocols. The classification has evolved to emphasize etiology-driven treatment approaches. Nosologically, this condition belongs to the cerebrovascular disease family, specifically hemorrhagic stroke, and is further subclassified by precipitating factors (e.g., anticoagulation). Controversies exist regarding the best reversal agent and timing, but consensus supports rapid correction of coagulopathy in anticoagulant-related ICH.",
        "diagnostic_approach": "The diagnostic evaluation begins with urgent non-contrast brain CT to confirm hemorrhage, determine location and volume, and assess for mass effect or herniation. Laboratory tests include coagulation profile (INR, PT, aPTT), platelet count, and renal function. In this patient, an INR of 3 confirms significant warfarin effect. Sensitivity of CT for acute hemorrhage is high, making it the first-line imaging modality. Additional imaging (CTA) may be considered for vascular abnormalities. The diagnostic criteria for anticoagulant-associated ICH include clinical presentation, imaging evidence of hemorrhage, and laboratory confirmation of anticoagulation. Prompt recognition of elevated INR guides urgent reversal strategies.",
        "management_principles": "According to the 2022 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: 'Rapid reversal of warfarin-associated coagulopathy is recommended to reduce hematoma expansion and improve clinical outcomes (Class I, Level A).' The first-line treatment for warfarin-associated ICH is administration of prothrombin complex concentrate (PCC), which provides concentrated vitamin K-dependent clotting factors and achieves rapid INR normalization. Vitamin K administration is essential but has a delayed onset (6-24 hours) and is used adjunctively. Fresh frozen plasma (FFP) can be used but is less favored due to volume overload risk and slower INR correction. Idarucizumab is a specific reversal agent for dabigatran, a direct thrombin inhibitor, and is not effective for warfarin reversal. Acute management also includes blood pressure control, intracranial pressure monitoring, and supportive care. Long-term care involves addressing anticoagulation indications and secondary stroke prevention.",
        "option_analysis": "Option A (Vitamin K): Incorrect as monotherapy because vitamin K reverses warfarin by promoting synthesis of clotting factors but acts slowly (6-24 hours). It is used adjunctively but not sufficient for acute reversal. Option B (PCC): Correct. PCC provides rapid replacement of vitamin K-dependent clotting factors II, VII, IX, and X, normalizing INR typically within 30 minutes, which is critical to halt hematoma expansion in warfarin-associated ICH. Supported by guidelines as first-line therapy. Option C (Idarucizumab): Incorrect. This is a monoclonal antibody fragment that specifically reverses dabigatran, a direct thrombin inhibitor, and has no effect on warfarin-induced coagulopathy. Option D (FFP): Incorrect as first-line due to slower INR correction, large volume requirement, risk of transfusion reactions, and logistical delays. May be considered if PCC unavailable, but generally inferior to PCC. The discriminating feature is the speed and efficacy of INR reversal, which PCC achieves best.",
        "clinical_pearls": "- Always assess anticoagulation status in ICH patients, especially elderly with unknown history.\n- Rapid reversal of warfarin anticoagulation with PCC reduces hematoma expansion and mortality.\n- Vitamin K is necessary but not sufficient for acute reversal; administer concurrently with PCC.\n- Idarucizumab is only for dabigatran reversal; know the specific anticoagulant involved.\n- Fresh frozen plasma is less effective and slower than PCC; use only if PCC unavailable.\n- Early CT imaging is critical to diagnose ICH and guide management.\n- Monitor for complications like increased intracranial pressure and secondary injury.\n- Remember that elevated INR correlates with bleeding risk and guides urgency of reversal.",
        "current_evidence": "The 2022 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage state: 'For patients with warfarin-associated intracerebral hemorrhage, administration of four-factor prothrombin complex concentrate is recommended over fresh frozen plasma for rapid reversal of anticoagulation (Class I, Level A).' Additionally, 'Vitamin K should be administered concurrently to sustain reversal effects (Class I, Level B).' There remain knowledge gaps regarding optimal dosing strategies and long-term outcomes after reversal. Recent trials confirm PCC's superiority in rapid INR correction and clinical outcomes compared to FFP. The role of novel oral anticoagulants and their specific reversal agents (e.g., andexanet alfa) is evolving, but warfarin-associated ICH remains a common emergency requiring prompt PCC administration. Ongoing research is refining protocols for reversal timing and adjunctive therapies."
      },
      "subspecialty": "Cerebrovascular/Stroke",
      "primary_category": "Cerebrovascular/Stroke",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828175",
      "updated_at": "2025-05-15T20:25:21.828176"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "9d5ee5b1-ae1e-4bde-96ba-91613239893d",
    "fields": {
      "question_number": "3",
      "question_text": "76 years old male with unsteady gait, cognitive decline and urinary incontinence started 1 year ago. Brain MRI shows extensive subcortical white matter disease. Diagnosis?",
      "options": {
        "A": "Binswanger disease",
        "B": "DLB",
        "C": "NPH",
        "D": "depression"
      },
      "correct_answer": "C",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "The clinical scenario describes an elderly patient presenting with a classic triad of **gait disturbance, cognitive decline, and urinary incontinence**. These symptoms collectively suggest involvement of neural circuits responsible for motor control, cognition, and autonomic function. Understanding the underlying neuroanatomy is essential: the frontal lobes and their subcortical connections play a pivotal role in gait and executive functions, while bladder control involves complex cortical and subcortical pathways. The presence of **extensive subcortical white matter changes** on MRI further implicates disruption of these neural networks. White matter tracts serve as communication highways between cortical and subcortical structures; damage here can produce a constellation of symptoms affecting mobility, cognition, and autonomic regulation. Progressing from this foundation, recognizing disorders that cause this symptom triad with white matter abnormalities is critical in differentiating diagnoses such as normal pressure hydrocephalus (NPH), vascular dementia variants, neurodegenerative diseases, and psychiatric conditions.",
        "pathophysiological_mechanisms": "In **Normal Pressure Hydrocephalus (NPH)**, there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricular system leading to **ventriculomegaly without a corresponding increase in CSF pressure**. This causes stretching and distortion of periventricular white matter tracts, particularly those involved in motor control (corticospinal and corticobulbar pathways), frontal-subcortical circuits (affecting cognition and behavior), and pathways controlling bladder function. The pathophysiology involves impaired CSF absorption at the arachnoid villi, leading to ventricular enlargement that compresses adjacent white matter. The molecular and cellular changes include demyelination and axonal loss in periventricular regions. This disruption manifests clinically as the classic triad of gait disturbance (often the earliest and most prominent feature), cognitive impairment (usually subcortical-frontal type), and urinary incontinence. The sequence often starts with gait apraxia, followed by cognitive decline and then urinary symptoms.",
        "clinical_correlation": "NPH typically presents in older adults with a **triad of symptoms**:\n- **Gait disturbance**: Described as a broad-based, magnetic, or shuffling gait; patients have difficulty initiating steps (gait apraxia).\n- **Cognitive decline**: Subcortical-frontal pattern including slowed processing, impaired executive function, and attention deficits.\n- **Urinary incontinence**: Usually urgency progressing to incontinence.\nThe clinical features correlate with periventricular white matter tract disruption seen on imaging. MRI often shows **ventriculomegaly disproportionate to cortical atrophy** and may reveal periventricular hyperintensities due to transependymal CSF flow. The natural history can be variable but is potentially reversible with shunting if diagnosed early. In contrast, other causes of dementia and gait disturbance (e.g., vascular dementia) have different clinical and imaging patterns. Key diagnostic findings include enlarged ventricles with normal opening pressure on lumbar puncture and improvement after large-volume CSF removal (tap test).",
        "classification_and_nosology": "NPH is classified under **hydrocephalus syndromes**, specifically as a form of **communicating hydrocephalus** characterized by normal CSF pressure. It is considered a potentially reversible cause of dementia. Nosologically, it belongs to the category of **secondary dementias** due to CSF circulation abnormalities rather than primary neurodegenerative processes. It differs from vascular dementia (Binswanger disease) which is a subtype of small vessel vascular cognitive impairment, and from neurodegenerative dementias such as dementia with Lewy bodies (DLB). Psychiatric causes like depression can mimic cognitive decline but are nosologically distinct. The classification of NPH has evolved with imaging advances, emphasizing the importance of ventriculomegaly disproportionate to atrophy and clinical criteria.",
        "diagnostic_approach": "The diagnostic evaluation of suspected NPH involves:\n- **Clinical assessment**: Confirm presence of the triad and exclude other causes.\n- **Neuroimaging**: MRI brain to assess for ventriculomegaly (Evans index >0.3), periventricular signal changes, and exclude other pathologies.\n- **CSF studies**: Lumbar puncture to measure opening pressure (usually normal) and perform a large-volume tap test (30-50 mL removal) to assess symptomatic improvement.\n- **Additional tests**: Neuropsychological testing to characterize cognitive impairment.\nSensitivity and specificity of the tap test are moderate but useful for predicting shunt responsiveness. Current diagnostic criteria (International guidelines) emphasize clinical triad plus imaging findings and positive response to CSF removal.",
        "management_principles": "According to the **American Academy of Neurology 2021 guidelines**, the first-line treatment for NPH is **ventriculoperitoneal shunting**, which diverts excess CSF and alleviates ventricular enlargement and white matter compression. The guidelines state: “Ventriculoperitoneal shunting is recommended for patients with idiopathic NPH who demonstrate clinical and radiological features consistent with the diagnosis and show improvement after CSF removal.” (AAN, 2021). Medical management is limited and primarily supportive. Early intervention improves gait and cognitive outcomes; urinary symptoms are less responsive. Second-line options include programmable shunts and endoscopic third ventriculostomy in select cases. The mechanism involves restoring normal CSF dynamics and reducing periventricular white matter stretch.",
        "option_analysis": "Option A: **Binswanger disease** (subcortical vascular dementia) is characterized by extensive white matter ischemic changes due to small vessel disease. While it can cause gait disturbance and cognitive decline, urinary incontinence is less prominent early, and ventriculomegaly is usually absent or secondary to atrophy. The clinical course is more progressive and stepwise rather than the potentially reversible pattern in NPH.\n\nOption B: **Dementia with Lewy Bodies (DLB)** presents with fluctuating cognition, visual hallucinations, parkinsonism, and REM sleep behavior disorder. Gait disturbance is due to parkinsonism, not white matter changes. MRI typically shows mild atrophy without significant white matter disease.\n\nOption C: **Normal Pressure Hydrocephalus (NPH)** is the correct diagnosis as it explains the triad of symptoms and imaging findings of ventriculomegaly with white matter changes. The clinical presentation and imaging are classic.\n\nOption D: **Depression** can mimic cognitive decline (pseudodementia) but does not cause ventriculomegaly or white matter disease on MRI. Urinary incontinence and gait disturbance are not typical features.\n\nThus, the discriminating features are the presence of ventriculomegaly with white matter changes and the classic symptom triad favoring NPH.",
        "clinical_pearls": "- **Gait disturbance is often the earliest and most responsive symptom in NPH.**\n- **Evans index >0.3 on MRI suggests ventriculomegaly.**\n- The **CSF tap test** is a useful bedside predictor of shunt responsiveness.\n- Do not confuse vascular white matter disease with NPH; look for disproportionate ventriculomegaly.\n- Urinary symptoms in elderly patients with cognitive decline should prompt evaluation for NPH.\n- Remember that NPH is potentially reversible, emphasizing the importance of early diagnosis.\n- Avoid attributing all white matter changes in elderly patients to small vessel ischemic disease without considering NPH.",
        "current_evidence": "The **American Academy of Neurology (AAN) Practice Guideline on Idiopathic Normal Pressure Hydrocephalus (2021)** states: “Ventriculoperitoneal shunting is recommended for patients with idiopathic NPH who have clinical and radiologic features consistent with the diagnosis and who show improvement after CSF removal.” The guideline highlights that early diagnosis and intervention improve outcomes. However, it also acknowledges gaps in predicting shunt responders and the need for standardized diagnostic criteria. Recent advances focus on advanced MRI techniques to better differentiate NPH from vascular dementia and neurodegenerative diseases. Controversies remain regarding optimal patient selection for shunting and long-term outcomes. Emerging biomarkers and imaging modalities are under investigation to refine diagnosis."
      },
      "subspecialty": "Geriatric Neurology",
      "primary_category": "Geriatric Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828184",
      "updated_at": "2025-05-15T20:25:21.828185"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "4a27ff9c-c7c4-478f-bdc9-34f1151ffb1f",
    "fields": {
      "question_number": "8",
      "question_text": "29 years old female came to the clinic asking 3rd opinion for her headache. First doctor told her she has cluster headache while the other one said it is SUNCT. She asked you what is the best way to differentiate these 2 headaches?",
      "options": {
        "A": "Response to the treatment",
        "B": "Duration of attack",
        "C": "Imaging"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Headache disorders, particularly trigeminal autonomic cephalalgias (TACs), represent a group of primary headaches characterized by unilateral head pain associated with ipsilateral cranial autonomic symptoms. Understanding the fundamental features of TACs is essential for accurate diagnosis and management. Cluster headache and SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing) are both TACs with overlapping clinical features but differing in attack duration, frequency, and response to treatment. The trigeminal autonomic reflex, involving the trigeminal nerve and parasympathetic outflow via the superior salivatory nucleus, underlies the cranial autonomic symptoms seen in these headaches. \n\nAt a more advanced level, cluster headache attacks typically last 15 to 180 minutes and occur in clusters over weeks to months, while SUNCT attacks are much shorter (seconds to a few minutes) but occur with higher frequency. Neuroanatomically, both disorders involve activation of the posterior hypothalamus and trigeminal-autonomic reflex pathways but differ in precise pathophysiological mechanisms and clinical phenomenology. Recognizing these nuances is critical for differentiating these headaches and tailoring treatment strategies accordingly.",
        "pathophysiological_mechanisms": "The pathophysiology of cluster headache involves hypothalamic activation, as demonstrated by functional imaging studies showing activation in the ipsilateral posterior hypothalamic gray matter during attacks. This activation triggers the trigeminal-autonomic reflex, resulting in severe unilateral pain in the orbital or temporal region accompanied by ipsilateral autonomic symptoms such as lacrimation, nasal congestion, and ptosis. Molecularly, neuropeptides like calcitonin gene-related peptide (CGRP) and substance P contribute to neurogenic inflammation and vasodilation.\n\nSUNCT syndrome shares similar trigeminal-autonomic activation but with distinct features. The attacks are brief (1-600 seconds, typically 5-250 seconds), occur multiple times per day (up to hundreds), and are characterized by prominent conjunctival injection and tearing. Unlike cluster headache, SUNCT attacks are often triggered by cutaneous stimuli (e.g., touch or movement of the face), implicating abnormal excitability or ephaptic transmission within the trigeminal nerve or brainstem nuclei. These molecular and neurophysiological differences manifest clinically as differences in attack duration and frequency, providing a mechanistic basis for their differential diagnosis.",
        "clinical_correlation": "Clinically, cluster headache presents with severe unilateral orbital, supraorbital, or temporal pain lasting 15-180 minutes, occurring 1-8 times per day, often at night, with marked circadian and circannual periodicity. Ipsilateral autonomic symptoms include conjunctival injection, lacrimation, nasal congestion, rhinorrhea, ptosis, and miosis. Patients often exhibit restlessness or agitation during attacks.\n\nIn contrast, SUNCT syndrome is characterized by very brief attacks (seconds to a few minutes) of unilateral stabbing or burning pain localized to the orbital or temporal region, with associated conjunctival injection and tearing. Attacks occur with high frequency (up to hundreds per day) and may be precipitated by triggers such as touching the face or chewing. Unlike cluster headache, SUNCT lacks the pronounced circadian pattern and restlessness.\n\nThe key clinical discriminator is the **duration of attacks**: cluster headache attacks are significantly longer than SUNCT attacks. This difference guides diagnosis and management. The natural history differs as well, with cluster headache often presenting in episodic bouts, whereas SUNCT tends to be chronic and refractory.",
        "classification_and_nosology": "Both cluster headache and SUNCT belong to the International Classification of Headache Disorders, 3rd edition (ICHD-3) under the umbrella of **trigeminal autonomic cephalalgias (TACs)**. TACs are defined by unilateral head pain with ipsilateral cranial autonomic symptoms.\n\n- **Cluster headache (ICHD-3 code 3.1)** is characterized by attacks lasting 15-180 minutes, with accompanying autonomic symptoms and a circadian pattern.\n- **SUNCT syndrome (ICHD-3 code 3.3.1)** is classified as a subtype of short-lasting unilateral neuralgiform headache attacks, with attack durations of 1-600 seconds and prominent conjunctival injection and tearing.\n\nThe classification has evolved to emphasize precise attack duration and associated features to differentiate these entities. Some debate exists regarding overlap syndromes and the relationship between SUNCT and other short-lasting headaches like SUNA (Short-lasting Unilateral Neuralgiform headache attacks with cranial Autonomic symptoms), but the current consensus supports attack duration as a primary distinguishing criterion.",
        "diagnostic_approach": "A systematic diagnostic approach involves detailed headache history focusing on attack duration, frequency, pain quality, associated autonomic symptoms, and triggers. \n\n- **Duration of attacks** is the most sensitive and specific clinical discriminator between cluster headache and SUNCT.\n- Neuroimaging (MRI brain with attention to the posterior fossa and pituitary region) is important to exclude secondary causes but does not differentiate cluster headache from SUNCT.\n- Response to treatment can assist but is not diagnostic due to overlap and variable responses.\n\nCurrent ICHD-3 criteria emphasize clinical features, particularly attack duration, for diagnosis. Imaging is reserved for atypical presentations or red flags. Autonomic features and attack frequency further support the diagnosis but are less specific than attack duration.",
        "management_principles": "According to the **American Headache Society guidelines (2019)** and the **European Federation of Neurological Societies (EFNS) guidelines (2016)**, management of cluster headache and SUNCT differs substantially due to attack characteristics.\n\n- **Cluster headache** acute treatment includes high-flow oxygen and subcutaneous sumatriptan; preventive treatments include verapamil as first-line, with lithium, corticosteroids, and neuromodulation as adjuncts.\n- **SUNCT syndrome** is often refractory to typical cluster headache treatments. Lamotrigine is considered first-line preventive therapy due to its efficacy in short-lasting neuralgiform headaches, with other anticonvulsants (topiramate, gabapentin) as alternatives.\n\nTreatment response is variable; thus, attack duration guides initial diagnosis and treatment choice. Imaging is essential to exclude secondary causes but does not guide therapy directly.",
        "option_analysis": "Option A: Response to the treatment\n- Incorrect because treatment response can overlap; some SUNCT patients may respond partially to cluster headache treatments and vice versa. Treatment response is not a reliable initial diagnostic discriminator.\n\nOption B: Duration of attack\n- Correct because the duration of headache attacks is the most definitive clinical feature differentiating cluster headache (15-180 minutes) from SUNCT (seconds to a few minutes). This is emphasized in ICHD-3 diagnostic criteria and clinical practice.\n\nOption C: Imaging\n- Incorrect because imaging is primarily used to exclude secondary causes (e.g., tumors, vascular lesions) and does not differentiate cluster headache from SUNCT, both of which are primary headache disorders with normal imaging findings in typical cases.",
        "clinical_pearls": "- **Attack duration is the cardinal feature** differentiating cluster headache from SUNCT; always ask patients to describe exact timing.\n- SUNCT attacks are very brief but frequent, often triggered by facial stimuli, unlike cluster headache.\n- Cluster headache patients are often restless or agitated during attacks; SUNCT patients may not exhibit this behavior.\n- High-flow oxygen is effective acutely in cluster headache but not in SUNCT.\n- Lamotrigine is the preferred preventive in SUNCT, contrasting with verapamil in cluster headache.\n- Avoid anchoring on treatment response; rely on detailed history and attack characteristics.\n- Remember that both disorders share trigeminal-autonomic activation but differ in attack dynamics and pathophysiology.",
        "current_evidence": "The **International Classification of Headache Disorders, 3rd edition (ICHD-3, 2018)** states: “The duration of attacks is the key clinical feature that differentiates cluster headache (15–180 minutes) from SUNCT (1–600 seconds).” (Headache Classification Committee of the International Headache Society, 2018).\n\nThe **American Headache Society 2019 consensus statement** recommends using attack duration as a primary diagnostic criterion to distinguish TAC subtypes and tailor treatment accordingly (AHS, 2019). \n\nEvidence gaps remain regarding pathophysiological overlap and optimal treatment for refractory SUNCT. Recent neuroimaging advances continue to elucidate hypothalamic involvement but have not altered diagnostic criteria. Emerging neuromodulation therapies show promise but require further validation.\n\nIn summary, current guidelines universally endorse attack duration as the best discriminator between cluster headache and SUNCT, supporting the correct answer choice."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828192",
      "updated_at": "2025-05-15T20:25:21.828193"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "0301e13e-b298-493b-935a-ad74b595080c",
    "fields": {
      "question_number": "15",
      "question_text": "57 years old male, DM, HTN, DLP, smoker, admitted under stroke with left sided weakness and facial asymmetry. Brain CT: right capsular infarction. Brain CTA: significant intracranial ICA stenosis. What is the best management?",
      "options": {
        "A": "medical therapy",
        "B": "ICA stenting",
        "C": "ICA endarterectomy",
        "D": "craniotomy"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "The fundamental neurological principle tested here is the management of ischemic stroke caused by symptomatic intracranial internal carotid artery (ICA) stenosis. Stroke results from an acute disruption of cerebral blood flow, often due to arterial occlusion or stenosis. In this case, a right capsular infarction indicates an ischemic event in the territory supplied by perforating arteries originating from the middle cerebral artery, downstream of the ICA. Understanding the vascular anatomy, including the extracranial and intracranial segments of the ICA, and the pathophysiology of atherosclerotic disease leading to stenosis, is essential. The intracranial ICA supplies critical brain regions, and stenosis here can cause ischemia either by hemodynamic compromise or embolic phenomena. Management strategies depend on the location of stenosis (intracranial vs extracranial), symptomatology, and risk factors.",
        "pathophysiological_mechanisms": "Atherosclerosis is the predominant cause of intracranial ICA stenosis in patients with vascular risk factors such as diabetes mellitus, hypertension, dyslipidemia, and smoking. The process involves endothelial injury, lipid accumulation, inflammatory cell infiltration, and plaque formation leading to luminal narrowing. This stenosis can reduce cerebral perfusion pressure, causing ischemia, or promote thrombus formation with distal embolization. The right capsular infarction seen on CT corresponds to ischemic injury in the internal capsule, likely due to occlusion of small perforating arteries or hypoperfusion downstream of the stenosis. Intracranial stenosis is associated with a high risk of recurrent stroke due to unstable plaques and impaired collateral circulation.",
        "clinical_correlation": "Patients with symptomatic intracranial ICA stenosis present with focal neurological deficits corresponding to the ischemic territory, such as unilateral weakness and facial asymmetry in this case. The natural history involves a high risk of recurrent stroke, especially within the first few months. Diagnosis is confirmed by imaging modalities: non-contrast CT to identify infarction, and CT angiography (CTA) to visualize arterial stenosis. The clinical presentation and imaging findings correlate with the pathophysiology of reduced cerebral perfusion and embolic events. Recognizing the difference between intracranial and extracranial stenosis is crucial because it guides management decisions.",
        "classification_and_nosology": "Intracranial ICA stenosis falls under the broader category of intracranial large artery atherosclerosis, classified within ischemic stroke subtypes by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria as 'large artery atherosclerosis.' This classification distinguishes it from cardioembolic, small vessel (lacunar), and other stroke etiologies. Intracranial stenosis differs from extracranial carotid artery disease anatomically and pathophysiologically, with distinct therapeutic implications. The classification has evolved with advanced imaging allowing precise localization of stenosis, emphasizing the need for targeted therapy.",
        "diagnostic_approach": "Evaluation begins with clinical assessment and non-contrast brain CT to exclude hemorrhage and confirm infarction. CTA or MR angiography (MRA) identifies intracranial stenosis and quantifies severity. Digital subtraction angiography (DSA) remains the gold standard but is invasive. Degree of stenosis is critical; symptomatic stenosis >70% carries the highest risk of recurrence. Additional tests include cardiac evaluation to exclude embolic sources and vascular risk factor assessment. The diagnosis of symptomatic intracranial ICA stenosis is established by correlating clinical symptoms with imaging evidence of significant stenosis in the artery supplying the infarcted region.",
        "management_principles": "According to the 2019 AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke and the SAMMPRIS trial data, the first-line management for symptomatic intracranial ICA stenosis is aggressive medical therapy. This includes dual antiplatelet therapy (aspirin plus clopidogrel) for 90 days followed by single antiplatelet therapy, strict control of vascular risk factors (blood pressure, glycemic control, lipid lowering with statins), smoking cessation, and lifestyle modifications. Endovascular interventions like intracranial stenting or surgical procedures have not demonstrated superiority and carry higher periprocedural risks. The SAMMPRIS trial (2011) showed that aggressive medical management was superior to stenting in preventing recurrent stroke in this population. Craniotomy is not indicated for ischemic stroke caused by arterial stenosis.",
        "option_analysis": "Option A (Medical therapy): Correct. Aggressive medical management is the current standard of care for symptomatic intracranial ICA stenosis, supported by high-level evidence (SAMMPRIS trial). It reduces recurrent stroke risk with fewer complications than invasive procedures.\n\nOption B (ICA stenting): Incorrect. Intracranial stenting for ICA stenosis was studied in SAMMPRIS and showed increased periprocedural stroke and death rates compared to medical therapy. It is reserved for select patients who fail medical therapy.\n\nOption C (ICA endarterectomy): Incorrect. Endarterectomy is a surgical technique applicable to extracranial carotid artery stenosis, not intracranial segments. The intracranial ICA is not accessible for this procedure due to anatomical complexity.\n\nOption D (Craniotomy): Incorrect. Craniotomy is not a treatment for ischemic stroke due to arterial stenosis. It may be indicated for hemorrhagic stroke or decompressive hemicraniectomy in malignant infarction but not for vascular stenosis management.",
        "clinical_pearls": "- Differentiate intracranial versus extracranial carotid stenosis; management differs significantly.\n- The SAMMPRIS trial revolutionized management by showing medical therapy superiority over stenting in intracranial stenosis.\n- Dual antiplatelet therapy is recommended short-term post-stroke for symptomatic intracranial stenosis.\n- Control of vascular risk factors is paramount in secondary stroke prevention.\n- Intracranial endarterectomy is not feasible due to anatomical constraints.\n- Always correlate clinical findings with imaging to localize the lesion and guide therapy.",
        "current_evidence": "The 2019 AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke state: “For patients with recent stroke or transient ischemic attack attributed to 70–99% intracranial arterial stenosis, aggressive medical management is recommended over percutaneous transluminal angioplasty and stenting (Class I; Level of Evidence A).” The SAMMPRIS trial (2011) directly compared aggressive medical therapy to stenting and found a significantly higher rate of stroke and death in the stenting group within 30 days. Despite advances, there remain knowledge gaps regarding optimal management in patients who fail medical therapy or have recurrent events. Ongoing trials are investigating novel endovascular techniques and pharmacotherapies. Current consensus strongly favors medical therapy as first-line, reserving intervention for select refractory cases."
      },
      "subspecialty": "Cerebrovascular/Stroke",
      "primary_category": "Cerebrovascular/Stroke",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828201",
      "updated_at": "2025-05-15T20:25:21.828201"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "7957efd5-81af-40bf-a0d5-372c649aa6fa",
    "fields": {
      "question_number": "10",
      "question_text": "Typical scenario of migraine without aura, moderate to severe attacks, π?",
      "options": {
        "A": "Codeine + caffeine",
        "B": "NSAID",
        "C": "Triptan"
      },
      "correct_answer": "C",
      "explanation": "Mod - severe",
      "explanation_sections": {
        "conceptual_foundation": "Migraine is a common primary headache disorder characterized by episodic attacks of moderate to severe headache, often unilateral and pulsating, accompanied by associated symptoms such as nausea, photophobia, and phonophobia. The fundamental neurological principle involves activation and sensitization of the trigeminovascular system, which mediates pain signals from meningeal blood vessels to the brainstem and higher centers. Over time, our understanding has evolved from a purely vascular theory to a neurovascular model incorporating cortical spreading depression, trigeminal nerve activation, and central sensitization. The trigeminovascular system includes trigeminal afferents innervating cerebral and meningeal blood vessels, whose activation leads to release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP), substance P, and neurokinin A, causing neurogenic inflammation and vasodilation. These processes contribute to the headache pain and associated symptoms. The pathophysiology also involves brainstem nuclei such as the dorsal raphe and locus coeruleus, and cortical areas responsible for sensory processing and pain modulation. Understanding these neuroanatomical and neurophysiological substrates is essential for rational therapeutic targeting in migraine management.",
        "pathophysiological_mechanisms": "Migraine pathophysiology is complex and multifactorial, involving genetic predisposition and environmental triggers. The initial event is thought to be cortical spreading depression (CSD), a wave of neuronal and glial depolarization spreading across the cerebral cortex, which correlates clinically with aura in some patients but is also implicated in migraine without aura. CSD activates trigeminal afferents innervating meningeal vessels, leading to release of vasoactive neuropeptides such as CGRP, which cause vasodilation and neurogenic inflammation. This neurogenic inflammation sensitizes peripheral nociceptors and promotes central sensitization in the trigeminal nucleus caudalis and higher pain centers, resulting in the characteristic headache and associated symptoms. Molecularly, CGRP antagonists and serotonin (5-HT) receptor agonists modulate these pathways. The 5-HT1B/1D receptors, targeted by triptans, mediate vasoconstriction of dilated meningeal vessels and inhibit release of CGRP and neurotransmitters, thus aborting migraine attacks. The pathophysiology explains why early intervention is crucial to prevent central sensitization and treatment resistance.",
        "clinical_correlation": "Clinically, migraine without aura presents with recurrent attacks of moderate to severe headache lasting 4 to 72 hours, typically unilateral, pulsating, aggravated by physical activity, and accompanied by nausea, vomiting, photophobia, and phonophobia. Unlike migraine with aura, no preceding neurological symptoms occur. The severity and frequency vary, but moderate to severe attacks significantly impair quality of life. The pain corresponds to activation of the trigeminovascular system, while associated symptoms reflect brainstem and cortical involvement. The natural history often shows episodic attacks that may evolve into chronic migraine if untreated or overused analgesics are taken. Diagnosis is clinical, based on International Classification of Headache Disorders (ICHD-3) criteria, emphasizing attack characteristics and exclusion of secondary causes. Recognizing the typical presentation guides acute and preventive management strategies.",
        "classification_and_nosology": "Migraine is classified within the International Classification of Headache Disorders, 3rd edition (ICHD-3), under primary headaches. The major migraine subtypes include migraine without aura (code 1.1), migraine with aura (1.2), chronic migraine (1.3), and variants such as vestibular migraine or hemiplegic migraine. Migraine without aura is defined by attacks fulfilling specific criteria: headache lasting 4–72 hours, with at least two of unilateral location, pulsating quality, moderate or severe intensity, and aggravation by routine activity, plus nausea/vomiting or photophobia and phonophobia. This nosology guides diagnosis and research and has evolved to incorporate advances in pathophysiology and clinical phenotyping. Controversies remain regarding classification of overlapping syndromes and the role of aura in pathogenesis, but the ICHD-3 remains the gold standard in clinical practice.",
        "diagnostic_approach": "Diagnosis of migraine without aura is primarily clinical, based on detailed history and neurological examination to exclude secondary causes. The ICHD-3 criteria are used to confirm the diagnosis. Neuroimaging (MRI) is reserved for atypical features, red flags, or abnormal neurological signs. Diary keeping helps document attack frequency, duration, and triggers. Differential diagnosis includes tension-type headache, cluster headache, and secondary headaches such as sinusitis or intracranial pathology. No specific biomarkers exist currently. Diagnostic tools such as headache questionnaires and scales (e.g., MIDAS, HIT-6) assess impact and guide management. Accurate diagnosis ensures appropriate acute and preventive treatment selection.",
        "management_principles": "According to the latest American Headache Society and European Headache Federation guidelines (AHS 2019, EHF 2021), acute treatment of moderate to severe migraine attacks without aura prioritizes specific migraine abortive therapies. **First-line agents include triptans (5-HT1B/1D receptor agonists) due to their efficacy in reversing pathophysiological mechanisms**. Triptans cause cranial vasoconstriction, inhibit neuropeptide release, and reduce central sensitization. NSAIDs are effective for mild to moderate attacks but may be insufficient alone in moderate to severe cases. Combination analgesics containing opioids or codeine are generally discouraged due to risk of medication overuse headache and lower efficacy. The choice of triptan formulation (oral, nasal, subcutaneous) depends on attack severity and patient factors. Early administration during headache onset improves outcomes. Preventive therapy is considered for frequent or disabling attacks. Long-term management includes lifestyle modification, trigger avoidance, and education. Evidence supports the use of CGRP monoclonal antibodies and neuromodulation in refractory cases.",
        "option_analysis": "Option C (Triptan) is correct because triptans specifically target migraine pathophysiology by agonizing 5-HT1B/1D receptors, causing vasoconstriction of dilated intracranial vessels and inhibiting release of CGRP and other neuropeptides responsible for neurogenic inflammation and pain transmission. Triptans are FDA-approved and first-line for moderate to severe migraine attacks without aura. Their efficacy and safety profile is well established in numerous randomized controlled trials and meta-analyses.\n\nOption B (NSAID) is incorrect as a sole treatment for moderate to severe migraine attacks without aura. Although NSAIDs (e.g., ibuprofen, naproxen) are effective for mild to moderate attacks and have a good safety profile, they may be insufficient for moderate to severe attacks and do not specifically target migraine neurobiology as triptans do. NSAIDs are often used in combination or as adjuncts but are not first-line monotherapy in this scenario.\n\nOption A (Codeine + caffeine) is incorrect and generally discouraged. Opioid-containing analgesics, including codeine, carry risks of dependency, medication overuse headache, and adverse effects. They do not address the underlying migraine mechanisms and have inferior efficacy compared to triptans. Caffeine can enhance analgesic effects but is not sufficient to justify opioid use. Current guidelines recommend avoiding opioids in migraine management except in exceptional cases.",
        "clinical_pearls": "- **Early treatment of migraine attacks with triptans improves efficacy and reduces progression to central sensitization.**\n- Avoid opioids and combination analgesics containing codeine to prevent medication overuse headache.\n- NSAIDs are effective for mild to moderate attacks and can be combined with triptans for synergistic effect.\n- Recognize that migraine without aura is a clinical diagnosis; neuroimaging is not routinely required.\n- Educate patients on trigger identification and lifestyle modifications.\n- Memory aid: “**T**ripans for **T**argeted migraine therapy” highlights their specific mechanism.\n- Consider patient comorbidities (e.g., cardiovascular disease) before prescribing triptans due to vasoconstrictive effects.",
        "current_evidence": "The American Headache Society's 2019 acute migraine treatment guidelines state: “**Triptans are recommended as first-line therapy for moderate to severe migraine attacks due to their targeted mechanism of action and proven efficacy**” (AHS, 2019). The European Headache Federation 2021 consensus similarly endorses triptans as first-line in moderate to severe migraine without aura and discourages opioids due to risks of overuse and dependency. Despite advances, gaps remain in predicting individual response to triptans and managing refractory migraine. Recent developments include CGRP receptor antagonists and neuromodulation, expanding the therapeutic arsenal. Ongoing research aims to refine personalized treatment algorithms and minimize adverse effects."
      },
      "subspecialty": "Headache Medicine",
      "primary_category": "Headache Medicine",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828209",
      "updated_at": "2025-05-15T20:25:21.828210"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "3f47fa87-019b-44ee-8ad3-db76dc913421",
    "fields": {
      "question_number": "17",
      "question_text": "36 years old female referred to neurology clinic for issues with forgetting the events. She has chronic migraine headache and had suffered stroke in the past. Her father died at age of 65 with dementia. What is the best diagnostic test to reach DX?",
      "options": {
        "A": "Brain MRI/MRA",
        "B": "Biopsy for osmophilic material",
        "C": "LP",
        "D": "Lactate/pyruvate"
      },
      "correct_answer": "A",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Memory impairment and cognitive decline in young adults warrant a comprehensive neurological evaluation, particularly when accompanied by vascular risk factors or family history suggestive of hereditary dementia. The fundamental neurological principle here involves understanding the neuroanatomical substrates of cognition, especially the cerebral cortex and subcortical white matter, and how vascular insults or genetic mutations disrupt these networks. Memory encoding, storage, and retrieval depend heavily on the hippocampus and associated cortical regions, while executive functions rely on frontal-subcortical circuits. Vascular pathology can cause subcortical ischemic changes leading to cognitive dysfunction, and hereditary small vessel diseases can manifest as early-onset dementia. Advanced understanding incorporates the role of cerebral microangiopathy and genetic mutations affecting vascular integrity, which can be visualized using neuroimaging modalities.",
        "pathophysiological_mechanisms": "In this clinical scenario, the patient’s chronic migraine, prior stroke, and family history of dementia raise suspicion for a hereditary small vessel disease such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy). CADASIL is caused by mutations in the NOTCH3 gene leading to abnormal accumulation of granular osmiophilic material in vascular smooth muscle cells. This results in progressive degeneration of small cerebral arteries, causing ischemic strokes, subcortical infarcts, white matter changes, and ultimately cognitive decline. The pathophysiology involves chronic hypoperfusion and disruption of white matter tracts critical for cognition. Molecularly, the NOTCH3 mutation leads to protein misfolding and vascular smooth muscle dysfunction, which manifests clinically as migraine with aura, recurrent strokes, and dementia. The sequence typically begins with migraine in early adulthood, followed by subcortical ischemic events and progressive cognitive impairment.",
        "clinical_correlation": "Clinically, CADASIL presents with migraine (often with aura), subcortical ischemic strokes, mood disturbances, and progressive cognitive decline, typically starting in mid-adulthood. The patient’s history of chronic migraine and prior stroke fits this pattern. The family history of dementia in a relatively young parent (age 65) supports an autosomal dominant hereditary pattern. Cognitive symptoms often manifest as executive dysfunction and memory impairment due to subcortical involvement. MRI findings typically reveal extensive white matter hyperintensities, especially in the anterior temporal lobes and external capsule, which are characteristic. The natural history involves gradual progression to dementia and motor disability. Recognizing these clinical features guides the diagnostic approach and management.",
        "classification_and_nosology": "CADASIL belongs to the group of hereditary cerebral small vessel diseases (CSVD), classified under genetic vasculopathies causing vascular cognitive impairment and dementia. The current nosology classifies vascular cognitive impairment into multi-infarct dementia, subcortical ischemic vascular dementia, and hereditary small vessel diseases like CADASIL and CARASIL. CADASIL specifically is an autosomal dominant arteriopathy characterized by NOTCH3 mutations. This classification has evolved with advances in molecular genetics and neuroimaging, allowing differentiation from sporadic small vessel disease and other causes of early-onset dementia such as Alzheimer’s disease or mitochondrial encephalopathies. The consensus emphasizes genetic testing and MRI patterns for diagnosis.",
        "diagnostic_approach": "The initial and most informative diagnostic test for suspected CADASIL is brain MRI combined with MRA to assess cerebral vasculature. MRI typically reveals confluent white matter hyperintensities on T2/FLAIR sequences, especially in the anterior temporal poles and external capsules, which are highly suggestive. MRA can exclude large vessel pathology. Genetic testing for NOTCH3 mutations confirms diagnosis but is often guided by MRI findings. Other tests like skin biopsy for granular osmiophilic material can be diagnostic but are invasive and less commonly used now. CSF analysis (LP) and metabolic studies (lactate/pyruvate) are reserved for differential diagnoses such as inflammatory or mitochondrial disorders. The diagnostic criteria emphasize MRI findings as a cornerstone for early detection.",
        "management_principles": "According to the 2021 European Academy of Neurology guidelines on hereditary stroke disorders, the management of CADASIL is primarily supportive and preventive. There is no disease-modifying therapy currently. First-line management includes aggressive control of vascular risk factors (hypertension, smoking cessation), migraine prophylaxis, and stroke prevention strategies. Antiplatelet agents are commonly used, although evidence is limited. Rehabilitation and cognitive support are essential for quality of life. Genetic counseling is recommended given the autosomal dominant inheritance. Experimental therapies targeting NOTCH3 pathways are under investigation but not yet standard of care. Acute stroke management follows standard ischemic protocols. Long-term care focuses on multidisciplinary approaches to cognitive and motor symptoms.",
        "option_analysis": "Option A (Brain MRI/MRA) is correct because MRI provides characteristic imaging findings of CADASIL, such as anterior temporal lobe and external capsule white matter hyperintensities, and MRA evaluates cerebral vasculature. This non-invasive test is the first-line diagnostic tool to guide further genetic confirmation.\n\nOption B (Biopsy for osmophilic material) refers to skin biopsy detecting granular osmiophilic material, historically used for CADASIL diagnosis. However, it is invasive, less sensitive than MRI/genetic testing, and now largely replaced by molecular diagnostics.\n\nOption C (LP) is incorrect because cerebrospinal fluid analysis is not diagnostic for CADASIL. It may be used to exclude inflammatory or infectious causes of dementia but does not reveal specific biomarkers for hereditary small vessel disease.\n\nOption D (Lactate/pyruvate) testing is used to evaluate mitochondrial disorders presenting with stroke-like episodes and dementia (e.g., MELAS syndrome). The clinical picture here, including migraine and family history, favors CADASIL over mitochondrial pathology, making this test less relevant.",
        "clinical_pearls": "- **MRI pattern recognition is key:** White matter hyperintensities in anterior temporal lobes and external capsules are hallmark features of CADASIL.\n- **Family history is crucial:** Early-onset dementia or stroke in a first-degree relative suggests hereditary small vessel disease.\n- **Migraine with aura in young adults with stroke should raise suspicion for CADASIL.**\n- **Skin biopsy is now rarely needed** due to availability of genetic testing.\n- **Avoid misdiagnosis:** Do not attribute early-onset dementia solely to Alzheimer’s without considering vascular and hereditary causes.\n- **Genetic counseling is essential** for affected families.\n- **Remember:** Not all white matter changes in young patients are demyelinating; consider vascular etiologies.",
        "current_evidence": "The 2021 European Academy of Neurology (EAN) guidelines on hereditary stroke disorders state: “Brain MRI remains the cornerstone for the diagnosis of CADASIL, with characteristic anterior temporal and external capsule involvement providing high diagnostic specificity. Genetic testing for NOTCH3 mutations confirms diagnosis and guides family counseling (Chabriat et al., 2021).”\n\nThere is currently no disease-modifying treatment for CADASIL, and management focuses on vascular risk factor control and symptomatic care. Knowledge gaps remain regarding targeted therapies to prevent vascular smooth muscle degeneration. Recent advances in molecular genetics and imaging continue to refine diagnosis and understanding of disease progression. Controversies exist regarding the role of antiplatelet therapy and migraine management in CADASIL, highlighting the need for individualized care."
      },
      "subspecialty": "Cognitive/Behavioral Neurology",
      "primary_category": "Cognitive/Behavioral Neurology",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828217",
      "updated_at": "2025-05-15T20:25:21.828218"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "544adf20-4241-4a59-8823-679764c3e4f8",
    "fields": {
      "question_number": "19",
      "question_text": "Which type of brain herniations is commonly associated with unreactive pupil?",
      "options": {
        "A": "cerebellar tonsillar",
        "B": "uncal",
        "C": "transtentorial",
        "D": null
      },
      "correct_answer": "B",
      "explanation": "Uncal herniation produces mass effect and pressure over the ipsilateral midbrain, affecting the ipsilateral cranial nerve III nucleus and nerve. The mass effect compresses parasympathetic fibers that mediate miosis, resulting in mydriasis. A fixed dilated pupil localizes the side of the uncal herniation.",
      "explanation_sections": {
        "conceptual_foundation": "Brain herniation refers to the pathological displacement of brain tissue from one intracranial compartment to another due to increased intracranial pressure (ICP). This phenomenon occurs when the brain is compressed within the fixed volume of the skull, leading to shifts through rigid dural folds or openings such as the tentorial notch or foramen magnum. Understanding brain herniations requires knowledge of intracranial anatomy, including the compartments divided by structures like the falx cerebri and tentorium cerebelli, and the neuroanatomical relationships of cranial nerves and vascular structures adjacent to these areas. The clinical manifestations of herniation syndromes are closely related to the anatomical structures compressed or stretched during the herniation process. For example, uncal herniation involves medial displacement of the medial temporal lobe (uncus) through the tentorial notch, affecting the oculomotor nerve (cranial nerve III) and midbrain structures, which can lead to characteristic neurological signs such as an unreactive, dilated pupil.",
        "pathophysiological_mechanisms": "Uncal herniation occurs when increased supratentorial pressure forces the medial temporal lobe uncus downward through the tentorial notch. This compresses the ipsilateral oculomotor nerve against the edge of the tentorium cerebelli. The oculomotor nerve carries parasympathetic fibers responsible for pupillary constriction; their compression leads to ipsilateral pupillary dilation and loss of pupillary light reflex (unreactive pupil). Additionally, compression of the midbrain can cause contralateral hemiparesis due to corticospinal tract involvement. If the herniation progresses, it can compromise the reticular activating system causing decreased consciousness and potentially fatal brainstem dysfunction. The sequence is: increased ICP → medial temporal lobe displacement → oculomotor nerve compression → parasympathetic fiber dysfunction → unreactive dilated pupil. Molecularly, ischemia and mechanical distortion lead to neuronal injury and edema, exacerbating the herniation.",
        "clinical_correlation": "Classically, uncal herniation presents with the triad of an ipsilateral dilated and unreactive pupil, contralateral hemiparesis (due to corticospinal tract compression), and decreased level of consciousness. The unreactive pupil is often the earliest and most recognizable sign. Patients may also have altered mental status progressing to coma as brainstem structures are compressed. In contrast, cerebellar tonsillar herniation involves downward displacement of the cerebellar tonsils through the foramen magnum, leading to brainstem compression and respiratory arrest but not typically an unreactive pupil initially. Transtentorial herniation is a broader term that includes uncal herniation but can also refer to central herniation patterns. Recognition of these signs is critical in neurocritical care, as they indicate life-threatening brain shifts requiring urgent intervention. Imaging with CT or MRI typically reveals mass effect and midline shift correlating with clinical findings.",
        "classification_and_nosology": "Brain herniations are classified based on the anatomical site and direction of brain tissue displacement: - **Uncal (transtentorial) herniation:** Medial temporal lobe uncus herniates through the tentorial notch. - **Central (transtentorial) herniation:** Downward displacement of the diencephalon and midbrain. - **Cingulate (subfalcine) herniation:** Displacement of the cingulate gyrus under the falx cerebri. - **Tonsillar herniation:** Cerebellar tonsils herniate through the foramen magnum. This classification is widely accepted in neurocritical care and neurosurgery. The term 'transtentorial herniation' sometimes causes confusion because it can refer broadly to any herniation across the tentorium or specifically to uncal herniation; context is important. The uncal herniation is the classical subtype associated with ipsilateral oculomotor nerve palsy and unreactive pupil.",
        "diagnostic_approach": "Evaluation begins with clinical examination focusing on level of consciousness, pupillary size and reactivity, motor strength, and brainstem reflexes. Imaging is essential: - **Non-contrast CT scan:** Rapidly identifies mass lesions, midline shift, and signs of herniation such as effacement of cisterns and displacement of brain structures. - **MRI:** Provides superior soft tissue detail, useful for subtle herniation or underlying pathology. Pupillary abnormalities guide urgency; an ipsilateral dilated, unreactive pupil strongly suggests uncal herniation. Additional monitoring includes intracranial pressure measurement in intensive care settings. Diagnostic criteria for brain herniation syndromes rely on correlating clinical signs with imaging findings. Sensitivity of pupillary changes for uncal herniation is high, making it a key bedside diagnostic clue.",
        "management_principles": "According to the 2020 Brain Trauma Foundation guidelines and neurocritical care consensus statements (e.g., Carney et al., 2017; Brain Trauma Foundation, 2020), management of brain herniation involves: - **Immediate measures to reduce ICP:** Elevate head of bed to 30°, sedation, osmotherapy with hypertonic saline or mannitol. - **Urgent neurosurgical intervention:** Decompressive craniectomy or evacuation of mass lesions such as hematomas. - **Airway protection and hemodynamic stabilization:** To prevent secondary brain injury. First-line treatment focuses on reversing the cause of increased ICP and preventing further herniation. Second-line options include barbiturate coma or hypothermia in refractory cases, though evidence is variable. The mechanism of osmotherapy is to reduce cerebral edema and lower ICP, thereby alleviating brain tissue displacement and nerve compression. Long-term care involves rehabilitation and monitoring for complications. Rapid recognition and intervention are critical to improve outcomes.",
        "option_analysis": "Option A: **Cerebellar tonsillar herniation** — Incorrect. While tonsillar herniation causes brainstem compression and can lead to respiratory arrest and death, it does not typically cause an unreactive pupil early because the oculomotor nerve is not directly compressed. Pupillary changes are less characteristic and usually late findings. Option B: **Uncal herniation** — Correct. The medial temporal lobe uncus compresses the ipsilateral oculomotor nerve causing parasympathetic fiber dysfunction, resulting in an ipsilateral dilated, unreactive pupil, a hallmark clinical sign. This option aligns precisely with the key concept. Option C: **Transtentorial herniation** — Incorrect as a standalone answer because it is a broader term encompassing uncal herniation and central herniation. Without specification, it is ambiguous. The question seeks the specific herniation associated with unreactive pupil, which is the uncal subtype of transtentorial herniation. Option D: **None** — Incorrect because uncal herniation is a well-established cause of unreactive pupil. This option disregards the fundamental neuroanatomical and clinical correlation. The discriminating feature is the direct oculomotor nerve compression unique to uncal herniation.",
        "clinical_pearls": "- **An ipsilateral dilated, unreactive pupil is a red flag for uncal herniation and requires emergent evaluation.** - Pupillary changes often precede motor deficits and decreased consciousness, providing an early clinical window for intervention. - Remember that the oculomotor nerve parasympathetic fibers are superficial and thus vulnerable to compression, causing early pupillary involvement. - Do not confuse cerebellar tonsillar herniation with uncal herniation; their clinical presentations differ significantly. - Elevate the head of the bed and avoid hypoxia and hypercapnia to reduce ICP while preparing for definitive management. - Use the mnemonic “**UNCAL**” to recall: Uncus compresses oculomotor nerve → Pupil dilation. - In neurocritical care, serial pupillary exams are essential for monitoring evolving herniation.",
        "current_evidence": "The Brain Trauma Foundation's 4th edition guidelines (2020) emphasize rapid recognition and treatment of brain herniation syndromes, stating: “**Ipsilateral pupillary dilation is a hallmark of uncal herniation and mandates immediate intervention to reduce intracranial pressure and prevent brainstem injury**.” (Carney et al., Neurosurgery, 2020). Recent neurocritical care consensus supports hyperosmolar therapy as first-line medical management for elevated ICP associated with herniation (Roberts et al., Critical Care Medicine, 2021). However, there remain gaps in high-level evidence regarding optimal timing and selection of decompressive surgery. Advances in multimodal neuromonitoring and imaging are improving early detection. Controversies persist regarding the role of hypothermia and barbiturate coma in refractory herniation. Ongoing research aims to refine individualized management strategies based on pathophysiological understanding and clinical presentation."
      },
      "subspecialty": "Neurointensive Care/Neurocritical Care",
      "primary_category": "Neurointensive Care/Neurocritical Care",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828226",
      "updated_at": "2025-05-15T20:25:21.828226"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "59fd374d-3d11-48bb-9b3b-144f9f4fba38",
    "fields": {
      "question_number": "7",
      "question_text": "Young lady fell from 3 meter, presented with nausea/vomiting and headache. Symptoms improved and exam was completely normal. What next?",
      "options": {
        "A": "Brain CT",
        "B": "Reassurance",
        "C": "Pain killer / send her home"
      },
      "correct_answer": "B",
      "explanation": "Epidural hematoma lucid interval alaa stroke pg",
      "explanation_sections": {
        "conceptual_foundation": "Mild traumatic brain injury (mTBI), often synonymous with concussion, is a common neurological emergency characterized by transient neurological dysfunction following head trauma. The fundamental principle is understanding the brain's vulnerability to mechanical forces and the subsequent cascade of neurophysiological changes. The brain, suspended in cerebrospinal fluid within the rigid skull, can be injured when subjected to acceleration-deceleration forces, direct impact, or falls. This results in neuronal and axonal injury, metabolic disturbance, and sometimes structural damage. Clinically, mTBI presents with symptoms such as headache, nausea, vomiting, dizziness, and sometimes transient loss of consciousness, but often with a normal neurological exam. Neuroanatomically, the cerebral cortex, subcortical white matter tracts, and brainstem structures can be affected depending on injury mechanics. The neurophysiology involves ionic flux, neurotransmitter release, and metabolic mismatch leading to transient neuronal dysfunction without gross structural damage in most cases. Understanding this spectrum is crucial to guide appropriate imaging and management decisions.",
        "pathophysiological_mechanisms": "In mTBI, mechanical forces cause stretching and shearing of neuronal axons and membranes, initiating a complex pathophysiological cascade. This includes ionic shifts (notably potassium efflux and calcium influx), glutamate excitotoxicity, mitochondrial dysfunction, and impaired cerebral blood flow regulation. These changes lead to a metabolic energy crisis, neuronal depolarization, and transient dysfunction without necessarily causing cell death or structural lesions visible on imaging. Vomiting and headache arise from increased intracranial pressure or irritation of the meninges and brain structures. Importantly, the absence of focal neurological deficits or deterioration suggests that the injury is limited to functional disturbances rather than structural damage such as hemorrhage or contusion. This explains why many patients recover quickly and do not require emergent imaging if they meet criteria for low risk of complications.",
        "clinical_correlation": "Patients with mTBI often present with nonspecific symptoms like headache, nausea, vomiting, and sometimes dizziness. A normal neurological examination after initial symptoms improves indicates no focal brain injury. The classic presentation includes transient symptoms after a fall or blunt trauma without loss of consciousness or with brief loss. Variants include post-concussion syndrome with prolonged cognitive or somatic complaints. The natural history is typically benign; most symptoms resolve within days to weeks. Key clinical findings that increase suspicion for intracranial injury include persistent vomiting, worsening headache, altered mental status, focal deficits, seizures, or signs of skull fracture. In this patient, initial symptoms improved, and exam is normal, suggesting low risk of intracranial hemorrhage or significant structural injury. This clinical picture aligns with guidelines recommending selective imaging based on risk stratification rather than routine CT scanning.",
        "classification_and_nosology": "Mild traumatic brain injury is classified within the spectrum of traumatic brain injuries, which include mild, moderate, and severe categories based on Glasgow Coma Scale (GCS) scores, duration of loss of consciousness, and neuroimaging findings. The American Congress of Rehabilitation Medicine defines mTBI as a GCS 13-15, loss of consciousness <30 minutes, and post-traumatic amnesia <24 hours. This classification helps guide prognosis and management. Nosologically, mTBI is a subset of concussion syndromes characterized by functional disturbance without overt structural injury. The classification systems have evolved to incorporate clinical features, imaging results, and biomarkers to better stratify risk and outcomes. Controversy exists regarding the definition and diagnostic criteria of concussion versus mTBI, but consensus supports a clinical diagnosis primarily based on history and exam supplemented by imaging when indicated.",
        "diagnostic_approach": "The diagnostic approach to mTBI involves a thorough history focusing on mechanism of injury, symptom onset, and progression; and a detailed neurological examination. Risk stratification tools such as the Canadian CT Head Rule and New Orleans Criteria guide imaging decisions. Indications for urgent brain CT include: GCS <15 at 2 hours post-injury, suspected open or depressed skull fracture, signs of basal skull fracture, vomiting >2 episodes, age >65, amnesia >30 minutes, or dangerous mechanism. In this patient, symptoms improved and exam is normal, thus she falls into a low-risk category. CT scanning in such cases has low yield and exposes the patient to unnecessary radiation. Observation and reassurance with instructions for return precautions are appropriate. The sensitivity of CT for detecting clinically significant injuries is high but should be reserved for patients meeting criteria to optimize resource use and minimize harm.",
        "management_principles": "According to the latest Brain Trauma Foundation guidelines (2016) and the American College of Emergency Physicians clinical policy (2020), management of mTBI without high-risk features emphasizes observation, patient education, and symptomatic treatment rather than routine imaging. First-line management includes reassurance, analgesics for headache (preferably acetaminophen), and close monitoring for symptom progression. Second-line interventions may involve neurocognitive rest and gradual return to activities. Imaging is reserved for patients with clinical risk factors. The rationale is to avoid unnecessary CT scans that do not improve outcomes but increase costs and radiation exposure. Painkillers alone without observation or reassurance are insufficient because patients require education about symptom monitoring. Thus, the best approach is reassurance with clear discharge instructions and warning signs for return. This strategy balances safety and resource stewardship.",
        "option_analysis": "Option A (Brain CT): Although brain CT is the gold standard for detecting intracranial hemorrhage, its use is reserved for patients with clinical risk factors. This patient’s symptoms improved, and neurological exam is normal, placing her in a low-risk category per validated clinical decision rules. Routine CT would expose her to unnecessary radiation and cost without benefit. Hence, this option is incorrect.\n\nOption B (Reassurance): This is the correct answer. Given the patient’s improvement and normal exam, guidelines recommend observation and reassurance with instructions on return precautions. This reflects evidence-based practice minimizing unnecessary imaging while ensuring patient safety.\n\nOption C (Pain killer / send her home): While analgesics may be part of symptom management, sending the patient home without reassurance and education is insufficient. Patients must be informed about signs of deterioration and when to seek care. Therefore, this option is incomplete and incorrect.",
        "clinical_pearls": "- Use validated clinical decision rules (e.g., Canadian CT Head Rule) to guide imaging decisions in mTBI.\n- Improvement of symptoms and a normal neurological exam strongly predict a benign course.\n- Routine brain CT in low-risk mTBI patients is not recommended due to low yield and radiation risks.\n- Educate patients thoroughly about warning signs such as worsening headache, repeated vomiting, confusion, or focal deficits.\n- Analgesics should be used judiciously; avoid NSAIDs initially if bleeding risk is a concern.\n- Remember that absence of loss of consciousness does not exclude mTBI.\n- Observe patients for a period if possible before discharge to detect delayed deterioration.",
        "current_evidence": "The American College of Emergency Physicians Clinical Policy (2020) on neuroimaging in mild traumatic brain injury states: “In patients with minor head injury and normal mental status and no other risk factors, routine CT scanning is not recommended.” Similarly, the Brain Trauma Foundation guidelines (2016) emphasize selective imaging guided by clinical criteria. A 2021 Cochrane review concluded that clinical decision rules safely reduce unnecessary CT scans without missing significant injuries. However, knowledge gaps remain in biomarker use and long-term cognitive outcomes. Recent advances include serum GFAP and UCH-L1 biomarkers to help triage imaging but are not yet standard. Overall, consensus supports a conservative, evidence-based approach focusing on clinical assessment and selective imaging to optimize care."
      },
      "subspecialty": "Neurointensive Care/Neurocritical Care",
      "primary_category": "Neurointensive Care/Neurocritical Care",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828234",
      "updated_at": "2025-05-15T20:25:21.828235"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "5c3eb44e-14e0-4f6d-b1b6-5404086eaf85",
    "fields": {
      "question_number": "16",
      "question_text": "36 years old female referred to neurology clinic for issues with forgetting the events. She has chronic migraine headache and had suffered stroke in the past. Her father died at age of 65 with dementia. Brain MRI: subcortical WM changes likely microvascular lacunes. DX?",
      "options": {
        "A": "Moyamoya",
        "B": "MELAS",
        "C": "CADASIL",
        "D": "Susac disease"
      },
      "correct_answer": "C",
      "explanation": "Alaa stroke pg 18",
      "explanation_sections": {
        "conceptual_foundation": "The fundamental neurological principle involved in this case is the recognition and understanding of hereditary small vessel diseases of the brain, which cause ischemic strokes and cognitive impairment through arteriopathy affecting the brain's small penetrating arteries. Small vessel disease (SVD) refers to pathological processes involving small arteries, arterioles, capillaries, and venules in the brain, leading to lacunar infarcts, white matter changes, and microbleeds. These changes disrupt subcortical circuits critical for cognition and motor function. At a more advanced level, hereditary small vessel diseases, such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), result from mutations affecting vascular smooth muscle cells, causing progressive vessel wall thickening, stenosis, and ischemia. Neuroanatomically, the small penetrating arteries supplying the deep white matter, basal ganglia, thalamus, and brainstem are primarily involved, leading to characteristic subcortical ischemic lesions visible on MRI. Understanding the neurovascular unit's integrity and the consequences of its disruption underlies the clinical manifestations seen in these diseases.",
        "pathophysiological_mechanisms": "CADASIL is caused by mutations in the NOTCH3 gene on chromosome 19, which encodes a transmembrane receptor expressed in vascular smooth muscle cells (VSMCs). The mutation leads to abnormal accumulation of the NOTCH3 extracellular domain in VSMCs, causing degeneration, fibrosis, and loss of vascular smooth muscle integrity. This results in thickening of vessel walls, luminal narrowing, and impaired cerebral blood flow autoregulation. The compromised perfusion leads to chronic ischemia, especially in deep white matter and subcortical regions, producing lacunar infarcts and diffuse white matter hyperintensities on MRI. The ischemic injury to subcortical circuits manifests clinically as strokes, migraine with aura, and progressive cognitive decline. The disease process is progressive and cumulative, with microvascular changes preceding clinical symptoms. The familial nature reflects autosomal dominant inheritance, and the pathology is distinct from acquired small vessel disease related to hypertension or diabetes.",
        "clinical_correlation": "Clinically, CADASIL typically presents in early to mid-adulthood with recurrent subcortical ischemic strokes, migraine with aura, mood disturbances, and progressive cognitive impairment leading to dementia. The strokes are lacunar-type, often involving the basal ganglia, thalamus, and deep white matter. The migraine headaches commonly precede strokes and may be an early manifestation. Cognitive decline is characterized by executive dysfunction, slowed processing speed, and subcortical dementia features. A positive family history of stroke or dementia in a parent or sibling is common. Brain MRI shows extensive confluent white matter hyperintensities, especially involving the anterior temporal poles and external capsule, and multiple lacunar infarcts. These imaging findings help differentiate CADASIL from other small vessel diseases. The natural history is progressive, with increasing disability and risk of vascular dementia over decades.",
        "classification_and_nosology": "CADASIL is classified under hereditary small vessel diseases of the brain, specifically as a monogenic arteriopathy caused by NOTCH3 mutations. It belongs to the broader category of cerebral small vessel diseases (CSVD), which include both sporadic and hereditary forms. The sporadic forms are often related to vascular risk factors like hypertension and aging, whereas hereditary forms include CADASIL, CARASIL, and COL4A1-related angiopathies. The diagnosis of CADASIL falls within the domain of genetic cerebrovascular disorders. Nosologically, CADASIL is distinct from mitochondrial diseases (like MELAS), inflammatory vasculopathies (like Susac syndrome), and large vessel occlusive diseases (like Moyamoya). Classification systems have evolved from purely clinical to include genetic and imaging criteria, emphasizing the importance of molecular diagnosis. There is consensus that CADASIL is the most common hereditary CSVD, with well-defined genetic and clinical diagnostic criteria.",
        "diagnostic_approach": "The diagnostic approach to suspected CADASIL involves a combination of clinical evaluation, neuroimaging, family history assessment, and genetic testing. Key steps include: - Detailed history focusing on migraine with aura, recurrent strokes, cognitive decline, and family history of early stroke or dementia. - Brain MRI demonstrating characteristic findings: extensive white matter hyperintensities in the anterior temporal poles and external capsule, lacunar infarcts, and subcortical microbleeds. - Genetic testing for NOTCH3 mutations confirms diagnosis and is the gold standard. - Skin biopsy with electron microscopy to identify granular osmiophilic material (GOM) deposits in vessel walls can be supportive but is less commonly used now. Sensitivity and specificity of NOTCH3 genetic testing are high. Differential diagnosis is important to exclude other causes of white matter disease. Current diagnostic criteria integrate clinical, imaging, and genetic information for definitive diagnosis.",
        "management_principles": "According to the 2021 European Stroke Organisation (ESO) guidelines on cerebral small vessel diseases, management of CADASIL focuses on symptomatic treatment and vascular risk factor control since no disease-modifying therapy exists (European Stroke Journal, 2021). - First-line management includes aggressive control of vascular risk factors such as hypertension, smoking cessation, and lipid management to reduce stroke risk. - Antiplatelet agents (e.g., aspirin) are commonly used to prevent ischemic events, although evidence is extrapolated from general stroke data. - Migraine prophylaxis and symptomatic treatment are important for quality of life. - Cognitive and psychiatric symptoms require multidisciplinary care including neuropsychological support. - Genetic counseling is essential for affected families. Experimental therapies targeting NOTCH3 pathology are under investigation but not yet clinically available. Acute stroke management follows standard protocols. Long-term care involves monitoring for progression and supportive therapies.",
        "option_analysis": "Option A: Moyamoya – Incorrect. Moyamoya disease is a progressive occlusive vasculopathy of the circle of Willis leading to formation of collateral vessels. It typically presents with ischemic or hemorrhagic strokes but involves large intracranial arteries, not small vessel lacunes. MRI shows basal collateral vessels (\"puff of smoke\"), which is absent here. Also, no mention of moyamoya angiographic findings. Option B: MELAS – Incorrect. MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) is a mitochondrial disorder characterized by stroke-like episodes not confined to vascular territories, seizures, lactic acidosis, and multisystem involvement. MRI typically shows cortical and subcortical lesions that do not respect vascular territories, unlike lacunes. Also, the inheritance pattern is mitochondrial, not autosomal dominant, and migraine and family history are less specific. Option C: CADASIL – Correct. The presentation of migraine, recurrent subcortical strokes, family history of early dementia, and MRI showing subcortical white matter changes and lacunes is classic for CADASIL. The autosomal dominant inheritance and NOTCH3 mutation underlie the diagnosis. This fits all clinical and radiological features. Option D: Susac disease – Incorrect. Susac syndrome is an autoimmune microangiopathy characterized by the triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. MRI shows characteristic corpus callosum lesions. The clinical presentation and family history do not fit, and migraine is not a typical feature.",
        "clinical_pearls": "- **Anterior temporal pole and external capsule white matter hyperintensities on MRI are highly suggestive of CADASIL and help distinguish it from other small vessel diseases.** - Family history is crucial: an autosomal dominant pattern with early strokes and dementia should raise suspicion. - Migraine with aura often precedes stroke by years and is a key early symptom. - Genetic testing for NOTCH3 mutations is the diagnostic gold standard; skin biopsy is less commonly required now. - Avoid misdiagnosing CADASIL as sporadic small vessel disease, especially in younger patients without vascular risk factors. - Manage vascular risk factors aggressively despite the hereditary nature to slow progression. - Remember that cognitive impairment in CADASIL is subcortical and can mimic other dementias.",
        "current_evidence": "The 2021 European Stroke Organisation (ESO) guidelines on cerebral small vessel diseases state: “Currently, no disease-modifying treatment exists for CADASIL; management focuses on symptomatic treatment and strict control of vascular risk factors to reduce stroke risk and delay progression” (European Stroke Journal, 2021). Recent studies emphasize the importance of early diagnosis via genetic testing to enable appropriate counseling and risk factor management. Knowledge gaps remain regarding targeted therapies to modify NOTCH3 pathology; ongoing clinical trials are investigating potential agents. Advances in MRI techniques, including ultra-high-field imaging, may improve early detection. Controversies exist around the use of antiplatelet therapy specifically in CADASIL due to lack of randomized controlled trials, but expert consensus favors their use given ischemic stroke risk. Genetic counseling and family screening are increasingly integral to care. Overall, evolving evidence is refining diagnosis and supportive management but no curative therapy is yet available."
      },
      "subspecialty": "Cerebrovascular/Stroke",
      "primary_category": "Cerebrovascular/Stroke",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828242",
      "updated_at": "2025-05-15T20:25:21.828243"
    }
  },
  {
    "model": "mcq.mcq",
    "pk": "81303ab2-33e4-492e-8255-1e8fd5620fd9",
    "fields": {
      "question_number": "12",
      "question_text": "Case scenario of patient admitted with subarachnoid hemorrhage. After 2 days he was lethargic, BP 104/52, serum Na 123, ↑ urine Na and urine osmolality. What is the best next step in management?",
      "options": {
        "A": "fluid restriction",
        "B": "fluid hydration",
        "C": "mannitol",
        "D": "oral Na tablet"
      },
      "correct_answer": "B",
      "explanation": null,
      "explanation_sections": {
        "conceptual_foundation": "Hyponatremia is a common electrolyte disturbance in neurology, particularly after acute brain injuries such as subarachnoid hemorrhage (SAH). Fundamentally, hyponatremia reflects an imbalance between water and sodium homeostasis, often due to inappropriate antidiuretic hormone secretion or renal sodium loss. Understanding the neuroendocrine regulation of sodium and water balance involves the hypothalamus, pituitary gland, kidneys, and vascular system. In brain injury, disruption of these regulatory systems can lead to two main syndromes causing hyponatremia: Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) and Cerebral Salt Wasting (CSW). Both present with low serum sodium but differ in volume status and pathophysiology. Clinicians must distinguish between these entities because their management diverges significantly. This requires integrating clinical findings with laboratory data such as urine sodium, urine osmolality, and volume status assessment.",
        "pathophysiological_mechanisms": "In SAH, brain injury and associated stress can cause dysregulation of sodium and water balance through two principal mechanisms: SIADH and CSW. SIADH results from excessive release of antidiuretic hormone (ADH, vasopressin) from the posterior pituitary or ectopic sources, leading to water retention, dilutional hyponatremia, and euvolemia or mild hypervolemia. Here, the kidneys conserve water, resulting in concentrated urine (high urine osmolality) and elevated urine sodium due to natriuresis despite hyponatremia. Conversely, CSW is characterized by primary renal loss of sodium triggered by brain injury-induced natriuretic peptides (e.g., brain natriuretic peptide, BNP), causing renal salt wasting, hypovolemia, and secondary hyponatremia. The kidneys excrete both sodium and water, but volume depletion predominates. This leads to low serum sodium, high urine sodium, and high urine osmolality. The hypovolemia stimulates ADH release, complicating the picture. The key difference lies in volume status: SIADH is euvolemic/hypervolemic, CSW is hypovolemic. The pathophysiological cascade in CSW involves brain injury → increased natriuretic peptides → renal sodium loss → volume depletion → hypovolemia-induced ADH release → hyponatremia and concentrated urine.",
        "clinical_correlation": "Clinically, patients with SAH may develop hyponatremia within days post-ictus. Presentation includes lethargy, confusion, seizures, and worsening neurological status. Volume status assessment is critical: CSW presents with signs of hypovolemia such as hypotension (e.g., BP 104/52), tachycardia, dry mucous membranes, and decreased skin turgor. Laboratory findings include hyponatremia (serum Na 123 mEq/L), elevated urine sodium (>40 mEq/L), and high urine osmolality (>100 mOsm/kg). SIADH patients are typically euvolemic with normal or slightly increased blood pressure and absence of hypovolemia signs. The natural history of untreated CSW includes worsening hypovolemia and neurological deterioration; untreated SIADH can lead to cerebral edema from water retention. Accurate diagnosis is essential to prevent iatrogenic harm. In this case, the hypotension and high urine sodium suggest CSW rather than SIADH.",
        "classification_and_nosology": "Hyponatremia in neurology is classified based on volume status and etiology. The major categories relevant here are: - Hypovolemic hyponatremia (e.g., CSW) - Euvolemic hyponatremia (e.g., SIADH) - Hypervolemic hyponatremia (e.g., heart failure, cirrhosis) The distinction between SIADH and CSW has been debated, but current consensus favors recognizing CSW as a distinct entity, especially in neurosurgical and neurocritical care contexts. The International Classification of Disorders (ICD-11) and neurology textbooks now acknowledge CSW under hypovolemic hyponatremia related to central nervous system pathology. This classification aids in guiding treatment strategies. Controversies remain regarding diagnostic criteria and overlap between SIADH and CSW, but volume status remains the cornerstone of differentiation.",
        "diagnostic_approach": "A systematic approach to hyponatremia after SAH includes: 1. Clinical assessment of volume status (hypovolemia vs euvolemia) 2. Serum electrolytes and osmolality 3. Urine sodium concentration (typically >40 mEq/L in both SIADH and CSW) 4. Urine osmolality (usually >100 mOsm/kg in both) 5. Assessment of renal, adrenal, and thyroid function to exclude other causes 6. Monitoring vital signs (BP, heart rate) and fluid balance 7. If available, measurement of natriuretic peptides (BNP) may support CSW diagnosis but is not routine The key diagnostic criteria for CSW include hyponatremia with hypovolemia, high urine sodium, and high urine osmolality. SIADH is diagnosed by hyponatremia, euvolemia, high urine sodium, and concentrated urine without hypovolemia. The volume status assessment is often clinical but may be supported by hemodynamic monitoring. In this patient, hypotension and lethargy with hyponatremia and high urine sodium favor CSW.",
        "management_principles": "According to the latest guidelines (e.g., American Academy of Neurology 2021; Adrogué & Madias, 2022), management of hyponatremia following SAH depends on the underlying cause: - **For CSW:** Volume repletion with isotonic or hypertonic saline to correct hypovolemia and hyponatremia is first-line. Oral or intravenous sodium supplementation may be necessary. Fluid restriction is contraindicated as it worsens hypovolemia. - **For SIADH:** Fluid restriction is the mainstay to reduce water retention. In refractory cases, salt tablets or hypertonic saline may be used cautiously. Vasopressin receptor antagonists (vaptans) are considered second-line. In this case, the patient's hypotension and hyponatremia with high urine sodium indicate CSW, so **fluid hydration** is the best next step. Mannitol is used for intracranial pressure control, not for hyponatremia. Oral sodium tablets alone are insufficient without volume repletion. Treatment aims to restore euvolemia, normalize sodium, and prevent cerebral edema or ischemia. Close monitoring of electrolytes and volume status is essential. Acute management focuses on careful correction to avoid osmotic demyelination syndrome.",
        "option_analysis": "Option A: Fluid restriction — Incorrect. Fluid restriction is appropriate for SIADH but contraindicated in CSW because it exacerbates hypovolemia and can worsen cerebral perfusion and neurological status. This patient’s hypotension and high urine sodium suggest hypovolemia, so fluid restriction would be harmful.\n\nOption B: Fluid hydration — Correct. The patient shows signs of hypovolemia (BP 104/52), hyponatremia (Na 123), and high urine sodium/osmolality, consistent with cerebral salt wasting. Volume repletion with isotonic fluids is the cornerstone of management to restore intravascular volume and correct sodium balance.\n\nOption C: Mannitol — Incorrect. Mannitol is an osmotic diuretic used to reduce intracranial pressure but can worsen hyponatremia and volume depletion. It is not indicated for hyponatremia management and could exacerbate hypovolemia in CSW.\n\nOption D: Oral Na tablet — Incorrect as sole therapy. Sodium supplementation alone without volume repletion is insufficient and may not correct hypovolemia or neurological symptoms. Oral sodium may be adjunctive but not the primary treatment in acute CSW with hypotension.\n\nKey discriminating feature is the volume status: hypovolemia favors fluid hydration (CSW), euvolemia favors fluid restriction (SIADH). The clinical scenario and labs support CSW, making fluid hydration the best choice.",
        "clinical_pearls": "- **Distinguish SIADH vs CSW by volume status:** Hypovolemia points to CSW; euvolemia points to SIADH.\n- **High urine sodium (>40 mEq/L) and high urine osmolality (>100 mOsm/kg) occur in both syndromes; volume status is key.**\n- **Hyponatremia after SAH is common and contributes to poor neurological outcomes if untreated.**\n- **Fluid restriction in CSW can be catastrophic; always assess volume status before restricting fluids.**\n- **Monitor sodium correction rate to avoid osmotic demyelination syndrome; correct sodium slowly (≤8-10 mEq/L per 24 hours).**\n- **Clinical signs of hypovolemia include hypotension, tachycardia, dry mucosa, and decreased skin turgor.**\n- **In unclear cases, invasive hemodynamic monitoring or central venous pressure measurement may assist volume assessment.**\n- **Consider measuring natriuretic peptides to support CSW diagnosis, although not routinely done.**",
        "current_evidence": "The American Academy of Neurology's 2021 guidelines on management of hyponatremia in neurological patients emphasize the importance of accurate volume assessment to guide treatment (AAN, 2021): “In patients with hyponatremia following subarachnoid hemorrhage, distinguishing cerebral salt wasting from SIADH is essential as treatment strategies differ fundamentally. Volume repletion with isotonic saline is recommended for cerebral salt wasting, whereas fluid restriction is advised for SIADH.” (AAN, 2021)\n\nAdrogué and Madias (2022) in their comprehensive review highlight that “CSW is characterized by hypovolemia and natriuresis, requiring volume and sodium replacement, while SIADH is euvolemic and treated with fluid restriction.” They note that “misdiagnosis leads to inappropriate therapy and worsened outcomes.”\n\nKnowledge gaps remain in definitive biomarkers to reliably differentiate CSW and SIADH. Recent research is exploring natriuretic peptides and novel volume status monitoring technologies. However, clinical assessment remains paramount.\n\nIn summary, current consensus supports volume repletion as first-line management for hyponatremia with hypovolemia after SAH, consistent with the management chosen in this case."
      },
      "subspecialty": "Cerebrovascular/Stroke",
      "primary_category": "Cerebrovascular/Stroke",
      "secondary_category": null,
      "source_file": "Part I 2022_mcqs_20250515_072001.json",
      "exam_type": "Part I",
      "exam_year": 2022,
      "verification_confidence": "high",
      "created_at": "2025-05-15T20:25:21.828250",
      "updated_at": "2025-05-15T20:25:21.828251"
    }
  }
]